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Synopsis
Carcinogenesis is a multi-factorial and multi-aetiological process involving 
suppressions, alterations and re-activation of key biomolecular markers. Some of 
these changes are recognised by the humoral system and are known as Tumour 
Associated Antigens (TAA) against which the humoral system is able to mount an 
auto-antibody response. Cancer cells are subject to two key mortality barriers (Ml & 
M2) as described in the "2-hit" hypothesis which are overcome by p53 dysfunction 
(Ml) and hTERT re-expression (M2). These two molecular events generate TAA 
which are recognised by the humoral immune system with a corresponding auto- 
antibody response. The aim of this thesis was to investigate the significance of the 
humoral anti-p53 auto-antibody and anti-hTERT auto-antibody responses in 
colorectal cancer (CRC). This was performed by evaluating all published literature 
(1979-2009) on anti-p53 auto-antibody response and its association with p53 mutation 
to provide the largest cumulative sample size to date spanning 30 years. A critical 
review was performed of all anti-p53 auto-antibody studies in CRC, followed by an 
investigation into the long-term prognostic significance (minimum 5 years follow-up) 
of anti-p53 auto-antibody in CRC. The second aim of this thesis was to optimise a 
method of detecting anti-hTERT in CRC patients and correlate this with anti-p53 
auto-antibody in order to investigate the significance of a joint humoral response 
against the two key TAA responsible for CRC immortality.
The overall prevalence of anti-p53 auto-antibody was 18.4% (3292/17,859) in all 
cancers and 2.2% (88/3,946) in normal/benign disease controls. The anti-p53 auto- 
antibody presence in all published cancers reports was plotted against the reported 
p53 mutational rates in individual cancers and showed partial correlation (R2=0.5, 
correlation=0.7) between anti-p53 auto-antibody presence and p53 mutation. Anti-p53 
was present in 21.5% (786/3,653) in all CRC only studies, and 19.9% (479/2,409) in 
CRC studies using ELISA. Anti-p53 was not associated with clinico-pathological 
factors or prognosis in majority of the studies. Only 4 studies associate anti-53 auto- 
antibody with adverse clinico-pathological parameters, mostly in selective groups. 
The weaknesses of these studies are discussed. This association leads to anti-p53 
association with adverse prognosis but only in selective analysis. The prognostic
significance is observed in univariate analysis but lost in multivariate analysis when 
stronger traditional prognostic factors are incorporated.
This thesis initially compared serum with plasma anti-p53 auto-antibody titres and 
excluded plasma titres from further analysis due to the potential contamination by 
non-specific binding leading to falsely elevated levels (17-73% variation) of anti-p53 
auto-antibody. Serum anti-p53 auto-antibody was present in 21.7% (20/92) CRC 
patients and 0% (0/20) controls. There was no association with age (p=0.750), sex 
(p-0.468), Dukes' / TNM stage (p=1.000), T- (p=0.900), N- (p=0.912), M-stage 
(p=0.632), location (p=0.175), differentiation (p=0.117) or mucinous component 
(p=0.699). The median follow-up was 97 months with median DPS and OS of 73 
months and 62 months respectively. Dukes' / TNM stage, T-, N-, M-stage were 
prognostic indicators in univariate DPS and OS analysis. Only Dukes'/TNM stage 
remained an independent prognostic indicators in multivariate analysis (p=0.001). 
Anti-p53 auto-antibody did not display prognostic significance in univariate or 
multivariate analysis of OS or DPS.
Anti-hTERT auto-antibody has only been reported once in the literature, using 
molecular recombination to develop hTERT antigen. This thesis optimisation 
processes aimed develop a method of detecting anti-hTERT using less restrictive 
technology, and further development of a WB or ELISA to allow mass detection of 
serum anti-hTERT. The first step aimed to isolate hTERT using a streptavidin 
immune-affinity column with biotinylated anti-hTERT to capture hTERT from cancer 
cell lysates. This was unsuccessful and further attempts were made at identifying 
hTERT using Western blot (WB). Five different anti-hTERT antibodies and a 
multitude of WB conditions were trialled in duplicate (>100 WB), each with multiple 
ECL exposures. hTERT was not identified. The reason for this was narrowed down in 
the final experiments to the lack of specificity of the primary antibodies available. The 
raising of a sufficiently specific anti-hTERT antibody is required to isolate hTERT 
antigen.
Early CRC detection is vital in improving outcomes. The humoral response to TAA in 
carcinogenesis could enable earlier identification of CRC and impact prognosis.
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1 Chapter 1: Introduction
Section 1.1 introduces colorectal cancer (CRC), Section 1.2 describes the 
mechanisms of p53 genetic mutation and potential pathways of anti-p53 auto- 
antibody induction and Section 1.3 demonstrates the relevance of telomerase re- 
activation in cancer cell immortality.
1.1 Introduction to Colorectal Cancer
The epidemiological significance of CRC is discussed, followed by pathways of 
carcinogenesis. CRC treatment is outlined with emphasis on current trials attempting 
to resolve controversies in adjuvant therapy which is one of the most intensively 
researched aspects of CRC treatment.
1.1.1 Epidemiology
CRC is the third most common cancer in the United Kingdom after breast and lung 
cancer. Incidence of CRC increases dramatically after 60 years of age and 85% of 
new diagnosis occurs in this group (Office of National Statistics, 2009, Information 
Services Division Scotland, 2009, Welsh Cancer Intelligence and Surveillance Unit, 
2010, Northern Ireland Cancer Registry, 2006). The lifetime risk of CRC in 2009 was 
1:16 in males and 1:20 in females (Office of National Statistics, 2009). The all cancer 
prevalence in the UK in 2008 was 3.3% (approximately 2,000,000 patients). CRC was 
the second most prevalent cancer with an estimated 250,000 diagnoses, next to breast 
cancer with 550,000 diagnoses (Office of National Statistics, 2009). Worldwide, CRC
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is the third most common cancer after lung and breast cancer (Horner et al., 2008, 
International Agency for Research on Cancer, 2005). The majority of CRC (> 60%) 
are diagnosed in developing countries with significant differences in incidence 
between individual countries, ranging from < 5 / 100,000 in Africa to > 45 /100,000 
in Australia / New Zealand (Ferlay et al., 2007, International Agency for Research on 
Cancer, 2005). This is attributed to dietary, environmental and cultural differences, 
rather than genetic factors, as migrants moving from low risk regions (Asia) to high 
risk regions (USA) demonstrate a rapid increased in CRC risk which almost doubles 
in the second generation (Flood et al., 2000). Furthermore, traditionally low-incidence 
CRC countries such as Japan which have recently assimilated a high-fat, low-fibre 
"Western" diet have demonstrated a rapid increase CRC incidence over the last 20 
years (Marchand, 1999, Koyama and Kotake, 1997).
1.1.2 Aetiology
The exact aetiology of CRC is unknown. The majority of CRC (70 - 90%) is known 
as "sporadic", which probably occurs due to a multi-factorial combination of 
environmental and as yet unclassified genetic factors (Section 1.1.6.4). The remaining 
15% of CRC is attributed to inherited familial conditions and non-malignant diseases 
which predispose to CRC. The major inherited diseases are Hereditary Non-Polyposis 
Coli (HNPCC), Familial Adenomatous Polyposis (FAP) and less commonly Peutz- 
Jehgers Syndrome (PJS), Juvenile Polyposis (JP) and Cowden Disease. The main 
non-malignant disease leading to non-sporadic CRC is Inflammatory Bowel Disease 
(Burstein and Fearon, 2008). These disease conditions are discussed in more detail 
later (Section 1.1.6.1 to Section 1.1.6.5). The potential molecular pathways of
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carcinogenesis are discussed first as there are significant differences in carcinogenesis 
mechanisms of sporadic CRC (chromosomal inactivation, CIN) and non-sporadic 
CRC (mismatch repair, MMR gene). Both mechanisms are shown in the adenoma- 
carcinoma sequence.
1.1.3 Molecular Basis of Carcinogenesis: Adenoma-Carcinoma Sequence
Sporadic CRC is thought to arise from adenomas as supported by observational 
evidence in Table 1.1 and hallmarked in the adenoma-carcinoma sequence (Figure 
1.1) (Fearon and Vogelstein, 1990, Vogelstein et ah, 1988).
1.1.4 Mechanisms of Carcinogenesis : CIN and Methylation
Chromosomal instability (CIN) is the major carcinogenesis pathway in sporadic CRC 
and occurs in 85% of sporadic CRC (Markowitz and Bertagnolli, 2009). CIN induces 
carcinogenesis occurs by (a) inactivation of tumour suppressor genes (APC, p53, 
TGF-|3) and/or (b) activation of oncogenic genes (RAS, BRAF). The sequence of 
events is postulated in the adenoma-carcinoma pathway (Figure 1.1). The remaining 
15% of sporadic CRC occurs through mismatch repair (MMR) defects caused by 
methylation of cytosine residues of the MMR promoter regions. In sporadic CRC, 
methylation typically occurs in Cp-G rich islands of the fcMLHl (an MMR gene) 
promoter, resulting in AMLH1 silencing and MMR defects with characteristic micro- 
satellite instability (MSI) appearance (Section 1.1.6.1) (Veigl et al., 1998, Herman et 
al., 1998). The MMR defects of sporadic CRC are a due to age-acquired somatic 
mutation, rather than inheritance of a defective MMR gene which occurs in non- 
sporadic CRC (Weisenberger et al., 2006, Issa, 2004, Liu et al., 1995).
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Figure 1.1: Adenoma-carcinoma sequence
I
Normal Hyperproliferative Adenoma Carcinoma 
Colon epithelium
t t t t t t
ARC Methylation ARC K-ras DCC p53 Further aaumulation 
hMSH2 annonmalities hMSH2 mutation deletion deletion ————————> 
hMLH1 hMLH1 of genetic abnormalities 
abnormalities inactivation 
(Hereditary 
Syndromes)
http://radiographics.rsnajnls.org/content/vol24/issuel/images/large/g04j"ael8clx.jpeg 
Table 1.1: Observational evidence supporting adenoma to carcinoma progression
Adenoma prevalence correlates with carcinoma prevalence with the average patient 
age 5 years younger than the carcinoma patient
Adenoma distribution in the colon is similar to that of CRC distribution
Adenoma tissue often accompanies CRC and vice versa
Adenomas are present in up to 30% CRC specimens
Larger adenomas develop increasing cellular atypia compared to smaller adenomas
Sporadic adenomas are microscopically identical to adenomas in FAP which have 
100% malignancy risk of CRC
(Steele, 2009)
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1.1.5 CIN : Tumour-suppressor gene inactivation
The main tumour suppressor genes inactivated by CIN are Adenomatous Polyposis 
Coli (APC), p53 and Transforming Growth Factor- p (TGF-P).
1.1.5.1 Tumour-suppressor Inactivation : APC "Gate-keeper"
APC, also known as "the gate-keeper" of the adenoma-carcinoma sequence, is among 
the first steps in preventing CRC carcinogenesis development in the pre-adenoma 
stage (Half et al., 2009). Hence, APC mutation is a key event in the entry into the 
adenoma-carcinoma sequence (Goss and Groden, 2000). The wild-type APC protein 
functions include cell adhesion, signal transduction and transcriptional activation and 
P-catenin degradation. P-catenin is an oncoprotein transcription factor which promotes 
Wnt signalling, cellular activation and expression of other proto-oncogenes (Half et 
al., 2009). The APC proteolytic complex down-regulates p-catenin thus functioning as 
a tumour suppressor. APC mutation leads to unregulated p-catenin expression and 
inappropriate Wnt pathway signalling which in turn promotes unregulated cell 
growth. APC mutation is the hallmark of Familial Adenomatous Polyposis (FAP) 
(Section 1.1.6.2). The importance of APC is emphasised by the inevitable progression 
to CRC in FAP.
1.1.5.2 Tumour-suppressor Inactivation : p53 "Guardian of the Genome"
Mutation of the p53 gene is one of the final events in the adenoma-carcinoma 
sequence (Section 1.2). Other mechanisms of p53 inactivation are discussed (Section 
1.2.2) and induction of anti-p53 auto-antibody response is outlined (Section 1.2.5).
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1.1.5.3 Tumour-suppressor Inactivation : TGF-p
TGF-p is a family of proteins with various functions including anti-proliferation at Gl 
stage of cell cycle, and induction of apoptosis (Blobe et al., 2000). TGF-P induced 
apoptosis is thought to occur via the SMAD or the DAXX pathways (Salomoni and 
Dyer, 2005, ten Dijke and Hill, 2004). TGF-p is inactivated in 30% of CRC through 
TGFBR2 mutation, usually at the TGFBR2-kinase domain. TGF-P function is also 
indirectly inactivated by mutations of its regulators such as SMAD4 (Wood et al., 
2007). Deletions in SMAD4 and another TGF-p regulator, BMPR1 A, are found in 
40% of JPS patients (van Hattem et al., 2008). TGF-P inactivation occurs in the final 
steps of the adenoma-carcinoma sequence, during transition from adenoma to high- 
grade dysplasia or invasive carcinoma (Compton, 2003, Grady et al., 1998).
1.1.5.4 Oncogene Activation : KRAS
Kirsten Rat Sarcoma viral oncogene homolog (KRAS) is a family of genes coding for 
small GTPases that are involved in cellular signal transduction. KRAS mutations 
occur in 20 - 40% cancers and are up to 90% specific for neoplasia (Markowitz and 
Bertagnolli, 2009). KRAS protein activation occurs primarily through gene mutation. 
This activates the GTPase pathway signalling leading to RAS production and 
activation of the Mitogen-activated protein kinase (MAPK) pathway (Rajagopalan et 
al., 2002). MAPK is a signal transduction pathway, which when activated leads to 
binding of growth factors. These signals activates serine / threonine-specific kinases 
which regulate cell functions and ultimately promote cell proliferation (Pearson et al., 
2001).
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1.1.5.5 Oncogene Activation : BRAF
The BRAF gene encodes for serine / threonine protein kinases which also involves 
signal transduction and activation of the MAPK pathway (Davies et al., 2002). 
Inherited BRAF mutations cause cardio-facio-cutaneous syndrome, a disease 
characterized by heart defects, mental retardation and a distinctive facial appearance. 
Acquired BRAF mutation activation occurs in 13% of CRC (Rajagopalan et al., 
2002). BRAF mutations in particular are also linked with hyperplastic polyp 
syndrome with an increased CRC risk (Table 1.2 )(O'Brien, 2007).
1.1.5.6 Oncogene Activation : PI3K
Phosphatidylinositol 3-kinase (PI3K) is another group of enzymes involved in signal 
transduction and growth promotion which is up-regulated in 30% of CRC. PI3K 
activation occurs through mutation of the gene itself, or mutations of its regulators 
such as its inhibitor pTEN, or its upstream activator AKT. The roles of PTEN, PI3K 
and AKT are shown schematically in Figure 1.3. The most recent uncovered clinical 
relevance of PI3K mutation is that, like that of kRAS and BRAF mutations, CRC 
containing these mutations is unresponsive to EGFR-based immunotherapy (Amado 
et al., 2008, Karapetis et al., 2008).
1.1.6 Non-sporadic CRC : MMR Defects
MMR defects are less important than CIN in sporadic CRC, accounting for only 15% 
- 25% of sporadic CRC (usually through hMLHl silencing). However, MMR defects 
are the main pathway of carcinogenesis in non-sporadic or familial CRC.
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1.1.6.1 Non-sporadic CRC : HNPCC
Hereditary Non-Polyposis Coli (HNPCC) accounts for 2 - 5% of all CRC and is the 
biggest cause of non-sporadic CRC. HNPCC is autosomal dominant, with an average 
age of CRC presentation of 45 years and a life-time CRC risk of 80% (Lynch et al., 
2008). HNPCC is characterised by defective MMR genes which normally correct 
errors in base-sequence pairing during DNA replication. Wild-type MMR gene 
function is therefore tumour-suppressive. The most common MMR defects (90%) 
occur in hMSHl, hMSH2, hMSH6, hPMS2 and hMSH3 (Di Fiore et al., 2004, 
Papadopoulos and Lindblom, 1997). Defective MMR function is characterised by 
microsatellite instability (MSI) which is detectable by DNA sequencing of tumour 
tissue. Microsatellites are normally occurring short DNA repeats (usually 5 nucleotide 
sequences) which contain non-coding DNA. MMR defects lead to defective base- 
pairing resulting in changes in the microsatellite sequence and length, known as MSI 
(Clark, 2009). MSI is not exclusive to HNPCC as MSI can occur in up to 25% of 
sporadic CRC as a result of acquired methylation silencing rather than inherited MMR 
defects.
1.1.6.2 Non-sporadic CRC : FAP
FAP is the less common of the two major inherited CRC syndromes, accounting for 
1% of CRC. Patients with FAP have an almost inevitable progression to CRC by the 
fourth decade of life (Cancer Research UK, 2010). FAP is autosomal dominant and 
caused by mutation of the tumour-suppressor gene APC located on the short arm of 
chromosome 5q21 (Clark, 2009). Patients with FAP have thousands of polyps
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throughout the colon giving the colonic mucosa a typical "carpet"-like appearance, 
FAP is also associated with extra-colonic tumours of ectodermal origin (epidermoid 
cysts, central nervous system tumours), mesodermal origin (desmoids and connective 
tissue tumours), and most importantly to the gastrointestinal surgeon - adenomas and 
carcinomas of endodermal origin (gastric, duodenal, biliary, thyroid and adrenal) 
(Trainer, 2009). Intensive screening is advocated with annual flexible sigmoidoscopy 
at age 13-15 years, progressing to annual colonoscopy above the age of 20 years. 
Prophylactic colectomy is offered when FAP is detected on colonoscopy, or if FAP is 
diagnosed by predictive gene testing (even with absence of polyps) due to its almost 
inevitable progression to CRC (Gammon et al., 2009, Dunlop, 2002a).
1.1.6.3 Non sporadic CRC : Other inherited conditions
Several other lesser known inherited diseases are associated with CRC and an 
increased frequency of non-gastrointestinal cancers (Table 1.2). The majority of these 
are autosomal dominant and involve mutations of the cell cycle proliferation 
regulators.
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Table 1.2: Other fam
ilial conditions leading to non-sporadic CRC
Defect; Prevalence
D
escription
M
utY
 H
um
an
(M
YH)-associated
polyposis
Autosom
al recessive; M
YH 
chrom
osom
e Ip; 1/200 
heterozygote carrier
Sim
ilar in appearance to FAP, but later age at presentation (47 years). Alm
ost 
100%
 CRC risk but at a later age of 60 years (40 years in FAP) (Clark, 2009). 
Upper GI polyps in 33%
 (Half et al., 2009).
Peutz-Jeghers Syndrom
e
Autosom
al dom
inant; 
STK11 Chrom
osom
e 19pl3 
m
utation in 50-90%
; 1/8000 
-
 1/250,000
Life tim
e risk: any GI cancer (60%), Breast (40%), CRC (20%), gastric (5%) 
and pancreatic. Over 90%
 develop sm
all bowel polyps. Ovarian SCTAT is 
classical feature. M
ain m
ortality due to sm
all bowel polyp intussusceptions 
and m
ultiple laparotom
ies (W
esterman et al., 1999).
Juvenile Polyposis
Autosom
al dom
inant;
SM
AD4 m
utation; 
1/100,000, lesser extent 
BM
PR1A, PTEN
Gastrointestinal cancer risk 50%
. M
edian age of CRC diagnosis is 42 years 
with 68%
 CRC risk at age 60 years. Associated with Hereditary H
aem
orrhagic 
Telangectasia (HHT) (Gallione et al., 2006, Howe et al., 1998, Howe et al., 
2004).
PTEN
 H
am
artom
a 
Tum
our Syndrom
es
Autosom
al dom
inant; PTEN, 
chrom
osom
e 10q22 in 80%
 
CS and 60%
 BRRS; 
1/200,000
Includes Cowden disease and Bannayan-Riley Ruvalcaba syndrom
e (BRRS). 
GI polyps in 60%
 
-
 gastric (75%), colon (66%), oesophagus (66%). Lifetim
e 
cancer risk: Breast (40%), endom
etrial (10%), thyroid (10%) (Eng, 2003, 
Lachlan et al., 2007).
STK 11 serine-threonine kinase; SCTAT Sex cord tum
ours with annular tubules
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1.1.6.4 Non-sporadic CRC : Unclassified family preponderance
Familial preponderance accounts for up to 15% - 30% of CRC but these are labelled 
"sporadic" as they do not fulfil the diagnostic criteria for familial CRC and do not 
possess an identifiable inherited mutation. Individuals with a first-degree relative with 
CRC have 1.7 times increased risk of developing CRC, which increases with the 
number of relatives affected (Lichtenstein et al., 2000, Strate and Syngal, 2005). 
Patients with two first-degree relatives with CRC and one first-degree relative 
diagnosed with CRC < 45 years have 3-6 fold increase in relative risk for CRC even 
in the absence of detectable genetic defects (Dunlop, 2002b, Houlston et al., 1990). 
The ongoing National Study of Colorectal Cancer Genetics (NSCCG) aims to identify 
the unclassified family preponderances and related biomarkers (Penegar et al., 2007). 
The NSCCG examines family histories and serum and tumour samples from 20,000 
CRC patients, using relatives-by-marriage or friends as controls. The pattern of 
familial history and CRC risk is correlated with several genetic markers, including 
p53, MSI, hMLHl, hMSH2 and hMSH6.
1.1.6.5 Non-sporadic CRC : Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBD) are chronic relapsing inflammatory 
gastrointestinal conditions. These are mainly Ulcerative Colitis (UC) and Crohns' 
disease (CD). IBD accounts for 1 - 2% of CRC and has the highest CRC risk among 
the non-malignant disease groups (Winawer et al., 2005, Choi and Zelig, 1994). The 
reported life-time risk of CRC in IBD varies due to differences in study methodology 
and population, IBD severity and treatment (e.g. short-term isolated enteritis vs.
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long-term severe pancolitis) and referral centre bias (Zisman and Rubin, 2008). A 
previous meta-analysis estimated overall 3.7% CRC prevalence in UC; which 
increased with disease duration - 2% at 10 years, 8% at 20 years and 18% at 30 years 
(Eaden et al., 2001). A more recent UK database reported a lower CRC probability 
(2.5% at 20 years of UC) which again increased with disease duration - 7.6% at 30 
years and 10.8% at 40 years (Rutter et al., 2006). The most likely reason for this 
decreasing CRC risk in IBD is more intensive screening, more aggressive therapy at 
diagnosis with more effective maintenance/ remission treatments, and possibly more 
aggressive prophylactic colectomy in patients with colonic dysplasia (Clark, 2009).
1.1.7 Prognostic factors in CRC
The major adverse prognostic indicators in CRC are advanced stage (which involves 
tumour depth, node involvement and metastases), poor differentiation and mucinous/ 
signet cell morphology. Lymphovascular invasion and tumour budding have been 
added recently.
1.1.7.1 Dukes' / TNM Stage
The American Joint Committee on Cancer (AJCC) / International Union Against 
Cancer (UICC) TNM staging system supersedes that of the previous Dukes' and 
modified Astler-Collier staging systems. The advantage of the TNM stage is that each 
aspect of CRC - depth of penetration (T), nodal stage (N) and presence of metastases 
(M), are assessed independently making this a more discriminating system ( Table 
1.3). TNM stage is the strongest independent predictor of survival. The 5-year overall 
survival by TNM and corresponding Dukes' stage is shown (Table 1.4).
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Table 1.3: AJCC / UICC TNM Stage Definitions
T
Tx
TO
Tis
Tl
T2
T3
T4
Cannot be assessed
No evidence of tumour
Carcinoma in situ (intramucosal)
Invades submucosa
Invades muscularis propria
Invades subserosa or non-peritonealised peri-colic / peri-rectal tissue
Directly invades other organ / structures or perforates visceral peritoneum
N
NX
NO
Nl
N2
Cannot be assessed 
No lymph node metastases 
Metastases in 1 - 3 lymph nodes 
Metastases in > 4 lymph nodes
M 
MX 
MO 
Ml
Cannot be assessed 
No distant metastases 
Distant metastases
Table 1.4: 5-year survival by TNM and Dukes' stage
TNM Stage
Stage 0 (Tis, Tl NO Mo)
Stage I (T2 NO MO)
Stage II (T3, NO, MO)
Stage II (T4, NO, MO)
StageIII(T2,Nl-3,MO)
Stageffl(T3,Nl-3,MO)
StageIII(T4,Nl-3,MO)
Stage IV (any T/N, Ml)
5 Year Survival
> 90%
80-85%
70-75%
70-75%
70 - 75 %
50-65%
25 - 45 %
<3%
Dukes Stage
-
Dukes' Bl
Dukes' B2
Dukes' B3
Dukes' Cl
Dukes' C2
Dukes' C3
Dukes' D
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1.1.7.1.1 T-stage
T-stage assesses the depth of tumour penetration with early T-stage (Tl / T2) 
predicting better prognosis (Table 1.4). The prognostic influence of T-stage does not 
increase in a uniform linear stepwise progression, but increases almost exponentially, 
especially when associated with co-existing nodal involvement. For example, in node 
negative CRC, early progression (Tl  »  T2) only reduces 5-year survival by <5% 
whereas late progression (T3 >T4) reduces 5-year survival by 5 - 15%. Furthermore, 
when nodal involvement (Nl-3) is present, T2 »T4 progression exponentially reduces 
survival by up to 50%. Hence, Tl and T2 node-negative CRC are often grouped 
together in studies as there is minimal survival difference but allow larger sample 
numbers for more robust statistical analysis. Complete serosal penetration (T4) is an 
extremely strong adverse prognostic factor, especially when combined with nodal or 
peritoneal disease, and indicates tumour escape and high probability of 
micrometastases.
1.1.7.1.2 N - stage
Nodal spread occurs via the lymphatic chain which runs alongside the regional 
vascular supply. Nodal involvement is associated with poor prognosis Table 1.4 with 
5-year survival in node negative disease of 70-85% which decreases to 25-75% 
(depending on T-stage) in node positive disease. Nodal status is staged by number of 
nodes involved, and hence staging accuracy is a function of the number of nodes 
available for examination. A minimum of 12 - 15 lymph nodes are required to 
accurately predict N- stage (Tepper et al., 2001, Scott and Grace, 1989).
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Another important feature of nodal assessment is the differentiation between N3 and 
Ml disease. Regional node involvement outside the anatomical region should be 
considered metastatic disease, even in the absence of radiological evidence of distant 
metastases (Compton, 2003). Similarly, central (e.g. para-aortic) or proximal (e.g. 
external and common iliac) nodal involvement should also be considered metastatic 
and not nodal disease. The accurate differentiation between proximal / central 
regional node within anatomical distribution, nodal involvement outside anatomical 
region and metastatic disease is important to avoid misinterpretation of results as 
discussed in light of one of the major studies of anti-p53 auto-antibody in CRC 
(Section 3.5.2.1).
1.1.7.1.3 M-stage
The most common metastases at presentation is in the liver (Raftery, 2002). 
Significant improvements in surgical techniques of liver resection result in <5% 
operative mortality, and 5- year and 10- year survival of 25 - 40% and 20 - 25% 
respectively (Rees et al., 2008, Shah et al., 2007, Tomlinson et al., 2007, Wei et al., 
2006). Similarly, major advances in adjuvant therapy for unresectable liver metastases 
have also been demonstrated, initially with 5-FU, followed by oxaliplatin and 
irinotecan, and most recently with addition of EGFR, VEGF and COX2 inhibition 
(Cassidy, 2007, Van Cutsem et al., 2007, Cunningham et al., 2004, Goldberg et al., 
2004). Despite these improvements, Ml remains the strongest adverse prognostic 
indicator. The factors discussed next are of less prognostic significance than TNM 
stage, but are still recognised prognostic markers and were used for survival analysis 
in this thesis.
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1.1.7.2 Mucinous and signet cell CRC
Mucinous CRC is a morphological description characterized by excess abundant 
extracellular mucin which is associated with more advanced tumours (Sung et al., 
2008, Halvorsen and Seim, 1988). Signet cell carcinoma is characterized by the 
presence of signet cells which resemble signet rings, due to a large mucinous vacuole 
which displaces the nucleus to the periphery. Historically, mucinous and signet cell 
carcinomas were considered different morphological manifestation of the same CRC- 
type as they shared certain characteristics such as younger patients with nodal 
metastases and advanced disease at presentation (Nagtegaal and Quirke, 2008, Tung 
et al., 1996, Nozoe et al., 2000). The most recent multi-centre study compared 19 
patients with signet cell CRC with 5792 non signet CRC between 1993 - 2007 
(Mizushima et al.). All 19 signet cell CRC patients had > T3 stage with 74% (14 / 19) 
nodal involvement and 38% (7/19) metastases at presentation. The resulting 5-year 
survival was 24% (signet cell) compared with 58% (poorly differentiated / mucinous) 
and 78% (well / moderately differentiated) which proves a significant adverse 
prognostic influence of signet cell CRC, beyond that of mucinous CRC. Similarly, 2 
recent studies reported median survival of 33 months in signet cell compared with 68 
months in mucinous and 151 months in non-mucinous CRC. The 5-year survival rates 
were 27% (signet cell), 51% (mucinous) and 69% (non-mucinous) (Song et al., 2009, 
Sung et al., 2008). However, mucinous type is still used as a prognostic marker due to 
its association with advanced stage CRC, although signet cell carcinoma has greater 
significance. Both factors are sufficiently important to justify inclusion into Royal 
College of Patholegists dataset for colorectal cancer (Williams et al., 2007).
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1.1.7.3 Tumour Differentiation
The association between poor differentiation and advanced stage is also sufficient to 
warrant tumour differentiation as a core item in microscopic assessment of CRC 
(Williams et al., 2007).There are 4 grades of differentiation which and most clinical 
studies group into a 2-tier classification system (Table 1.5). Grade 1 (well 
differentiated) and Grade 2 (moderately differentiated) are grouped into a "Low 
Grade" tier, whereas Grade 3 (poorly differentiated) and Grade 4 (undifferentiated) 
are grouped into a "High Grade" tier. Heterogeneous tumour tissue containing 
multiple degrees of differentiation and inter-observer variability are acknowledged 
weaknesses of this system. The 2-tier system described above reduces the inter- 
observer error and increases diagnostic accuracy without markedly biasing survival 
data of groups. The 2-tier differentiation was also used in this thesis for this reason, 
and to obtain larger groups for analysis (Section 4.3.3 & Section 4.4.5). New trials 
incorporate mandatory quality control measures of pathological assessment such as 
attendance at educational sessions in pathological assessment, re-evaluation of the 
pathological assessments by a central committee, and random assessment of quality of 
pathological assessment from participating centres (Sebag-Montefiore et al., 2009, 
Ota and Nelson, 2007a, Kapiteijn et al., 1999).
Table 1.5: Grade of tumour differentiation
Grade 1: Well differentiated 
Grade 2: Moderately differentiated 
Grade 3: Poorly differentiated 
Grade 4: Undifferentiated
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1.1.7.4 Other pathological factors : Lymphovascular invasion and Tumour 
Budding
Several pathological factors have been described more recently, but are considered 
less important than the factors described previously. Lymphovascular invasion is a 
adverse prognostic factor with a recent study demonstrating decreased 5-year disease- 
free survival from 91% to 63% in CRC with lymphovascular invasion (Wang et al., 
2009). Tumour budding is another prognostic factor linked to more aggressive 
tumours and potential lymph node metastases (Ogawa et al., 2009). Recent studies 
confirm the independent adverse prognostic significance of tumour budding in 
multivariate analysis and others associate tumour budding with liver and peritoneal 
metastases. One recent large study reported decreased 5- and 10-year survival in Stage 
II CRC with high grade tumour budding compared to low-grade tumour budding. The 
5-year survival rates decreased from 94% to 74%, and 10-year survival decreased 
from 90% to 68% in patients with high-grade tumour budding. (Nakamura et al., 
2008). Furthermore, these was no survival difference between Stage II CRC with 
high-grade tumour budding and Stage III CRC.
These factors are especially important in staging CRC treated by local excision as 
strong prognostic factors such as T-stage and N-stage cannot be assessed on local 
excision specimens. The use of pathological criteria such as mucinous and signet cell 
morphology and poor differentiation, lymphovascular invasion and tumour budding 
are especially important in these cases to predict CRC stage and aggressiveness and 
the requirement for further surgery or adjuvant treatment.
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1.1.8 P53 mutation in CRC
The prognostic value of the anti-p53 auto-antibody response was examined in this 
thesis. As anti-p53 auto-antibody production occurs partly in response to p53 
mutation (Section 1.2.5 & Section 3.4), the reported prognostic significance of the 
p53 mutation itself requires examination. There is discrepancy in the literature with 
regards to the prognostic value of p53 mutations in CRC but most studies report no 
prognostic significance. (Bouzourene et al., 2000, Ahnen et al., 1998, Borresen-Dale 
et al., 1998, Hirvikoski et al., 1999, Tortola et al., 1999). The conclusions from all 
studies are severely hampered by several factors. These studies are inadequately 
powered for survival analysis, surrogate markers of p53 mutation such as p53 protein 
immuno-histochemical detection (EHC) detection are used, CRC stage heterogeneity 
and confounding bias of the sporadic association between p53 mutation and advanced 
stage CRC. Finally, the prognostic significance of each p53 mutation type may vary 
as it is probable that different mutations affect different p53 functions and will thus 
have a variable influence of prognosis. Several studies have specifically linked p53 
mutations in exon 7, codon 245, conserved areas and L3 structural domains as 
independent prognostic indicators but these are not reproduced (Russo et al., 2002, 
Samowitz et al., 2002, Goh et al., 1999, Iniesta et al., 1998, Jernvall et al., 1997)
The TP53-CRC Collaborative group produced the largest pooled review of p53 
mutations in CRC (Russo et al., 2005). This analysis included 3583 CRC patients 
from 25 study groups in 17 countries. The median follow up for survival analysis in 
all groups was a respectable 58 - 61 months. p53 mutation was strongly associated 
with CRC stage, nodal involvement, poor differentiation, lymphatic invasion (in
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rectal CRC) and lympho-venous invasion (in distal and rectal CRC) - all of which are 
independent prognostic indicators, which was further confirmed by highly significant 
survival effect (p < 0.001 or increased Odds ratio, OR = 1.3 - 7.2) for each clinico- 
pathological parameter in this review. Multivariate analysis demonstrated a non- 
significant trend toward decreased overall survival with p53 mutation in exon 5 - only 
in proximal CRC (Relative Risk, RR 1.36); and p53 amino acid loss - only in distal 
CRC (RR 2.52). Exon 5 mutations have previously been reported to confer poor 
prognosis in lung cancer but this was refuted in other studies (Huang et al., 1998, 
Vega et al., 1997). As such, p53 mutations are of little prognostic value. However, an 
interesting group analysis was performed in this study which is discussed next.
1.1.9 p53 mutation and adjuvant therapy
5- fluorouracil (5-FU) has been the mainstay of adjuvant treatment in CRC for > 40 
years. In vitro studies have shown that 5-FU induced apoptosis is partly p53 
dependant with decreased in vitro cell-kill recorded in p53 mutated cells treated with 
chemo-radiation (Bunz et al., 1999). Human trials also report decreased 5-FU efficacy 
as demonstrated by minimal or no survival benefit in Stage III CRC patients with p53 
mutation receiving 5-FU based adjuvant treatment (Liang et al., 2002, Elsaleh et al., 
2001). The TP53-CRC Collaborative Group review supported this finding in sub- 
group analysis of adjuvant chemotherapy. Only Dukes' C CRC were included in this 
analysis thus removing the effect of varying Dukes' stage on survival. These patients 
were then divided by p53 status thus reducing the bias caused by association between 
p53 mutation and other poor prognostic indicators such as lymphovascular invasion. 
Each group was then further divided by adjuvant chemotherapy provision (Table 1.6).
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Table 1.6: Summary Overall Survival of Dukes' C patients
Wild Type p53
No Chemotherapy
Chemotherapy
Mutant p53
No chemotherapy
Chemotherapy
Proximal RR (95%C1)
1.00
0.61 (0.43-0.87)
P = 0.006
1.00
0.61 (0.22 0.68)
P = 0.006
Distal RR (95%CI)
1.00
0.35(0.14-0.86)
P = 0.022
1.00
1.15(0.49-2.7)
NS
Rectum RR (95% CI)
1.00
0.55(0.43-0.71)
p = 0.006
1.00
0.78(0.57- 1.06)
NS
RR Relative Risk; (Russo et al., 2005)
This shows that when other prognostic indices are adjusted for, patients with wild- 
type p53 obtain significant benefit with chemotherapy whereas this survival benefit is 
not observed in those with mutant p53. This survival difference was observed in the 
proximal and rectal CRC, but not in distal CRC. This is most likely due to under- 
powering in the distal CRC group. The average number of patients in the proximal 
and rectal CRC groups were 183 (range: 98 - 305 per group) compared to only 28 
patients (range: 20 - 39 per group) in distal CRC. Despite these low numbers, there 
was already a trend towards improved overall survival with wild-type p53 (p = 0.022), 
suggesting the survival difference by p53 status observed in proximal and rectal CRC, 
would also be observed in a distal CRC group with larger sample size.
In summary, p53 mutation, when displaying prognostic significance, is always 
adverse and usually associated with stronger adverse prognostic factors such as 
advanced stage. Specific types of p53 mutation display have been related to poor 
prognosis but the complexity and diversity of p53 function hampers efforts to isolate a 
single mutation type, or function, which could independently predict prognosis.
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1.1.10 Surgical Treatment of CRC
Surgery for CRC is dependant on surgical intent of curative or palliative. Palliative 
procedures usually involve local transanal excision, endoscopic ablation or stenting, 
surgical defunctioning stoma or bypass procedures. The curative procedures are more 
radical and aim to remove the tumour, along its vascular supply and the closely 
associated lymphatic chain. This technique is known as "high tie" and results in 
resection of a devitalised segment of colon which is much larger than the tumour 
itself. There is no proven survival benefit of this technique (Lange et al., 2008). 
However, N-stage which is a strong prognostic predictor and also an indication for 
chemotherapy, is dependant on the number of nodes available for examination. This is 
best provided by the "high-tie" technique (Titu et al., 2008). Furthermore, 
approximately 15% lymph node involvement can "skip" sequential local lymph nodes 
and display node involvement node higher up the lymphatic chain. Thus whilst non- 
"high tie" technique benefits by less extensive resection, the specimen provides only 
local nodes for assessment and potentially misses "skip" nodes leading to 
understaging. Hence, "high-tie" is the recommended technique, provided it can be 
performed safely with no immediate surgical risk. The common curative surgical 
procedures are shown in Figure 1.2. (Permission obtained. Taken from 
CancerHelpUK, the patient information website of Cancer Research UK:
\   ,irKcrfk;!|] ;ii: L; y|,) These demonstrate the "high-tie" resection, as can be seen 
by the large devitalised colonic segment excised which is much larger compared to 
the smaller CRC segment.
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Figure 1.2: Commonly performed CRC curative resections using high-tie of 
supplying vasculature. Permission obtained( www.cancerhelp.org.uk)
Ascending 
colon
Large bowel 
joined up
to c.mall howel
Tumour
a) Right hemicolectomy for proximal (caecal and ascending colon) CRC.
Descending 
colon
Tumour
a) Left hemicolectomy for descending colon CRC.
Bowel 
rejoined
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Sigmoid 
colon
Bowel 
joined 
together
c) Anterior resection for sigmoid or upper rectal CRC
Stoma
d) Abdomino-perineal resection (APER) or Miles' procedure for low rectal tumours 
where anastomasis is not possible or suitable.
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1.1.11 (Neo) Adjuvant treatment in CRC
Adjuvant treatments represent one of the most costly and intensively researched 
aspects of CRC treatment. Neo-adjuvant treatment is only offered to rectal cancer 
patients. The mesorectal fascia is a fascial envelope which covers the rectum, 
surrounding mesorectal fat and lymph nodes. Mesorectal fascial tumour involvement 
is a poor prognostic indicator (Bernstein et al., 2009). Neo-adjuvant therapy in rectal 
cancer reduces tumour bulk and sterilises peri-rectal nodes leading to decreased 
mesorectal fascia involvement and hence lower local recurrence rates (Sebag- 
Montefiore et al., 2009, Kapiteijn et al., 1999, Martling et al., 2001). This radiation 
benefit does not extend to colon cancer which does not possess a circumferential 
fascia and radiation risks unnecessary toxicity (Peeters et al., 2005).
The Quasar-I trial which randomised Stage II CRC patients to post-operative 
observation or chemotherapy reported superior disease control in colon cancer 
patients with node-negative disease. It was suggested that neo-adjuvant chemotherapy 
in colon cancer may reduce nodal involvement, eradicate micrometastases earlier, 
reduce peri-operative tumour cell shedding and be more effective than in post- 
operative patients who have concurrent immunological and surgical stress. This forms 
the rationale for trials of neo-adjuvant therapy in colon cancer. This is investigated by 
the FOxTROT (Fluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative 
Therapy for colon cancer) trial, which additionally also introduces a concurrent 
chemo-immunotherapy trial arm using an Endothelial Growth Factor Receptor 
(EGFR) inhibitor, Panitumumab.
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The addition of EGFR inhibitors represents one of the major researched aspects of 
combined immuno-chemotherapy. However, ongoing trials (e.g. FOxTROT) have had 
to be re-designed following the announcement by the American Society of Clinical 
Oncology (ASCO) and Food and Drug Administration (PDA) that from 2009, all 
patients receiving EGFR monoclonal antibodies require proof of wild-type kRAS as 
patients with mutated kRAS did not benefit from EGFR inhibition (Oncogenetics.Org, 
2009). Trials using monoclonal EGFR may sustain yet another setback as there is 
increasing evidence that genes downstream of EGFR (e.g. PI3K, BRAF) which are 
mutated will similarly reduce efficacy of these EGFR inhibitors. Firstly, this will not 
only substantially impact future trial recruitment but will also confound retrospective 
analysis of EGFR-inhibition efficacy (Linot et al., 2010). Secondly, this demonstrates 
the need for continuous advancement development in biomolecular research, 
especially in a process as complex and multi-factorial as CRC.
1.1.12 The future of adjuvant therapies in CRC
Adjuvant therapies have undergone an interesting expansion from its previous role as 
an aide to "gold-standard" treatment of CRC treatment, which is surgery, to a more 
active role in treating CRC in conjunction with minimally invasive surgical 
technologies. This combined approach may be suitable in a significant proportion of 
patients who are deemed high surgical risk due to severe co-morbidity, or fit patients 
who are willing to accept a potentially increase in risk of recurrence in return for 
avoidance of mortality and morbidity of open surgery or stoma formation. Transanal 
Endoscopic Microsurgery (TEM) is one such local excision technique which provides 
an alternative to open surgery for low rectal cancer which would otherwise require
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APER and permanent colostomy. Only 1 RCT comparing TEM and open surgery has 
been published and this was insufficiently powered (n=20 in each group) for survival 
analysis (Winde et al., 1996). The remaining literature whilst favouring TEM, are 
retrospective case controls studies and significantly biased by case selection (Suppiah 
et al., 2008).
The combined local therapy and neo-adjuvant therapies are explored on both sides of 
the Atlantic. TEM and (neo)adjuvant treatment is explored in the proposed TREC 
(Transanal Endoscopic Microsurgery in Early rectal Cancer) trial, a Phase II / III trial 
which uses pre-operative SCRT and TEM in the UK; and American College Of 
Surgeons Oncology Group (ACOSOG) Z6041 Trial in the USA which uses pre- 
operative long-course chemoradiation with local transanal excision (Ota and Nelson, 
2007b). The International Contact Radiotherapy Evaluation (ICONE) group have also 
launched the CONTEM (Contact X-Ray and Transanal Endoscopic Microsurgery) 
which uses contact radiotherapy, transanal excision and chemotherapy. The limitation 
of this trial is the availability of specialised radiotherapy equipment required.
This "trade-off approach where recurrence rates are sacrificed for lower immediate 
morbidity rates in these trials represent the shifting paradigm that local recurrence 
rates, once considered the most important outcome measure, is no longer the sole 
predictor of oncological success. Almost all new trials evaluating CRC treatments 
also incorporate measures of gastrointestinal function (e.g. Faecal Incontinence and 
Severity Index), psychological functioning (e.g. Hospital Anxiety and Depression 
scale) and quality of life measures which combine daily function and psychological 
scores (e.g. Faecal Incontinence and Quality of Life score) as part of trial outcomes.
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1.2 p53 : Introduction
The p53 gene is located on the distal band of short of the short arm of chromosome 
17pl3.1 (IARC, 2008). It consists of approximately 20,000 base pairs spread over 11 
exons (Lutz and Nowakowska-Swirta, 2002). It was initially discovered in 1979, as a 
protein binding to a viral oncogene, Simian Vacuolating 40 (SV40) large T-antigen, 
and hence thought to be an oncogene itself (Levine, 2009, Wiman, 2006, Lane and 
Crawford, 1979). It has since established its role as a critical tumour-suppressor gene 
(Staples et al., 2008, Finlay et al., 1989). p53 inactivation predisposes to malignant 
transformation in rodent models and in human clinical syndromes such as Li- 
Fraumeni syndrome which is characterized by p53 germline mutation (Schwarzbraun 
et al., 2009, Donehower et al., 1992, Eliyahu et al., 1989). The tumour suppressive 
role of p53 is so crucial that it is referred to as "guardian of the genome" (Bueter et 
al., 2006). It is the most common mutation found in cancers and is present in half of 
all solid tumours thus emphasising its importance in protecting cell lines from 
carcinogenesis. The frequency of mutation varies in individual cancers ranging from 
5-12% in cervical and haemo-poietic malignancies to 40-50% in colorectal and 
ovarian cancer (IARC, 2008). Additionally, the remaining cancers with no detectable 
p53 mutation are still thought to have dysfunctional p53 caused by mechanisms other 
than mutation (Staples et al., 2008). As almost all recent advances in CRC treatment 
have been in molecular biology (e.g. Endothelial Growth Factor Receptor) and 
chemo-immunotherapy, p53 and its diverse function, may yet again be catapulted to 
the forefront. The normal p53 gene function (Section 1.2.1) and mechanisms of p53 
inactivation (Section 1.2.2) are described and summarised in Figure 1.3
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Figure 1.3: Norm
al p53 function highlighted in green boxes and blue figures as described in Section 1.2.1. M
echanisms of p53 inactivation 
shown in red boxes and described in Section 1.2.2.
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1.2.1 p53 gene and function
p53 acts as a tumour suppressor by preventing propagation of defective cells. It is up- 
regulated in response to cellular stress or damage by various upstream factors such as 
DNA damage or radiation (Figure 1.3). Activated p53 modifies downstream gene 
expression and co-factor transcription, which in conjunction with p53, lead to growth 
arrest (e.g. p21 / WAF) or apoptosis (e.g. PUMA) (Vousden and Lu, 2002). The p53 
gene encodes for a 393 amino-acid 53 kDA phospho-protein which is divided into 3 
domains - an amino (-NH2) terminal region (approximately amino acids 1-100), a 
central "core" domain (amino acids 100-300) and a terminal carboxyl (-COOH) 
region (amino acids 320-360) (Schlichtholz et al., 1992). Almost all mutations are 
harboured in the central "core" which contains the DNA-binding regions. Hence, it is 
likely that p53 dysfunction caused by mutations occurs by modifications in this 
central "core" p53-DNA binding complex. Interestingly, the central mutated core 
which harbours majority of the mutations is the least immunogenic. The anti-p53 
auto-antibody recognises epitopes of the 2 terminal regions which are possessed by 
both the wild-type and mutant p53 protein and harbour the least mutations (Saleh 
etal., 2004, Schlichtholz et al., 1992). The implications of recognition of terminal 
epitopes on anti-p53 auto-antibody production are discussed in Section 1.2.5.1.
Wild-type p53 protein is intra-nuclear and has a short half-life of 5- 30 minutes, 
primarily due to negative feedback regulation by Murine Double Minute 2 (Mdm2) 
(Moll and Petrenko, 2003, Iwakuma and Lozano, 2003). Mdm2 has an ubiquitin- 
dependant E3 ligase which targets wild-type p53 for active nuclear and cytoplasmic 
proteosome-mediated degradation (Shirangi et al., 2002, Haupt et al., 1997).
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Upregulated p53 binds to the Mdm2 promoter leading to upregulated Mdm2 
transcription. The Mdm2 gene product inhibits p53, resulting in a classic negative 
feedback loop which controls p53 expression and function. p53 and various co-factors 
of the mdm2-p53 interaction constitute a dynamic negative feedback loop which 
maintains low levels of intra-nuclear p53 (Figure 1.3) (Staples et al., 2008, Kubbutat 
etal., 1997).
In normal cells, excessive cellular stress threatens DNA stability which leads to 
upstream modifications and post-translational alterations in p53 protein (e.g. 
phosphorylation) which impairs the p53-Mdm2 interaction. This results in inability of 
Mdm2 to degrade p53 and hence increases p53 levels. In addition, Mdm2 can also 
undergo post-translational modifications (e.g. ATM kinase phosphorylation), or self- 
ubiquinate to target itself for degradation (Fang et al., 2000, Honda and Yasuda, 
2000). These mechanisms lead to p53 accumulation which then triggers a 
transcription cascade of downstream factors leading to cell arrest or apoptosis (Figure 
1.3). Cell cycle arrest provides the cell time to repair damaged DNA. Cells unable to 
repair damage after a certain amount of time has lapsed are directed towards apoptosis 
by shifts in the balance between pro-arrest and pro-apoptotic factors. Alternatively, in 
cases of severe damage, the cell is pushed directly towards apoptosis. These safe- 
guards prevent the propagation of potentially defective cells. In mutated cells, the 
disruption of p53 gene transcription function and subsequent production of an inactive 
mutant p53 protein allows cells to escape this cellular arrest / apoptosis controls. This 
allows unregulated propagation of abnormal cells and a predisposition to malignant 
transformation. Normal p53 function is summarised in the green boxes in Figure 1.3.
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1.2.2 p53 Inactivation : Mutation
The most common cause of p53 inactivation is mutation. Mutations of other co- 
factors and other mechanisms have been observed in different cancers and are also 
able to indirectly affect p53 function leading to p53 dysfunction despite presence of 
the wild-type p53. p53 inactivation by mutation most frequently occurs within the p53 
core (amino acids 100-300) whilst 70% occur at "hot spots" - amino acids 132-142, 
151-159, 172-179, 237-249 and 272-286 (lacopetta, 2003, Levine et al., 1991). The 
International Agency for Research on Cancer (IARC) TP53 database also reports the 
most frequent mutations to occur at codons 175, 245, 248, 249, 273 and 282; and is 
further corroborated by another international database spanning over 25 years, the 
UMD-TP53 mutation database (IARC, 2008, Soussi, 2008). The most common type 
of mutation is mis-sense (73%) followed by frame shift (9%), non-sense (8%), silent 
(4%) and others (6%) (IARC, 2008).
1.2.3 Mechanisms of p53 Indirect inactivation
p53 is also inactivated by mechanisms other than mutation. Some of the major 
pathways of indirect inactivation are described below, which include up- and down- 
stream modulation. These mechanisms in relation to p53 are shown in Figure 1.3 and 
described in the red text boxes.
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1.2.3.1 Indirect inactivation : Proto-oncogenes
Proto-oncogenes are proteins that predispose to tumour formation. These proteins are 
able to bind to p53 protein and induce p53 protein degradation. Human Papilloma 
Virus (HPV) 16 / 18 E6 protein which causes cervical cancer is one such proto- 
oncogene which explains the relatively low incidence of p53 mutation in cervical 
cancer. The rate of p53 mutation was 6% compared to >25% in most solid tumours as 
calculated in this thesis which included all published p53 reports over 30 years 
(Figure 3.1) (Soussi, 2008, Crook et al., 1991, Schefmer et al., 1990). In animal 
models, the SV40 large-T-antigen is able to inactivate wild-type p53 (Dong et al., 
1994).
1.2.3.2 Indirect inactivation : Mdm2 over-expression
a) Mdm2 is a p53 negative regulator, and Mdm2 over-expression leads to p53 
suppression and reduces the cell ability to trigger the pro-arrest/ apoptotic pathway in 
the event of cellular damage (Chene, 2003, Momand et al., 1992). Mdm2 over- 
expression can occur by gene amplification, gene over-expression or mRNA over- 
transcription (Soussi, 2008, Oren et al., 2002). Mdm2 over-expression is classically 
observed in soft tissue sarcomas (Leach et al., 1993, Oliner et al., 1992). Interestingly, 
instead of a decrease in p53 expression as would be expected due to rise in its 
inhibitor (Mdm2), the levels of both Mdm2 and p53 expression are increased. This 
suggests Mdm2 may have a separate p53-independent oncogenic mechanism (in 
addition to p53 suppression) which promotes tumour growth and overrides cellular 
arrest mechanisms despite increasing levels of p53 tumour suppressor protein.
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1.2.3.3 Indirect inactivation : Co-factors of the p53-Mdm2 loop
p53 is also inactivated by alterations in co-factors of the p53-mdm2 negative feedback 
loop such as AKT Kinase, PTEN and ATM Kinase. Alterations in these co-factors 
have been associated with other tumour suppressors' inactivation, e.g. BRCA1, Bcl-2, 
TGF-p, and CRC syndromes such as PTEN Hamartoma Syndrome (Table 1.2).
a) AKT kinase phosphorylates Mdm2 and induces migration of phosphorylated- 
Mdm2 into the nucleus where it inactivates p53. Hence, AKT over-expression can 
lead to p53 suppression (Ogawara et al., 2002, Gottlieb et al., 2002).
b) PTEN is upregulated with p53 activity in response to stress. PTEN reduces AKT 
activity which results in decreased Mdm2 phosphorylation and intranuclear migration. 
Intranuclear Mdm2 acts in the classic negative feedback loop within the nucleus 
(Soussi, 2008, Mayo and Donner, 2002). Mutated PTEN is inactive and unable to 
inhibit AKT. This promotes continuous Mdm2 phosphorylation and intranuclear 
migration leading to continuous p53 degradation thus reducing p53 tumour 
suppressive ability (Choi et al., 2006).
c) Other co-factors occur upstream of the p53 -Mdm2 interaction and are responsible 
for p53 induction. Ataxia Telangectasia Mutated (ATM) kinase phosphorylates p53 
and Mdm2 in response to irradiation. The phosphorylation of Mdm2 and p53 reduces 
the efficacy of the negative feedback loop resulting in p53 increase and cell cycle 
arrest/ apoptosis. Mutations of ATM kinase prevent this response allowing irradiated 
cells to escape cellular growth constraints.
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1.2.3.4 Indirect inactivation : Nuclear exclusion
Extrusion of p53 into cytoplasm has been observed in certain tumours such as breast 
(Moll et al., 1992) and colon (Bosari et al., 1995), and neuroblastoma and malignant 
melanoma (Weiss et al., 1995, Moll et al., 1995). It is thought the nuclear extrusion of 
p53 protein prevents p53 from performing its functions which are primarily through 
intra-nuclear interactions.
1.2.4 p53 : Loss of Protective & Gain of Oncogenic Function
p53 mutation is the most common mechanism of p53 dysfunction. The mutant p53 
has impaired DNA-binding and transcription abilities resulting in impaired cellular 
regulation. This is referred to as "loss of function" (Levine, 2009, Olivier et al., 2009). 
Furthermore, the mutant p53 is able to complex with, and inactivate, wild-type p53 in 
cell culture thus exhibiting a "dominant negative" effect on the "loss of function". 
Finally, certain mutant conformational changes can result in acquisition of new pro- 
oncogenic abilities, known as "gain of function". This includes transcription of 
tumour growth promoting factors such as MYC and VEGF (Sigal and Rotter, 2000); 
or disruption of other pro-apoptotic factors such as p73 (Wiman, 2006, Strano et al., 
2000).
These alterations in function not only promote tumour growth but may induce chemo- 
resistance with subsequent impact on prognosis. Hence, p53 mutations not only cause 
loss of tumour suppressive capacity, but can also additionally become pro-oncogenic, 
which allows these mutated cells to avoid both, p53-dependant and p53-independent 
apoptosis, resulting in unregulated propagation culminating in carcinogenesis.
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1.2.5 Anti-p53 auto-antibody
Anti-p53 auto-antibody was first reported by Crawford et al in 1982 in 9% (14/155) of 
patients with breast cancer (Crawford et al., 1982). Further interest in anti-p53 auto- 
antibody declined due to the lack of accurate quantification methods and no 
observable clinical relevance. Research into the auto-antibody was invigorated in the 
1990s when the role of p53 in carcinogenesis was increasingly recognized. The exact 
cause of induction of anti-p53 auto-antibody production is unknown but is thought to 
be associated with the presence of p53 mutation and p53 protein over-expression 
(Figure 1.4).
Anti-p53 auto-antibody is not normally present as the wild-type p53 protein is intra- 
nuclear, expressed at low concentrations, not expressed on surface of cells and hence 
escapes detection by the immune system (Bargonetti and Manfredi, 2002, Haupt et al., 
1997). In abnormal cells, p53 protein is stabilised mainly through p53 gene mutation, 
but can also be stabilised by other mechanisms such as proto-oncogene-binding or 
inhibition of negative regulatory pathways (Section 1.2.3). This causes high intra- 
nuclear p53 protein accumulation which then escapes into the cytoplasm. The 
resulting high cytoplasmic p53 levels increase the likelihood of p53 being degraded 
by proteosomes and presented on cell surfaces to be recognised by T-cells in a MHC 1 
response (Bueter et al., 2006). The auto-antibody recognises epitopes on the terminal 
regions of the protein, and hence auto-antibody production can be triggered by either 
the wild-type or the mutant p53, provided sufficiently high levels of these immuno- 
dominant epitopes at present at the cell surface (Schlichtholz et al., 1994).
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Figure 1.4: Proposed m
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Another possible antigen presentation mechanism is where cancer cells containing 
high cytoplasmic concentrations of p53 undergo necrosis and release p53 into the 
blood and lymphatic system. These antigens are captured Antigen Presenting Cells 
(APC) in their normal scavenging role and presented as MHC class II response 
(Bueter et al., 2006).
1.2.5.1 Increased p53 levels induce the auto-antibody response
Mutation alone is insufficient to trigger the immune response as evidenced by several 
observations. Firstly, only 20-50% of patients with detectable p53 mutations produce 
detectable auto-antibodies. This is attributed to the type of mutation. For instance, 
missense mutations are more likely to produce a stable mutant p53 protein which is 
more likely to accumulate to sufficient levels to increase the likelihood of antigen 
presentation. Other mutations such as non-sense, frameshift and deletions often lead 
to truncated mRNA and unstable protein sequences which are less likely to 
accumulate and induce auto-antibody production (Forslund et al., 2001). Secondly, 
anti-p53 auto-antibodies most frequently recognise terminal epitopes but not the 
central domain with the majority of mutations (Saleh et al., 2004, Lubin et al., 1995a, 
Schlichtholz et al., 1992). This suggests mutation is not essential for anti-p53 auto- 
antibody production. Thirdly, large SV40 T-antigen stabilises p53 protein leading to 
accumulation of the wild-type protein which also induces auto-antibody production. 
These observations suggest that humoral response is triggered by elevated p53 protein 
levels rather than specifically directed at a mutated sequence (Saleh et al., 2004, 
Schlichtholz et al., 1994, Legros et al., 1994, Lubin et al., 1993). Mutation simply 
happens to be the most common mechanism of p53 accumulation.
1.2.5.2 Differences in humoral response and presence of p53 mutation
There are discrepancies between the presence of mutation, protein expression and 
auto-antibody production which can be attributed to the methods of detection. 
Historically, direct sequencing for mutations localize most mutations to exons 5-8 and 
to a lesser extent 4,9,10. Many studies subsequently screened only these areas leading 
to substantial screening bias as it is now known that 10% mutations occur outside 
these areas (Chang et al., 2005, Forslund et al., 2001). p53 protein expression is 
subject to sampling/biopsy errors, and older studies have different immuno- 
histochemical, fixation, parafinisation, antigen and antibody retrieval and observer 
scoring techniques. Finally, the auto-antibody was initially detected using 
immunoblots or in-house ELISA. This led to a vast range of reported frequencies 
within individual cancers because of different cut-off values used (Table 3.1). 
Although commercial ELISA are now widely available, auto-antibody detection can 
still vary depending on different manufacturers (Table 3.2) (Rohayem et al., 1999).
Finally, the differences in the individual's immune systems cannot be ignored. The 
humoral response is dependant on an individual's unique MHC presentation. Patients 
with similar cancers and same mutations do not necessarily mount the same immune 
response (Angelopoulou et al., 1997). Also, anti-p53 auto-antibody titres increase and 
decrease reflecting tumour load. However, patients who are sero- positive at diagnosis 
do not generally sero-convert following curative complete resection i.e. the system 
has been primed (Metcalfe et al., 2000, Lubin et al., 1995b). Conversely, patients who 
are sero-negative do not develop an auto-antibody response, despite disease 
progression and metastases. This is discussed in more detail in Section 3.5.4.
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1.3 Anti-hTERT auto-antibody in Colorectal Cancer
Anti-hTERT auto-antibody is a humoral response to re-induction of hTERT which is 
the main component in reactivation of telomerase activity which is required for CRC 
cell immortalisation. The importance of hTERT and telomerase activity in normal and 
cancer cell immortality is discussed (Section 1.3.4). The results of the only study to 
detect anti-hTERT auto-antibody are summarised (Section 1.3.6). First, normal 
cellular mortality and the importance of DNA telomere length in mortality is 
discussed (Section 1.3.1), followed by the function of telomerase enzyme in telomere 
elongation (Section 1.3.3) and its impact on overcoming mortality.
1.3.1 Cellular mortality
Cells have a finite reproductive capability as demonstrated by in-vitro human 
fibroblasts studies. Hayflick showed that human fibroblasts entered a period of 
reduced replication after a certain number of population doublings (pd) suggesting the 
cells had reached a mortality barrier (Hayflick and Moorhead, 1961). Another elegant 
experiment compared senescence in population doublings of normal diploid cell in- 
vitro, with population doublings of its frozen counterparts which were frozen earlier 
on before senescence was reached. On thawing at a later date, the frozen cells 
resumed cell replication until it reached the same number of population doublings as 
had been reached by its non-frozen counterparts, showing that this mortality barrier 
was due to an internal mechanism controlling the number of population doublings, 
rather than the simple passage of time i.e. biological age, not chronological age. 
(Hayflick, 1965).
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Watson et al had previously described the mechanism of DNA replication (Watson, 
1972). The semi-conservative nature of eukaryotic DNA replication leads to 
progressive loss of terminal DNA sequences due to the mechanism of action of DNA 
polymerase which only acts in the 5' -> 3' direction. Thus, each replication cycle 
results in loss of terminal DNA sequences potentially leading to loss of vital DNA 
encoding for vital genes. This problem is overcome by telomeres.
Telomeres are terminal DNA repetitive tandem 6 base sequences (TTAGGG) which 
do not code for gene products. Telomeres are lOkbp long consisting of approximately 
1500 - 1800 of these TTAGGG repeats (Kirn et al., 1994). Telomeres protect DNA as 
these non-coding telomeric DNA sequences are shortened during cell replication, thus 
preventing loss of vital coding DNA. Telomeres are eroded at 50 -200 bp per 
population doubling in human lymphocytes and fibroblast studies (Allsopp et al., 
1992, Janknecht, 2004). As discussed before, cells eventually reach a period of 
senescence after a certain number of population doublings caused by an internal 
mechanism. Olovnikov postulated that this semi-conservative DNA replication model, 
with its resulting progressive loss of terminal DNA sequences leading to shorter 
unstable DNA, was responsible for the cellular senescence and growth arrest observed 
in these studies. The proposed term for this regulation of cell replication was the 
"mitotic clock" (Olovnikov, 1973).This postulation was only supported much later 
when the telomeric sequence was discovered, initially in protozoa, then in humans, 
thus enabling telomere length to be measured (Blackburn and Gall, 1978). Subsequent 
work confirmed telomeric shortening occurred with each DNA replication, and this 
also predicted the replicative capacity in human fibroblasts (Allsopp et al., 1992).
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1.3.2 Telomerase Enzyme
Telomerase is a eukaryotic ribonuclear RNA-dependant reverse transcriptase enzyme 
which functions to re-construct telomeres and increase telomere length. Kim et al 
showed that this ability to elongate telomerase led to indefinite proliferation not only 
in normal cells, but was also a necessary requirement for cancer cells. Rapid growing 
cancer cells are subject to the similar growth constraints of normal cells and would 
also reach a period of senescence i.e. mortality (Kim et al., 1994). Re-establishment of 
telomere length by telomerase activity allowed the cancer cells to proliferate 
indefinitely. Hence, telomerase was also known as the "immortality" enzyme.
Telomerase enzyme consists of 3 sub-units: a RNA template (hTR), human 
telomerase associated protein (hTAP) and human telomerase reverse transcriptase 
(hTERT) (Nakamura et al., 1997, Harrington et al., 1997, Feng et al., 1995). The hTR 
is complementary to the human telomeric TTAGGG sequence, and forms the template 
for telomere elongation. hTERT is the catalytic component and the rate-determinant 
of telomerase activity. The mechanism of telomere elongation is described (Section 
1.3.3). Telomerase was first described in Protozoa Tetrahymena (Greider and 
Blackburn, 1985). Telomerase activity peaks in utero, at 18 - 21 weeks gestation and 
is repressed to almost undetectable levels, except in proliferative self-renewing cells 
which require a low but indefinite proliferative rate, such as lymphocytes, trachea and 
bronchi, basal cells of the epidermis and intestinal crypt cells (Forsyth et al., 2002, 
Shay and Wright, 2005). Telomerase is re-expressed at higher levels in 90% of all 
cancers making it a sensitive marker for neoplasia (Masutomi et al., 2000).
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1.3.3 Telomerase Mechanism of Action
A variety of protein sites on the telomerase enzyme are involved and the exact motion 
in telomere elongation is unknown. However, the mechanism can be simplified as 
follows (Figure 1.5).
The first stage is "Binding", where the hTR template attaches to the complimentary 
TTAGGG terminal telomere sequence of the DNA. The hTR template overhangs 
beyond the telomere end.
The second stage is "Elongation" where complementary nucleotides are attached to 
the overhanging hTR sequence. The nucleotides are arranged and secured with the 
DNA deoxyribose backbone.
Finally, "Translocation" occurs, where the telomerase enzyme and hTR component 
slides forward onto the next terminal TTAGGG sequence.
The process is repeated, starting with "Binding", resulting in progressive elongation 
of the telomere.
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Figure 1.5: Telomerase mechanism of action
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1.3.4 Telomerase "Immortality" and Carcinogenesis
Normal cells have a finite replicative capacity determined by the internal mitotic 
clock caused by telomere shortening every DNA replication cycle. The cells then 
reach a period of "senescence", characterised by slow replication or cell growth arrest. 
Human fibroblasts display this "senescence" after 40 - 70 population doublings. This 
"senescence" was overcome by transfection of these cells with proto-oncogenic 
viruses such as SV40 large T-antigen, HPV16 E6 and HPV16 E7 (Ozer, 2000). These 
transformed cells were able to continue a further 20 - 30 population doublings. This is 
a substantial (approximately 50%) increase in replicative potential considering 
senescence occurs at 70 population doublings.
Following this additional population doublings, the cells enter a "crisis" phase which 
is characterised by DNA loss and cell death. Newbold showed that human dermal 
fibroblasts exposed to carcinogens were subject to this "crisis" (Newbold, 2002). In 
rare instances (< 106 cells), a single clone emerges from this phase to demonstrate a 
selective growth advantage over the other cells. This suggested another mechanism, in 
addition to oncogenic transformation to overcome senescence, was required for 
transformed cells to continue indefinite proliferation or "immortality". This indefinite 
proliferation would drive clonal selection in progression of neoplastic tissue. The 
importance of telomerase in overcoming "crisis" was hinted at by the presence of the 
active telomerase enzyme in human cancer tissue, cancer cell lines and in-vitro 
transformed cell lines (but not normal human cells) using a modified PCR known as 
Telomerase Repeat Amplification Protocol (TRAP) (Hirose et al., 1997).
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Wright et al suggested a "2-hit" hypothesis, introducing the term Mortality 1 (Ml) for 
the initial period of "senescence" which is overcome by transformation of tumour- 
suppressors; and Mortality 2 (M2) for the second mortality "crisis" barrier 
characterised by cell death (Wright et al., 1989). The importance of telomere length 
and telomerase activation in the 2-hit hypothesis is explained as follows. The aging 
cells have increasingly shorter telomeres because of semi-conservative DNA 
replication. Following a certain number of population doublings ("aging") the 
telomeres become critically short hence endangering vital DNA coding sequences. 
Certain telomeric changes, such as destabilisation of the telomere cap is recognised by 
cell growth regulators such as p53 (Hemann et al., 2001). This recognition is similar 
to recognition of DNA breaks. Senescence is initiated as a protective mechanism 
against propagation of these defective cells. This barrier is termed the Mortality 1 
(Ml) barrier. Ml can be overcome by inactivation of p53, or other tumour-suppressor 
genes ("Transformation"). The transformed cells are able to continue replications 
until telomeres are critically short, resulting in chromosomal destabilisation and end- 
to-end fusion. The resulting dicentric chromosomes and DNA breakage now promote 
apoptosis, not senescence, resulting in the second mortality barrier (M2). Re-initiation 
of telomerase activity stabilises telomere length and overcomes M2. This is required 
for even transformed cells to achieve immortality as human dermal fibroblasts 
exposed to carcinogens (SV40 large-T, HPV El6) are unable to overcome M2 
(Newbold, 2002). In landmark trials, cells similarly exposed, but with addition of 
hTERT, resulted in immortality (Hahn et al., 1999, Hahn et al., 2002). Other studies 
showed introduction of a mutant hTERT which inactivate telomerase in tumours 
resulted in telomere shortening and transformed cancer cell death (Hahn et al., 1999).
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1.3.5 Alternative Lengthening of Telomeres
Telomerase length and immortality is not solely dependant on telomerase activity as 
shown by 2 observations (Kirn et al., 1994). Firstly, in mice (mTR) knock-out studies, the 
mice cells were able to activate an alternative mechanism of telomere length 
maintenance. Secondly, not all in-vitro immortalised cell lines (e.g. with SV-T40 large 
antigen) have detectable telomerase activity.
Alternative Lengthening of Telomeres (ALT) is a mechanism of maintaining telomere 
length without telomerase, and was first described in humans by Bryan et al. (Reddel, 
2000, Bryan et al., 1995). The main mechanism is likely to be DNA recombinational as 
analysis of ALT dependant human cells show heterogeneous telomere length ranging 
from undetectable to abnormally long (Bryan et al., 1997a, Henson et al., 2002). 
Although up to 50% of SV4-irnmortalised fibroblasts used ALT, most epithelial and 
mesothelial cell lines are telomerase positive (Perrem et al., 2001). Furthermore, human 
tumours and human tumour derived cell lines display only 7% ALT (Bryan et al., 1997b). 
The high frequency of ALT in cell lines caused by tumour-suppressive DNA viruses 
suggest p53 suppression may activate ALT. Alternatively, ALT may be repressed by 
telomerase enzyme positivity as shown by low proportion of ALT in human telomerase 
positive cancer lines. This ALT mechanism is not explored in this thesis. However, this 
section is included as there is intense research into ALT, as its presence threatens the use 
of anti-telomerase therapy in cancer.
1.3.6 Anti-hTERT auto-antibody
Masutomi et al first described a technique of producing purified hTERT using 
recombinant technology (Masutomi et al., 2000). The recombinant hTERT protein was 
confirmed by WB. The WB confirmed a 127 kDa protein band in lysates of cells 
transfected by anti-hTERT antibody, but not in non-transfected cells. Secondly, in vitro 
procedures were used to transcribe hTR, which when combined the hTERT resulted in 
telomerase activity detected by TRAP. This purified hTERT was then tested in WB for 
the presence of anti-hTERT auto-antibodies. Serum samples from 18 healthy volunteers 
were compared with serum from 30 hepatocellular (HCC) patients, 16 liver cirrhosis 
(LC) patients, 7 patients with chronic hepatitis (CH) and 12 patients with other 
malignancies (colorectal, gastric and lung) in WB using the recombinant hTERT 
embedded in the membrane. Serum from patients with HCC and various malignancies 
produced a 127kDa band whereas no protein detection occurred with HCC, LC or normal 
or normal volunteers. The authors confirm this as anti-hTERT as it reacted to hTERT and 
was not present in non-cancer patients.
The levels of anti-hTERT auto-antibody were then measured in an ELISA. The serum 
anti-hTERT auto-antibody titres in HCC and other malignancies were significantly higher 
than normal controls. Furthermore, there was significant step-wise increase in anti- 
hTERT from CH to LC, and LC to HCC, suggesting and increased telomerase activity 
with carcinogenesis. No further analysis was performed on this pilot work, and neither 
have there been any published reports since then.
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1.4 Thesis Summary
This thesis aims to investigate the clinical significance and the correlation between the 
humoral response (anti-p53 and anti-hTERT auto-antibody) against the two key events in 
carcinogenesis resulting in Tumour Associated Antigens (p53 mutation and hTERT re- 
expression) required for cancer cell immortality. The methods used are described 
(Chapter 2). The significance of anti-p53 auto-antibody in cancer and in CRC is 
evaluated (Chapter 3). The long-term prognostic significance of anti-p53 auto-antibody 
is then investigated in a cohort of patients with minimum 5 years follow-up (Chapter 4). 
The optimisation of a method to detect anti-hTERT auto-antibody is described with 
suggestions for future improvement (Chapter 5).
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2 Chapter 2: Materials and Methods
Section 2.1 describes patient recruitment, Section 2.2 describes ELISA validation, 
Section 2.3 describes statistical methods used to investigate the significance of anti-p53 
auto-antibody in CRC and Section 2.4 describes WB optimisation in attempts to isolate 
anti-hTERT auto-antibody.
2.1 Subject Recruitment and Sample Collection
Blood samples were obtained following ethical approval for research purposes from 
patients with colorectal carcinoma (CRC) treated at Hull and North East Yorkshire NHS 
Trust, and from 28 controls (Kumar R, LEG 05/02/091; Rao VS LEC 10/03/213). Pre- 
operative sera from ninety two patients who were treated with curative intent for biopsy- 
proven CRC between 1996 and 2001 were available for analysis (Chin KF, LEC 
03/98/41, O'Hara R, LEC 07/09/102). All bloods were collected in pre-assessment clinic 
7-10 days prior to surgery. Each sample of whole blood was collected for simultaneous 
processing into serum and plasma.
2.1.1 Serum and plasma preparation
A sample of whole blood (7ml) was taken into BD Vacutainers (BD Bioscience, 
Oxford, UK) and refrigerated for 30 minutes. The sample was then centrifuged at 2000g 
for 10 minutes at room temperature. The supernatant was pipetted out to obtain the serum
70
sample. Sera was divided into SOOul aliquots in 1.5ml polypropylene tubes and stored at 
-80°C until analysis. Plasma was derived from whole blood collected in BD Vacutainers® 
ethylenediaminetetraacetic acid (EDTA) tube which prevents clotting and consumption 
of coagulation factors. The whole blood was refrigerated for 30 minutes and centrifuged 
at 1500g for 5 minutes. The supernatant (plasma) was similarly pippeted into SOOul 
aliquots hi 1.5ml polypropylene tubes and stored at -80°C until analysis. Repeated freeze- 
thaw cycles of serum and plasma were avoided.
2.1.2 Patient data collection
Sera were available for 92 CRC patients treated between 1996 and 2001 and 28 non- 
cancer controls of similar age and sex. Parameters recorded were patient demographics, 
date of diagnosis defined by date of biopsy, surgical procedure undertaken, final 
pathological staging and duration of follow-up (defined as time to death or time last seen 
in clinic / hospital). Death was recorded in hospital case notes. In addition to this, due to 
the relatively high probability of death hi patients in this series (elderly population, 
malignant disease with major surgery and long follow-up, up to 10 years in some) and the 
possibility of non-hospital death (e.g. in hospice or community) where death may not be 
recorded in hospital case notes, the electronic patient information system was checked 
and the general practitioners were contacted where doubt existed. This was especially 
valuable and identified 16 patients who had moved away, died at home / residential home 
and those with recurrent disease deemed as "palliative only" and were no longer followed 
up by the surgical teams. Causes of death were recorded as that registered on death
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certificates. Although this allowed greater completion of information, the cause of death 
in these circumstances was not issued by the cancer clinician. This could lead coding 
errors as non-cancer related death could be erroneously attributed to cancer (as patients 
were already in nursing / residential homes suggesting non-cancer co-morbidity). 
Alternatively, death in hospices due to end-stage cancer could be coded as non-cancer 
death (e.g. bronchopneumonia). The GP / health care worker notes of the final events pre- 
ceding death were not available and even if so, the retrospective information could still 
lead to potential inaccurate cancer death coding.
2.2 Enzyme Linked Immunosorbent Immunoassay (ELISA)
Enzyme Linked Immunosorbent Immunoassay (ELISA) is an immunological technique 
used to semi-quantitatively assess for presence of antibody/protein of interest (Adler et 
al., 2009, Engvall and Perlmann, 1971).
2.2.1 ELISA principles
The ELISA principles are illustrated in Figure 2.1. A suitable antigen which binds to the 
antibody of interest is fixed on an ELISA plate. The test sample containing the antibody 
is poured into these wells and the antibody binds to the immobilised antigen. The excess 
solution and non-specifically bound antibodies are washed away. A secondary antibody, 
which targets the species-specific portion of the primary antibody is poured in. The 
secondary antibody is conjugated to a detection enzyme such as horse-radish peroxidase. 
The excess solution is washed away along with non-specifically bound secondary
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antibodies. This leaves the antigen, bound to the primary antibody of interest, which is in 
turn attached to the secondary HRP-conjugated antibody. A suitable detection reagent is 
added. The HRP enzymatically oxidises the detection reagent leading to a change in 
colour of the solution over a 5 - 30 minutes. The optical density (OD) of each well is 
read on a plate spectrometer. The colour intensity is dependant on the amount of HRP, 
which is in turn dependant on the amount of secondary antibody and hence, the amount 
of the primary antibody. By using positive and negative controls, the primary antibody 
litres can be measured using sample OD. In this thesis, the antibody of interest (anti-p53 
auto-antibody) lies between the p53 antigen and the HRP- anti-human HRP.
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Figure 2.1: Principle of anti-p53 auto-antibody ELISA
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2.2.2 ELISA protocol for Measurement of Anti-p53 Auto-antibody
Anti-p53 auto-antibody titres were measured using a commercially available ELISA - 
p53 ELISA PLUS (Autoantibody) Kit (Cat. No. QIA53, Calbiochem, Darmstadt, 
Germany). The 96-well ELISA microplates were pre-coated with recombinant human 
wild-type p53 protein, to which any anti-p53 auto-antibodies within serum samples 
would be expected to bind. The manufacturer's protocols were used (User protocol 
QIA53. Rev. 19, May 2005). Subjects' sera were diluted 1:100 and incubated alongside 
the provided calibrator samples at dilutions of 1, 0.67, 0.5, 0.33 and 0.16; a negative 
control and 2 blank wells for 1 hour at room temperature. All samples were assayed in 
duplicate at lOOul/well. After incubation, the plate was washed five times with the 
manufacturer's wash buffer to remove non-specifically bound antibodies, leaving anti- 
p53 auto-antibodies bound to the plate. The detection reagent, a goat-HRP anti-human 
polyclonal antibody (lOOul), was added to each well to bind to any captured human anti- 
p53 auto-antibody. The plate was incubated for a further 1 hour at room temperature, 
followed by another five washes to remove the excess unbound HRP detection reagent. 
The manufacturer provided Substrate solution (3,5,5 tetramethylbenzidine, TMB) was 
added to the plate and incubated for 30 minutes in the dark. The HRP enzymatically 
converts the chromogenic TMB substrate from colourless to blue. The reaction was 
stopped with 50ul of the provided stop solution (2 M Hydrochloric Acid, HC1) which 
turns the reaction mix yellow. The optical density was measured at 450nm (OD45onm) 
using a 620nm reference filter in order to compensate for possible differences in the 
material of the microtitre plate (Labsystems, Multiskan MS, Finland).
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2.2.3 ELISA plate configuration
A sample ELISA plate is shown in Figure 2.2. Note the following:
1. Decreasing colour intensity from rows A to H, consistent with decreasing auto- 
antibody concentration of the calibrators i.e. Row A 1.0 U, Row B: 0.67; Row C: 0.5
2. A; Strongly positive sera sample
B; Positive but not as strong as sample A, suggesting auto-antibody presence, but at 
lesser concentration to sample A
C: Weak colour intensity. Visually, this intensity is between calibrators D (0.33 U) 
and E (0.16). Accurate quantification of is performed by means of a photo- 
spectrometer
3. All paired samples have similar colour intensity demonstrating accuracy of 
technique, i.e. no pipetting inaccuracies or sample variation
Figure 2.2: Typical ELISA plate: Vertical rows (A-H); Horizontal columns (1-12).
Calibrators 
(duplicates)
i i
Sera 
(duplicates)
A: Strongly positive
B: Positive sera 
(duplicates) but less 
intense than (A)
Ci Weakly 
positive sera Columns: 1 -» 12
2.2.4 ELISA Calibration Curve
Calibration graphs were constructed for each plate by plotting the calibrator dilutions, 
which represent the relative antibody titres (neat calibrator, 1 = 100U auto- 
antibody/ lOOul), on the>>-axis. The OD450nm of each calibrator dilution is plotted on 
the *-axis. A "line-of-best-fit" was generated with a resulting quadratic equation 
(Microsoft® Excel 2002) (Figure 2.3) The auto-antibody concentration is either read 
from the graph, or more accurately, by substituting the OD45onm of the sample into the 
equation obtained from the line-of-best-fit. Example from plate 2:
Auto-antibody titre (y) = 0.0114(jt2) + 0.7903(;c) -0.1652, where x = OD45onm sample 
Figure 2.3: Calibration curve generated using calibrator dilutions and corresponding
Plate 2
R2 = 0.9854
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2.3 Statistical analysis
Statistical advice was obtained from Rachel Waddington-Clarke, a statistician at the 
University of Hull. The Null Hypothesis was that there was no difference in clinico- 
pathological parameters or survival in colorectal cancer patients with anti-53 auto- 
antibody and those without. All tests were two-tailed and significance was set at a = 
0.05. Analysis was performed using the Statistical Package for the Social Sciences, 
SPSS, and v.14 for Windows (SPSS Inc, Chicago, USA).
2.3.1 Assessment of ELISA technique / methodology
The OD450nm of all samples were recorded. Accuracy of each ELISA plate was 
assessed by measuring the Co-efficient of Variation (CoV) of duplicate samples and 
the correlation co-efficient (R2) of the lines-of-best-fit. A CoV > 20% indicates a 
difference of >20% in duplicate OD450nm of a sample suggesting erroneous technique.
2.3.2 Categorical data
Categorical data was divided into nominal groups (e.g. anti-p53 auto-antibody 
positive vs. negative) or ordinal groups (age <70 and age > 70) and analysed using the 
Chi square test (y2) for presence or absence of anti-p53 auto-antibody. Data in each 
category (Categories: Control vs. patient; age <70 vs. age >70; sex; recurrence) were 
mutually exclusive, meaning a value can only belong to one group or the other. 
Additionally, when individual group numbers were small, the groups were collapsed 
in a rational fashion based on biological parameters to obtain larger sample sizes. y2 
analysis was performed for anti-p53 correlation with categorical variables. Fisher's 
Exact test was used when frequency in a group was < 5.
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2.3.3 Measurement of Prognosis
The follow-up distribution was assessed and the appropriate statistical tests chosen.
2.3.3.1 Follow up Distribution
Kolmogrov-Smirnov analysis showed the follow-up period to be to be skewed (p = 
0.015, Figure 4.5), thus limiting survival analysis to non-parametric tests - Mann 
Whitney U-test (comparing 2 means) and Kruskall-Wallis test (comparing > 2 
means). Survival analysis is calculated using the time it takes for an individual to 
reach a pre-defined end-point such as time to recurrence or metastases. In this study, 
the end-points used were Overall survival (OS) and Disease-Free Survival (DPS). 
Individuals who were lost to follow-up were appropriately censored.
2.3.3.2 Kaplan-Meier Survival Curve
Kaplan-Meier survival analysis displays possible survival differences in various 
groups within a single variable (e.g. Dukes A-D) over time. Significance is calculated 
using a log-rank test. The curve displays the cumulative probability of reaching the 
defined end points (OS and DPS) from a pre-determined starting point (date of 
diagnosis). As a test of validity of this data, Kaplan-Meier analysis was first 
performed on known CRC prognostic factors, and compared with current literature. 
Seven clinico-pathological factors were incorporated into univariate Kaplan-Meier 
survival analysis - Dukes' stage, TNM stage, T-stage, N-stage, M-stage, Location and 
Differentiation. Once the validity this patient cohort was confirmed, survival analysis 
curves were performed for anti-p53 in OS and DPS. A limitation of Kaplan-Meier
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analysis is that ability to analyse only a single variable at a time. In order to assess 
significance of multiple factors at the same time within the same sample, a 
multivariate analysis model, Cox Proportional Hazards Regression Analysis was used.
2.3.3.3 Cox Proportional Hazards Regression Analysis
This analysis calculates a hazard function of an event occurring at any particular point 
in time, /. Using individual hazard functions from different variables, the cumulative 
hazard (risk) of an event occurring, in a particular individual with certain prognostic 
factors, at a time t, can be calculated (Cox, 1972). In this study, the event is death, the 
individual is a patient with colorectal cancer, and the prognostic risk factors which 
could be potentially incorporated into this model were anti-p53 auto-antibody status, 
tumour differentiation, Duke's stage, T-stage, N-stage, and M-stage. The number of 
prognostic factors selected for the Proportional Hazards Model should be limited to 1 
variable per 10-20 patients in order to reduce the risk of over-analysing the data. 
Over-analysing a small sample size can lead to co-linearity errors where a false 
positive prognostic significance is displayed when a variable is associated with other 
prognostic indicators, but not in itself truly independent. Hence the 7 clinico- 
pathological factors used in univariate analysis were reduced to four factors (10-20 
patients / factor) for a sample of 92 patients. The 4 factors selected were anti-p53 
auto-antibody (as the primary objective of this thesis) and 3 clinico-pathological 
parameters (Dukes'/TNM stage, T-stage and differentiation). N- and M-stage are 
strong prognostic factors but strongly associated with Dukes' / TNM overall stage and 
hence not used
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2.4 Anti-hTERT Auto-antibody: Objective
The first objective was to isolate the hTERT protein to establish a positive control. 
This was attempted by immunoaffinity chromatography, and hTERT presence was to 
be confirmed by Western blot (WB). Once isolated, the hTERT could be immobilised 
on a nitrocellulose membrane, and probed with patient sera in using WB to detect 
anti-hTERT auto-antibody. Alternatively, the hTERT could be used as the antigen in 
ELISA (Figure 2.1) to quantify anti-hTERT is patients' sera.
2.4.1 Preparation of Cancer Cell Lysate
Cell concentrations of 0.5 - 1 x 106 cell equivalents per well were used, which was 
later increased to 1 x 108 cell equivalents per well. A cell scraper (Helena 
Biosciences, Gateshead, UK) was used to remove cancer cells from a confluent 75cm2 
culture flask (Sarstedt, Numbrecht, Germany). Colo205, Colo320, LoVo, Caco, 
TD47, MCF7 and HT29 cancer cells (see Appendix, Section 7.3 for cell line details) 
were cultured in RPMI 1640 (PAA Laboratories, GmbH, Colbe, Germany), 0.3g /L L- 
glutamine (Sigma-Aldrich, Poole, UK), 10% Foetal calf serum (Biosera, East Sussex, 
UK) and 1% Penicillin / Streptomycin (Sigma-Aldrich, Poole, UK) and incubated at 
37°C. Details of reagents are shown in Appendix, Section 7.1. The contents of the 
flask were poured into a 50 ml polypropylene tube and spun at 400g for 3 minutes. 
The supernatant was discarded and the pellet resuspended in 10 ml PBS. 20^1 was 
removed and the cells were counted using an Improved Neubaeur haemcytometer. 
The remainder solution in the tube was centrifuged at 400g for 3 minutes. The 
supernatant was discarded again and the pellet resuspended in 1 mL Lysis buffer
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Protease Inhibitor Cocktail Set III (539134, Calbiochem, Darmstadt, Germany) and 
incubated on ice for 30 minutes to reduce enzymatic activity which would denature 
proteins such as hTERT. The solution was centrifuged at 10,000g for 5 minutes after 
which the supernatant was removed and stored at -80°C until future use.
2.4.2 Principles of the Streptavidin-Biotin Interaction
Streptavidin is the 52-kDa tetrameric protein product of Streptomyces avidinii and 
consists quaternary subunits with a ~13-kDa p-barrel biotin binding site (Hendrickson 
et al., 1989). Its key biochemical feature is its ability to bind with biotin to form one 
of the strongest natural non-covalent bonds in the order of ~10 13" 15 M"1 . This 
interaction was used in an immuno-affinity column to isolate hTERT. The 
biotinylated anti-hTERT antibody (Santa Cruz, sc-7212, Appendix 7.7) was passed 
down a streptavidin-coated agarose column (Figure 2.4), where it would be 
immobilised by the streptavidin-biotin interaction. A sample containing hTERT 
would then be passed into this column. The immobilised biotinylated anti-hTERT 
antibody should capture any hTERT in this solution. An elution buffer would then be 
used to break the anti-hTERT and hTERT bond, resulting in hTERT being eluted 
from the column.
2.4.3 Protocol for the Streptavidin-Biotinylated anti-hTERT column
The HiTrap  Streptavidin HP columns (GE Healthcare UK Ltd, Buckinghamshire, 
UK) contain Streptavidin immobilised in a 6% (w/v) cross-linked agarose matrix 
(Figure 2.4). The manufacturers' recommended methods of binding a biotinylated 
substance were used.
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Figure 2.4: HiTrap  Streptavidin HP 1ml Column
SUlf
\\
(http://www4.gelifesciences.com/)
All steps were performed in a cold room (4°C) and every sample loaded by "drop-to- 
drop" technique to avoid inclusion of air into the column. The binding buffer (20mM 
sodium phosphate, 0.15 M NaCl, pH 7.5) was prepared and passed through a 0.45 urn 
filter (Pall Corporation, NY, USA) to remove potential contaminants such as bacterial 
cell wall fragments or salt crystals. The stopper at the top of the HiTrap  column was 
removed and the 10ml of the buffer was loaded into the column using a syringe and 
"drop-to-drop" technique at a rate of approximately 1 ml/minute, which corresponds 
to approximately 30 drops/minute.
The biotinylated anti-hTERT antibody was obtained by custom biotinylation of a 
rabbit polyclonal anti-hTERT (0.2 mg/ml;3 ml in PBS, sc-7212; Santa Cruz, Autogen 
Bioclear UK Ltd., Wiltshire, UK). The antibody was introduced into the column at 
approximately 0.1 - 0.3 ml/minute. The resulting elute was collected into serial 0.5ml 
polypropylene tubes. A further 10 column volumes (10ml) of binding buffer was used
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to wash the column and remove unbound antibody. The elute was similarly collected 
in 0.5ml polypropylene tubes. The column was washed with 20% (w/v) ethanol and 
stored at 4°C for later use. If stored in ethanol, the HiTrap  column was re- 
equilibrated with 10 column volumes (10ml) of Binding buffer at a rate of 1ml/ 
minute.
The cell lysate/protein samples were introduced using a syringe, again using drop-to- 
drop technique at 0.1 ml/minute (approximately 3 drops/ minute) in the cold room 
(4°C). The column was washed with a further 10 column volumes (10ml) of Binding 
buffer at 1 ml/minute. Finally, Elution buffer (8 M Guanidine - HCI, pH 1.5) was used 
to break the interaction between biotinylated anti-hTERT and hTERT. The eluate 
containing hTERT was collected in polypropylene tubes containing NaOH 10M to 
neutralise the pH 1.5 of the Elution buffer and protect the protein in the elute. The 
column was then discarded as the relatively harsh elution conditions will potentially 
have damaged the streptavidin ligand within the column.
2.4.4 Principles of optimising Western Blot conditions
Western Blot (WB) was first described in 1981 to detect specific proteins within a 
sample (Burnette, 1981). The proteins undergo polyacrylamide gel electrophoresis 
(PAGE) where they are separated based on electrophoretic mobility, which is a 
function of charge and molecular weight i.e. the smallest molecules with highest 
charge move faster and furthest. These proteins are transferred onto a membrane 
which is probed with antibodies to detect the protein location. The protein molecular 
weight obtained by comparing to a pre-stained protein ladder
84
2.4.4.1 Acrylamide content
PAGE conditions such as acrylamide content, native vs. non-native or reducing vs. 
non-reducing conditions can be modified to obtain different information about the 
proteins loaded. The acrylamide content in separating gels can vary between 5% - 
30% (w/v) which determines the gel pore size. Higher % acrylamide allows greater 
resolution of light weight proteins as these proteins are slowed down by the 
increasingly smaller pore sizes. The 12% gel (small pore size) slows the proteins thus 
enforcing resolution. Conversely, lower acrylamide (3%) leads to larger pore sizes 
where fast-moving proteins migrate and accumulate beyond the gel (Figure 2.5). 
Similarly heavy proteins require lower acrylamide content (large pores) as smaller 
pores would restrict migration leading to proteins accumulating at the start of the gel. 
The stacking gel has lower % acrylamide content than the separating gel so that the 
proteins concentrate or "stack" at the interface between the 2 gels prior to being 
resolved in the separating gel (Wittig and Schagger, 2005, Laemmli, 1970).
Figure 2.5: Effect of varying the percentage (%) acrylamide in separating gels.
3% 6% 9% 12%
Red arrow shows direction of protein migration (Hempelmann, 2003)
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2.4.4.2 Native and Non-native conditions
Electrophoretic migration is dependant on the protein shape and charge:mass ratio. 
Proteins with different weights can still migrate anomalously into the same location 
due to compensatory charge and shape factors. Alternately, same molecular weights 
may migrate into different locations due to complex shape which slows its passage 
through the gel. This is reduced with Sodium Dodecyl Sulphate (SDS, C^IfeNaCUS, 
Mw 288.38), a detergent with two functions. Firstly, SDS denatures complex proteins 
into individual polypeptides; secondly, SDS applies a uniform charge per length of 
peptide, which renders the intrinsic charge of the protein negligible. In doing so, the 
protein's electrophoretic mobility is determined by its molecular weight, not its 
complex structure or intrinsic charge (Wittig and Schagger, 2005). SDS-PAGE is 
more commonly used than native PAGE. Native PAGE (without SDS) is still used 
when the composition and structure/function of bioactive proteins in its natural state is 
required e.g. metalloproteinases (Kastenholz, 2006).
2.4.4.3 Reducing and Non-reducing conditions
Complex proteins may be further broken down by boiling with reducing agents such 
as 2-0 Mercaptoethanol (2p-ME, C2H6OH, Mw: 78.13) or dithithreitol (DTT, 
C^ioC^Sa, Mw: 154.25). Reduction in this thesis was performed by boiling the 
protein at 99°C for 5 minutes with 10% (w/v) 2|3-ME prior to loading into the 
stacking gel. This disrupts disulphide bridges of tertiary and quaternary proteins 
structures thus "reducing" complex proteins to monomeric chains. This process also 
ensures protein migration is based on molecular weight only.
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2.4.5 Western Blot Protocol
A gel casting apparatus consisting glass plates, spacers, an assembly unit with 
securing screws and a water-tight base was used. The glass plates were washed in 
distilled F^O and cleaned with ethanol and air-dried. The 2 glass plates were opposed 
with spacers in-between to create a square mould for the liquid polyacrylamide gel to 
polymerise. The plates were held vertically by the clamping screws with the bottom 
secured into the apparatus.
The separating gel was prepared (Appendix 7.4) in a chemical fume hood as 
acrylamide is potentially neurotoxic. APS and TEMED were added only when the 
gel-casting apparatus was ready as any delay leads to premature gel polymerisation 
within the flask. The liquid gel was pipetted into the space between the 2 glass plates 
leaving 2 cm from the top for the stacking gel. Water-saturated butanol was pipetted 
onto the liquid gel to reduce exposure to air as molecular oxygen inhibits 
polymerisation by reacting with the S(V free radical.
The stacking gel (Appendix 7.4) was similarly prepared in the fume hood, again 
adding APS and TEMED last. The liquid stacking gel was pipetted and a plastic comb 
inserted into the square gel to mould the sample loading wells. This was left for 20 
minutes. The comb was removed and the gels were ready for use.
The sample/ loading buffer were made (Appendix 7.5). Bromophenol blue (BPB, 3', 
5', 5' 5' tetrabromophenolsulfonphtalein, Ci 9HioBr4O5 S, Mw 669.99) is a small 
negatively charged molecule used in the sample buffer as a coloured marker to 
migrate ahead of proteins which are usually colourless in the separation gel. This
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allows visualisation of the advancing front in the gel and reduces the risk of proteins 
being run past the anode and lost. This also allows visualisation of anomalous 
directions of the protein separation which could be a result of overloaded wells or 
separating gel distortion.
The protein samples were mixed with the sample / loading buffer with 2P-ME 
(10%w/v, for non-native conditions) and boiled (99°C, Sminutes, for reducing 
conditions). The samples were loaded ensuring no more than 40 ul per well to avoid 
cross-contamination between wells. A protein ladder (lOul Benchmark , 
Invitrogen) was loaded in a pre-determined well. The in-house gels were run at 200V 
for 60-90 minutes; precast gels were run at 100V for 45-60 minutes, or until the 
bromophenol blue front crossed the anode terminal.
The transfer buffer was prepared (Appendix 7.5 & 7.6) within 2 hours of use and 
stored at -20°C to reduce protein interaction/degradation when added to the separating 
gel. The 20% (w/v) methanol allowed the buffer to be kept at this temperature without 
freezing. Once separation was complete, the transfer buffer was poured into a tray 
with the gel.
2.4.6 Protein transfer
Protein transfer was performed by electroblotting, where a voltage gradient attracts 
the anionic proteins away from the gel and into a suitable membrane, usually 
nitrocellulose or polyvinylidene fluoride (PVDF) membrane, which is performed in 
an electro-blotting apparatus (Figure 2.6). The "sandwich" cassette is assembled with 
the black plate down. The following materials are laid in order: 1 sponge pad, 2
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filter papers, gel, nitrocellulose membrane, 2 filter papers, 1 sponge pad, and the clear 
plate of the cassette. This creates the "sandwich" where the filter paper and sponge 
pad on either side of the cassette compact the nitrocellulose membrane and gel 
together to allow good contact and facilitate direct protein transfer. The final order 
(Figure 2.7) is important as the anionic proteins travel toward the red anode. Hence, 
the separating gel must be on the side of the black cathode and the nitrocellulose 
membrane on the side of the red/clear anode. Failure to do se results in protein from 
the gel being transferred onto the filter paper, in the opposite direction to the 
nitrocellulose membrane.
The "sandwich" cassette is placed in the tank, matching the anode and cathode 
terminals. A metallic stirrer is placed in placed at the bottom with an ice block 
between the 2 cassettes. The transfer is performed in a cold room (4°C) on a magnetic 
plate. The stirrer creates continuous buffer movement. Transfer was performed at 
either 100V for 1 hour at 4°C, or 30V overnight at 4°C. The ice block, cold transfer 
buffer and transfer in the cold room all aim to keep the temperature low during 
protein transfer process as the electrical conduction through the buffer could lead to 
increased temperature and protein degradation. Once the transfer was complete, the 
membrane was placed in a Petri dish with blocking buffer until ready for probing with 
primary, then secondary antibodies followed by ECL detection.
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Figure 2.6: Electroblot protein transfer apparatus.
(www.plant.uoguelph.ca)
Figure 2.7: "Sandwich" cassette and direction of protein transfer
Nitrocellulose membrane
Gel
Filter paper
Sponge
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2.4.7 Blocking and Probing
The blocking buffer (Appendix 7.5) was used to reduce non-specific binding between 
the primary antibody and the membrane which background reading and increases 
band clarity. The following transfer/blocking schedules were used to maximise time 
usage:
a) Transfer 100V at 4C for 1 hour + block overnight at 4C
b) Transfer 30V at 4C overnight + block 1 hour at room temperature on shaker
c) Transfer 100V at 4C for 1 hour + block 1 hour at room temperature on shaker. This 
was the least used schedule due to the length of time required to perform PAGE and 
Western Blot in the same day.
The membrane was removed from the blocking solution and placed in another Petri 
dish containing PBS-0.05% (v/v) Tween and washed for 3 cycles at 5 minutes per 
cycle. After each cycle, the PBS-Tween was emptied and replaced with fresh PBS- 
Tween. Once washed adequately, the membrane was incubated with a primary 
antibody in 1% Marvel in PBS and incubated for 1 hour at room temperature on a 
shaker. This was poured out and the membrane was washed again for 3 cycles for 5 
minutes per cycle with PBS-Tween. The membrane was then incubated in a new Petri 
dish containing 1% Marvel in PBS with the secondary HRP-antibody for another hour 
on the shaker. The membrane was then similarly washed with fresh PBS-Tween for 
another 3 cycles, at 5 minutes per cycle. Once washed, the membrane was left in PBS 
to avoid dehydration while the detection reagents were prepared.
91
2.4.8 Enhanced Chemiluminescence (ECL)
The immobilised protein is indirectly bound to a secondary HRP-antibody which 
oxidises luminol to emit light which is captured on X-ray film (Figure 2.8) Light 
emission is magnified with "enhancing" agents, such as phenol in the Detection 
Solution. This technique is highly sensitive, being able to detect proteins 
concentrations of picogram (10~12) / ml to femtogram (10"15) / ml (Ornberg et al., 
2005). The molecular weight of the protein is the determined by comparing its 
location to a pre-stained molecular weight ladder. ECL was performed in a dark room. 
An equal amount of Detection Reagent 1 and Detection Reagent 2 (Western Blotting 
Detection Reagents and Analysis System; Amersham, Biosciences UK) were mixed 
immediately before use and incubated with the membranes for 1 minute. The 
membrane was placed between 2 sheets of clear transparent film ensuring no air 
bubbles were trapped. The membrane was placed protein-side up, with an X-ray film 
on top and the cassette closed. The initial exposure time was 5 minutes but was varied 
(5 seconds to 60 minutes). Three trays were prepared - developer solution (Tray 1), 
acetic acid (Tray 2) and fixer solution (Tray 3). After 5 minutes, the X-ray film was 
removed and placed in Tray 1 until protein bands appeared (approximately 5 seconds 
to 5 minutes). The film was transferred to Tray 2 (30 seconds), and then rinsed in 
Tray 3 by continuous rocking (10 seconds to 1 minute) until the background was 
transparent. This ensures the rinsing solution covers the film, and that the film does 
not adhere to the bottom of the tray which irreversibly imprints the film and obscures 
protein bands. The final molecular weight of the protein is determined by comparison 
with the membrane containing the pre-stained protein ladder.
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Figure 2.8: Principles of ECL detection and com
parison with protein ladder to determ
ine m
olecular w
eight (e.g. 37.1 kDA)
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3 Chapter 3: Anti-p53 auto-antibody in Cancer; Focus on 
Anti-p53 auto-antibody in Colorectal cancer
3.1 Introduction
The anti-p53 auto-antibody represents a humoral response to tumour associated 
antigens (TAA). This response is partly related to the underlying p53 mutation, but its 
long-term prognostic significance is unknown. The aim of this study is to investigate 
the incidence of anti-p53 auto-antibodies in all cancers in relation to p53 mutation 
rates, and then review the significance of anti-p53 auto-antibody in CRC.
3.2 Methodological Quality of Anti-53 auto-antibody studies
All published studies on anti-p53 auto-antibody (1979 - 2009) were retrospective or 
cross-sectional case control series. Sample sizes in individual studies were small with 
heterogeneous mix of different stage cancers (27-220 subjects tested, number of sero- 
positive patients 17-47). The largest single study was published by Tang et al with the 
largest sample size of 130 sero-positive patients in a cohort of 998 colorectal cancer 
patients (Tang et al., 2001). This included all stages thus leaving relatively small 
numbers of patients for stage-specific analysis. A non-systematic review had larger 
numbers but was more severely limited by heterogeneous population sample and 
different detection methods in individual studies (Soussi, 2000a). The primary 
outcome was not stated in most studies. All studies were retrospective case- 
comparisons and none were powered for survival outcomes.
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3.3 Frequency of Anti-p53 auto-antibody in AH Cancer
The reported frequency of anti-p53 auto-antibody in individual cancer studies vary 
significantly due to small sample sizes, stage bias (usually greater proportion of 
advanced stage tumours especially in earlier studies) and different detection methods 
used. In a landmark review, Soussi compiled results of 80 anti-p53 auto-antibody 
studies in 18 cancer types over a 20 year (1979 - 1999) period (Soussi, 2000a). The 
mean sero-positivity across all cancer types was 16.9% (1600 / 9489 patients, range 0- 
31%) compared with 1.45% (35 / 2404) in controls thus demonstrating remarkable 
specificity but poor sensitivity. Furthermore, half (17) the sero-positive control 
subjects were from a single study which reported an extra-ordinarily high control 
sero-positivity (24%, 17/70) which is in contrast to almost all other publications that 
consistently report <1% sero-positivity in healthy samples (Wollenberg et al., 1997). 
Taking this into account, anti-p53 auto-antibody specificity should be near 100% for 
malignancy. Anti-p53 auto-antibody is usually measured in patients' sera but has also 
been detected in ascitic fluid of patients with ovarian cancer (Abendstein et al., 2000, 
Angelopoulou et al., 1997), saliva of patients with oral cancer (Tavassoli et al., 1998) 
and in pleural effusions (12.5%) associated with lung, colon and pancreatic cancer 
(Munker et al., 1996). This thesis summarises results of all anti-p53 auto-antibody 
related publications in all cancers from 1999 - 2010, and combines this with results of 
Soussi's review (1979-1999) to provide the largest anti-p53 auto-antibody review to 
date, spanning 30 years (1979-2010) (Table 3.1). Salient conclusions of individual 
studies are also included.
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Table 3.1: Cum
ulative reported frequencies of anti-p53 auto-antibody (anti-p53) in controls and individual cancers. Cancer types are listed in 
order of decreasing anti-p53 auto-antibody frequency. The reported studies within each cancer type are listed in reverse chronology.
G
roup
A
uthor (Year)
Anti-p53 positive %
 (n)
Sum
m
ary of Study and tum
our type
H
ealthy/ 
Benign
(Suppiahetal., 2008) 
(Cai et al., 2008) 
(Attaetal.,2008) 
(Mattioni etal., 2007) 
(Akere and Otegbayo. 2007) 
(M
uller etal. 
.2006) 
(Chang etal..2005) 
(Fonsecaetal.. 2003) 
(Shimada etal. 
.2003) 
(Neri etal.. 2003) 
fN
um
aet al.. 2001) 
(Mack etal..2000) 
(Chow etal.. 2001) 
(Moch etal..2001) 
(Hofele et al.. 2002) 
(Hagiwara et al., 2000) 
(Ralhan etal.. 2000) 
(Bielickietal., 1999) 
(Soussi, 2000a) 
Total
0(0/28) 
0(0/30)
17.2 (5/29): 50 (13/26)"
0(0/64)
8.9 (4/45)
0(0/57);0<0/379)b 
0(0/40) 
0(0/15)
6.3(10/205)a
:7(13/189)b
0(0/51)
0 (0/9)
2.2(1/46)
3.6(1/28)
1.5(2/130)
0(0/80)
0(0/13)
8(4/50)
0 (0/28)
1.5 (35/2404)
2.2 (88 / 3946)
Com
parative stud) 
with colorectal carcinom
a
Com
parative study \\iih o
esophageal carcinom
a
Com
parative stud\ \\ith hepatocellular carcinom
a
Com
parative study with gastric carcinom
a
Com
parative study with hepatocellular carcinom
a
Single study ot'am
i-p53 in v
arious can
cers
Com
parative study with colorectal carcinom
a
Com
parative study w
 ith gliom
a
M
ulti-institutional study ofanti-p53 in v
arious can
cers
Com
parative study with lung carcinom
a
Com
parative study with uterine, o
v
arian, cervical carcinom
a
Com
parative study w
 ith SCl.C
Com
parative study with head and neck carcinom
a
Com
parative study with skin carcinom
a (SCC/ BCC)
Com
parative study with oral SCC
Com
parative study with o
esophageal carcinom
a
Com
parative study with lung carcinom
a
Com
parative study with colorectal carcinom
a
Literature review
 ot'anti-p53 in v
arious can
cers (1979-1999)
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O
esophageal
(Cai et al.. 2008)
(Muller et al., 2006) 
(Bergstrom et al.. 2004)
(Shimada et al., 2003) 
(Kozlowski et al., 2001) 
(Shimada etal.. 2000)
(Hagiwaraetal., 2000) 
(Ralhan etal..2000)
(Soussi. 2000a) 
Total
39.1 (18/46)
20(10/50) 
73.8(31/42)
29.9(90/301)
26.6 (20/75)
40(14/35)
28(13/46) 
60 (36/60)
31(85/274) 
34.1 (317/929)
Correlates with advanced histological grade, stage, lym
ph node m
etastases
and decreased tum
our response following radiotherapy
No correlation with stage or prognosis
No correlation with elinico-pathological param
eters, tum
our size or
survival
M
ulti-institutional study of anti-p53 in various cancers
No correlation with stage, lym
ph node m
etastases or size.
Correlates with tum
our p53 protein expression but not elinico-pathological
param
eters
Correlates with increased stage and tum
our p53 protein expression but not
prognosis
Con-elates with tum
our p53 protein expression and m
issense m
utations but
not elinico-pathological param
eters.
Literature review of anti-p53 in various cancers (1979-1999)
Head/Neck"
(Chow etal.. 2001) 
(Shimada etal..2003) 
Total
31(23/75)
32.3(10/31)
31.1 (33 / 106)
Correlates with nodal m
etastases but not prognosis 
M
ulti-institutional study of anti-p53 in various cancers
Oral
(Castelli etal.. 2001) 
(Hofele et al.. 2002) 
(Soussi, 2000a) 
Total
18.7 (3/61): 69.2 (9/13)c
18.6 (l9/102)d; 50(12/24)'
29.1(309/1062)
28.5(343/1204)
Serum anti-p53 is useful as a screening tool in pre-m
alignant lesions
Correlates with poor prognosis
Literature review of anti-p53 in various cancers (1979-1999)
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Ovary
(Qiu et al.. 2007) 
(Shimadaetal.. 2003) 
(Numaetal., 2001) 
(Abendsteinetal., 2000)
(Soussi. 2000a) 
Total
39.1 (36/92)
7.4 (2/27)
27(8/30)
25(28/113)
19(21/113)'
22(140/635)
23.9(214/897)
Correlates with p53 expression, not clinico-pathological param
eters 
M
ulti-institutional study of anti-p53 in various cancers 
Correlates with p53 tum
our expression and poor prognosis 
Con-elation between serum
 and ascitic anti-p53. No correlation with stage 
or grade. Anti-p53 in ascites associated with poor prognosis 
Literature review of anti-p53 in various cancers (1979-1999)
Colorectal
(Detailed results in 
Table 3.2. Table
3.7)
(SuppiahetaL2008) 
(Nozoe et al.. 2007) 
(M
ulleretal.. 2006) 
(Changetal.. 2005) 
(Lechpammer et al.. 2004) 
(Shimadaetal.. 2003) 
(Forslund et al.. 2001) 
(Tang etal., 2001)
(Broil etal., 2001)
(Takeda et al., 200 Ib) (Shiota
et al., 2000)
(Bielickietal., 1999)
(Soussi. 2000a)
Total
21.7(20/92)
47.2(17/36) 
(63/197)*: 15.2(7/46)h 
28.1 (47/167)
18.2(40/220) 
23.9(46/192)
27.3 (24/88)
13(130/998)
15.4(20/130) 
63(17/27)
25.4(18/71)
20.7(30/145) 
24.7(307/1244) 
21.5(786/3653)
No correlation with stage or prognosis
Correlates with advanced lymph node status and stage
No correlation with stage or prognosis
p53 m
utation, not anti-p53. correlates with poor prognosis
? Correlation with stage or prognosis in Dukes" A/B1 (Table 3.7)
M
ulti-institutional study of anti-p53 in various cancers
Correlates with p53 m
utation
Correlates with advanced lym
ph node involvem
ent but not prognosis
(Section 3.5.2.1: N 
-stage)
No correlation with stage or prognosis
95%
 negative sero-con\ ersion within 3 w
eeks post-surgery
Correlates with advanced stage and poor prognosis
? C
orrelation w
ith D
ukes'A —
»B
Literature review of anti-p53 in various cancers (1979-1999)
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H
CC
(Atta et al., 2008) 
(Akere and Otegbavo. 2007) 
(Muller et al.. 2006) 
(Charuruksetal.. 2001) 
(Tangkijvanich et al.. 2000a)0
(Sitruk et al.. 2000) 
(Soussi, 2000a)
Total
68.3(28/41) 
12.2(5/41) 
23.8(19/80) 
18.4(26/141) 
13.2(16/121)
12(19/159) 
1.2(82/387)
20.1 (195/970)
Correlates with advanced stage and shorter survival.
Correlates with increased Okuda stage
Non-significant trend tow
ards poor prognosis
Correlates with stage but not tum
our p53 protein expression
Prelim
inary report ot'Charuruks et al (2001). No correlation with severity.
stage or prognosis. Survival too short for survival analysis (3 vs. 4 m
onths)
Correlates with m
ultinodular. inllltrative tum
our but not survival
Literature review of anti-p53 in various cancers (1979-1999)
Bladder
(Muller et al.. 2006) 
(W
atanabe et al.. 2005)
(Gumus et al.. 2004b) 
(Gumus et al., 2004a)
(Shimada et al.. 2003) 
(M
oritaetaL 2000) 
(W
underlich et al.. 2000) 
(Soussi. 2000a)
Total
12.5(3/24) 
27(17/63)'
17.5(14/80) 
33 (25/76)
12.1 (4/33) 
12(12/100) 
12.5(4/32) 
27.6(8/29)
20.1(88/437)
No correlation with prognosis
Correlates with higher grade, stage, lym
ph node m
etastases and tum
our
p53 protein expression, but not prognosis
Correlates with tum
our p53 protein expression and poor prognosis.
Negative sero-conversion post-treatm
ent (35%. 8/23) associated with good
prognosis.
M
ulti-institutional study of anti-p53 in various cancers
Correlates with stage, and p53 protein expression but not prognosis
Correlates with tum
our protein p53 expression but not stage.
Literature review of anti-p53 in various cancers (1979-1999)
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Lung
U
terus
Cervix
(Bergqvist et al.. 2004)
(Bergqvist et al.. 2003)
(Neri et al., 2003)
(Cioffietal.,2001)
(Zalcman et al., 2000)
(Mack et al., 2000)
(Shimadaetal., 2003)
(Soussi. 2000a)
Total
(Numaetal., 2001)
(Shimadaetal., 2003)
Total
(Numaetal., 2001)
(Shimadaetal., 2003)
Total
16.6(14/84)
20.7(12/58)
6.7 (2/30V; 16.7(8/48)k
32.1(35/109)
20.6 (20/97)
11. 1(4/35)'; N
SCLC 13.3
(13/99)m
14.4(18/125)
17.1 (219/1282)
17.5(345/1967)
12(5/41)
22.7 (5/22)
15.9(10/63)
14(12/86)
18.9(10/53)
15.8(22/139)
N
o co
rrelation with tum
our v
olum
e. Correlates with su
rvival in
adenocarcinom
a, but not SCC
No co
rrelation with tum
our v
olum
e or lym
ph n
ode m
etastases
N
o co
rrelation w
ith stage, histology o
r prognosis. N
on-significant
increased survival in LC but not M
M
Low sen
sitivity, but high specificity (100%) and accu
racy (69%). Only
14%
 agreem
ent with other tum
our m
arkers (CEA/TPA. CY
FRA
21-1.
NSE.)
Correlates with poor prognosis in lim
ited stage SCLC. but not all SCLC
Correlates w
ith stage and prognosis in N
SCLC but not SCLC
M
ulti-institutional study of anti-p53 in v
arious can
cers
Literature review of anti-p53 in v
arious can
cers ( 1979-1999)
No co
rrelation w
ith tum
our p53 expression/prognosis (see Cervix, Ovary)
M
ulti-institutional study of anti-p53 in v
arious can
cers
N
o co
rrelation with tum
our p53 protein expression or prognosis
M
ulti-institutional study of anti-p53 in v
arious can
cers
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G
astric
Breast
(Qiu et al.. 2007)
(Mattioni etal.. 2007)
(Lawniczak et al., 2007)
(M
ulleret al.. 2006)
(Shimada et al., 2003)
(Nakajima et al.. 1999)
(Maehara et al.. 1999)
Soussi et al (2000)
Total
(M
uller etal. 
.2006)
(Gao etal. 
.2005)
(Shimada etal. 
.2003)
(Volkmann et al.. 2002)
(Metcalfe etal. 
.2000)
(Soussi. 2000a)
Total
31.1 (19/61)
15.3(17/111)
22.5(16/71)
11.5(14/122)
10.6(13/123)
16(13/81)
19.2(23/120)
14.1 (105/727)
15.5 (220 / 1416)
34(17/50)
21.5(31/144)
18.3(13/71)
10.9(18/165)
15.4(155/1006)
14.8(296/2006)
15.4(530/3442)
Correlates with tum
our size but not prognosis.
Correlates with tum
our p53 protein expression, prognosis and su
rvival
Correlates with tum
our type and age. but not stage or prognosis
No co
rrelation with prognosis
M
ulti-institutional study of anti-p53 in v
arious can
cers
Correlates with lym
ph node m
etastases but not stage or prognosis
Correlates with increased stage and tum
our p53 protein expression but n
ot
prognosis
Literature review of anti-p53 in v
arious can
cers (1979-1999)
N
on-significant trend tow
ards poor prognosis
Correlates with stage, lym
ph node m
etastases. ER n
egative, c-erb-2 and
tum
our p53 protein expression
M
ulti-institutional study of anti-p53 in v
arious can
cers
Poor co
n
co
rdance between reco
m
binant/native p53 EL1SA, im
m
unoblot
and im
m
unofluoresence
No co
rrelation with stage and prognosis
Literature review of anti-p53 in v
arious can
cers (1979-1999)
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Pancreas
Biliary tract*
Lym
phom
a
G
liom
a
H
aem
atological
(M
ulleretal.. 2006)
(Shimadaetal. 2003)
(Ohshioetal.. 2002)
(Soussi, 2000a)
Total
(Limpaiboon et al.. 2006)
(Shimadaetal.. 2003)
(Tangkijvanich et al.. 2000b)
Total
(Soussi. 2000a)
(Fonseca et al.. 2003)
(Shimadaetal.. 2003)
(Soussi. 2000a)
Total
(Shimadaetal.. 2003)
(Soussi. 2000a)
Total
22.7(5/22)
10.7(3/28)
23.2(19/82)
9.2 (60/650)
11.1 (87/782)
12.2(6/49)
16.7(1/6)
7.3 (6/82)
9.5<13/ 137)
7.7(19/248)
20.8(5/24)
6.5(2/31)
4.2(6/144)
6.5(13/ 199)
6.3 (32/364)"
3.3(14/428)°
5.8 (46 / 792)
Increase sensitivity in conjunction with CA 19-9. No correlation with
prognosis.
M
ulti-institutional study of anti-p53 in various cancers
No con-elation with tum
our p53 expression or prognosis
Literature review of anti-p53 in various cancers (1979-1999)
Correlates vvilh tum
our p53 protein expression but not stage
M
ulti-institutional study of anti-p53 in various cancers
Correlates with tum
our p53 m
utation
Literature review of anti-p53 in various cancers ( 1979-1999)
No correlation \\ith p53 protein but increased in patients<16 years
M
ulti-institutional stud\ of anti-p53 in various cancers
Literature review of anti-p53 in \arious cancers ( 1979-1999)
M
ulti-institutional study ofanti-p53 in \ariouscancers
Literature review of anti-p53 in various cancers (1979-1999)
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Prostate
Skin
Testicular
M
elanom
a
Total
(Shimadaetal.. 2003) 
(Soussi. 2000a) 
Total
(M
ochetal.. 2001)
(Soussi. 2000a)
(Soussi. 2000a)
17.4(4/23) 
2.7(4/148) 
4.7 (8 / 171)
2.9(3/105)
0(0/144)
0(0/58)
18.4(3292 / 17«5*)|
M
ulti-institutional study of anti-p53 in v
arious can
cers 
Literature revie\\ ofanti-p53 in v
arious can
cers ( 1979- 1999)
No difference between co
ntrols and patients. Increased in aggressive SCC 
(8%) vs. slow
-grow
ing BCC (1.5%)
Literature review of anti-p53 in v
arious can
cers ( 1979-1999)
Literature review
 of anti-p53 in v
arious can
cers ( 1979-1999)
All can
cers (1979-2009)
Squam
ous cell carcinom
a (SCC); basal cell carcinom
a (BCC), hepatocellular carcinom
a (HCC), carcino-em
bryonic antigen (CEA). Tissue 
polypeptide antigen (TPA), CYFRA21-1, Neurone-specific enolase (NSE), Oestrogen receptor (ER), c-erb-2.
a Cirrhosis; b benign disease;
c oral 
pre-m
alignant lesions-excluded from
 calculation; d prim
ary carcinom
a;
e secondary/recurrent carcinom
a; f ascitic titre, not included in calculation 
of serum
 litres; g colon; h rectum
; l upper renal tracl tum
ours, excluded from
 anti-p53 litres in bladder carcinom
a; J m
alignanl m
esotheliom
a 
(MM); k lung carcinom
a (LC);' sm
all cell lung carcinom
a (SCLC); m non-sm
all cell lung carcinom
a (NSCLC);
n m
yelom
a; 
° leukaem
ia; A 
tum
our type not specified. a excluded as is prelim
inary report of the sam
e cohort (duplicate) reported in Charuruks et al., 2001.
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3.4 Anti-p53 auto-antibody and p53 mutation in Cancer
The International Agency for Research on Cancer (IARC) TP53 Mutation Database 
compiles information on p53 mutations in various cancers reported in all published 
literature and from other databases. This is the most authoritative report on p53 
mutation rate in various cancers (IARC, 2008). The 30-year cumulative anti-p53 auto- 
antibody frequencies calculated in this thesis was plotted against the p53 mutation rate 
reported by the IARC to ascertain the relationship between p53 mutation and anti-p53 
auto-antibodies (Figure 3.1). The graph shows partial correlation (R2 : 0.49, 
correlation 0.699) between auto-antibody and p53 mutation. Cancers with the highest 
p53 mutation rate such as lung (39%), colorectal (43%) and oesophageal (43%) also 
demonstrate highest anti-p53 auto-antibody rates of 18%, 22% and 34% respectively 
(Soussi, 2000a, Shimada et al., 2003). Conversely, hepatoma, melanoma and testicular 
carcinoma with the lowest mutation rate also have the lowest anti-p53 auto-antibody 
rates (<1%) (Soussi, 2000a). The two obvious exceptions are gliomas and skin 
cancers. Proposed reasons for this are poor brain antigenicity, poor antigen- 
presentation across the blood-brain barrier, and use of immuno-suppressive steroids 
(dexamethasone) in the majority of gliomas (Soussi, 2000a, Weller et al., 1998). 
Similar arguments about antigen presentation and auto-antibody production are made 
for skin cancer (Moch et al., 2001). Only one study on 5 sero-positive patients with 
glioma has been published since and is unable to provide further information (Fonseca 
et al., 2003). In summary, anti-p53 auto-antibody has average (35%) to poor (1%) 
sensitivity depending on cancer type but is 95 - 100% specificity for any malignancy 
which may provide clinical relevance. This is critically evaluated in this thesis.
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Figure 3.1: p53 m
utations (IARC,2008) and anti-p53 autoantibody incidence (Suppiah, 2010) in individual cancer types. (R2 0.49, Correlation 0.699)
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3.5 Anti-p53 Auto-antibody In Colorectal Cancer
CRC has among the highest anti-p53 auto-antibody sero-positivity rates due to high 
frequency of p53 mutation. The variables rates reported pre-1999 report (Table 3.1) 
are probably due to lack of methodology standardisation; 8 "in-house" ELISA, 1 WB, 
1 immuno-precipitation, 1 using all 3 methods (Soussi, 2000a). Ten of these 11 
studies report a consistent sero-positivity rate between 12.5% and 32%. The 
remaining study, which was also the only study to use WB only, reported a much 
higher 68% sero-positivity thus demonstrating the importance of the detection method 
(Shibata et al., 1996).
Commercial ELISA kits have been developed since and results of ELISA-only studies 
are shown (Table 3.2). Mean sero-positivity is 19.9% (479/2409) with individual 
studies reporting between 13% - 27%, except two studies which report inconsistently 
high rates of 47% and 63% (Nozoe et ah, 2007, Takeda et al., 2001b). Both studies 
used the same ELISA (Pharmacell, France) and the high sero-positivity (2.6%, 1/38) 
in controls suggest a lower cut-off value for auto-antibody detection may have been 
used (Takeda et al., 200 Ib). The same authors, using the same ELISA, also reported 
an unusually high sero-positivity of 40% (14/35) in superficial oesophageal carcinoma 
compared with the other reports of 20 - 30% (Shimada et al., 2000). Interestingly, a 
later study by the same authors, but using a different ELISA kit (anti-p53 EIA Kit II, 
MESACUP), in a similar Japanese cohort reported a more consistent sero-positivity of 
24% in CRC and 30% hi oesophageal cancer, again highlighting problems with 
quantification, even with commercially available ELISA (Shimada et al., 2003).
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Table 3.2: Sum
m
ary of all ELISA studies on anti-p53 auto-antibody (anti-p53) in colorectal cancer (CRC).
A
uthor (Year)
(Suppiah et
ah, 2008)
(Nozoe et ah,
2007)
(M
uller et al.,
2006)
M
ethod and
m
an
ufacturer
ELISA
(p53 ELISA
PLUS
,
Calbiochem
,
Darm
stadt,
Germ
any)
ELISA
(Pharmacell,
France)
Im
m
unoblot
Sam
ples,
%
 (n)
21.7(20/92);
0 (0/20)a
0 (0/8 )b
47.2(17/36)
Colon 32
(63/197);
Rectum
 15.2
(7/46);
0 (0/57)a
0 (0/379)b
Follow-up
M
edian 97
m
onths
Not stated
CRC patients
enrolled into
trial with 5 year
follow-up
Key findings
No correlation with tum
our stage, differentiation or location.
M
ultivariate analysis show only Stage (Dukes' and TNM) to be
independent prognostic factors
Antip53-ab (+) associated with greater lym
phatic invasion (94.1%;
16/17 vs. 68.4%
; 13/19), nodal involvem
ent (70/6%; 12/17 vs. 17.6%
;
3/17) and advanced stage (p=0.02). Anti-p53 frequency higher in p53
protein expressing tum
ours (74%; 14/19 vs. 18%
; 3/17). Only 3 patients
with D
ukes' A CRC, all sero-negative
No correlation with clinico-pathological param
eters or prognosis. Trend
tow
ard higher anti-p53 sero-positivity in N2/3 disease, poor
differentiation and m
etastases. There w
ere no patients with D
ukes' A
 in
this study. Anti-p53 independent of CEA and CA19-9 with 16%
inform
ation gain. This is the only study to report negative to positive
sero-conversion (3.6%, 11/303)
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(Chang et al.,
2005)
(Lechpammer
et al., 2004)
(Shimada et
al., 2003)
(Forslund et
al., 2001)
ELISA (p53-AK,
Dianova,
Ham
burg,
Germ
any)
ELISA
(ELISAPLUS
Oncogene
Research
Products,
Cam
bridge, USA)
ELISA (Anti-p53
EIA Kit II,
M
ESACUP anti-
p53 Test; M
BL;
Nagoya, Japan)
ELISA (Dianova,
Ham
burg,
Germ
any)
28.1 47/167);
0 (0/40)a
18.2(40/220);
0 (0/42)a
23.9(46/192);
4.9(10/205)a;
6.9(13/189)b
27 (24/88)
M
edian 36.3
m
onths (4-58)
40 patients up
to 20 w
eeks: 8
patients up to
48 w
eeks
Not reported
Not reported
Anti-p53 correlates with p53 m
utation (43% vs. 1 8%) but not tum
our
p53 expression, clinico-pathological features or prognosis. p53
m
utations, advanced stage and pre-operative CEA>5ng/m
l w
ere
independent prognostic factors (in that order). p53 m
utation strongly
associated with advanced stage and poor differentiation
Anti-p53 had higher tum
our p53 expression (70% vs. 52%). Anti-p53
frequency shows highest increase in D
ukes' A (0%, 0/28) 
 
 >Dukes' B:
(24%, 21/87) but no increase in progression to D
ukes' C (18%, 19/1 05).
No correlation with overall tum
our grade or m
etastases. Anti-p53
reflects tum
our load following surgery, during chem
otherapy and with
disease recurrence. (Table 3.6)
Validation study for M
ESACUP ELISA using prevalence of anti-p53 in
various cancers. Good intra- and inter-assay coefficient of variation of
1 
.85-2.37%
 and 0.3-3.2%
 respectively. D
em
onstrates stability of anti-
p53 litres at room
 tem
perature for 7 days and following 10 freeze-thaw
cycles. No com
m
ent on correlation with clinico-pathological param
eters
or prognosis.
Cross-sectional study on relationship between p53 m
utations and anti-
p53 presence. Frequency of p53 m
utation higher in anti-p53 sero-
positive group (92%, 22/64 vs. 34%
, 22/64) Correlation with clinico-
pathological and survival param
eters not reported
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(Tang et al.,
2001)
(Broil et al.,
2001)
(Takeda et al.,
2001b)
(Takeda et al.,
2001a)
ELISA
(Calbiochem-
Novabiochem
,
Darm
stadt,
Germ
any)
ELISA (P53-
autoantikorpfer
ELISA, Dianova,
Ham
burg,
Germ
any)
Anti-p53 EIA
(PharmaCell,
Paris, France)
ELISA (Anti-p53-
EIA kit,
Pharmacell, Paris,
France)
13(130/998);
l(2/211)c
15(20/130);
0 (0/44)a
63(17/27);
2.6(l/38)c
40 patients
with anti-p53
ab from
previous
studies
Not reported
M
edian 25.5
Up to 2 years
M
edian not
reported
Up to 29
m
onths
Anti-p53 sero-positivity increases in progression from N
2  »N3 (2.9% to
10.6%); but not NO->N1 (11. 7%
 to 12.3%), M
l 
->N2 (12.3% to 10.6%)
or M
O
^M
 1 ( 1 2%
 to 1 7%). No correlation with CEA, overall TNM
stage or m
etastases. Anti-p53 associated with shorter survival in uni- but
not m
ulti-variate analysis. Largest study on anti-p53 in CRC.
Anti-p53 positive predictive value of 100%
, but accuracy 37%
 and
negative predictive value 29%
 due to poor sensitivity (15%). Anti-p53
correlated with p53 expression (p<0.05), but not TNM
 stage, grade or
location (exact num
bers not shown). Approxim
ately 70%
 of series Stage
I/II CRC
Anti-p53 correlates with p53 protein expression and independent of
CEA and C A- 19-9. Sero-conversion in 94%
 (16/17) within 3 w
eeks of
endoscopic resection. No correlation with clinico-pathological
param
eters or prognosis/recurrence as all patients had early superficial
CRC (23 m
ucosal, 4 subm
ucosal invasion). This study reports
exceptionally high anti-p53, especially considering very early CRC
No correlation between post-operative anti-p53 sero-positivity and
histological (depth, lym
phatic or venous invasion) or clinico-
pathological features of lym
ph node or liver m
etastases. High (96%;
27/28) sero-conversion in patients with com
plete tum
our resection. No
sero-conversion in patients with residual disease.
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(Shiota et al..
2000)
(2000)
(Bielicki et ah,
1999)
(Soussi, 2000a)
Total (1999-
2009)
Thesis Total
(1979-2009)
ELISA (GIF,
M
unster.
Germany)
ELISA
(Dianova,
H
am
burg,
G
erm
any)
ELISA7W
B IP
25(18/71);
6(l/18)c
21 (30/145);
0 (0/20)b;
0 (0/8)c
24.7
(307/1244)
19.9
(479/2409)
21.5
(786/3653)
N
ot stated.
m
edian survival
56 m
onths
antip53 ab
n
egative
N
ot stated.
Cross sectional
study
ELISA/W
B/1P
A
nti-p53 co
rrelates with TNM
 stage (Stage I-IIIb: 9%
, 4/45 vs. IV:
56%
, 14/25), D
ukes' stage (A-C: 9%
, 4/45 vs. D: 56%
, 14/25), CEA,
CA19-9 and tum
our p53 protein expression. A
nti-p53 asso
ciated with
shorted survival (56 m
o
nths vs. 20 m
o
nths) and is w
eak poor prognostic
indicator. A
nti-p53 prognostic significance seco
ndary to other factors.
including w
eak factors e.g. CEA and CA19-9. Only sm
all n
u
m
ber of
Stage l-lllb patients.
N
o co
rrelation with D
ukes' Stage (A/B: 22%
, 16/73 vs. C/D 19%
14/72), size, location, CEA. Highest increase in anti-p53 frequency from
D
ukes' A (0%, 0/6) to Dukes Bl (28%, 5/18) but no further difference
in progression to D
ukes' C (19%, 7/36). Only 6 D
ukes' A patients in
study, all sero
-n
egative
Review
 co
m
bining all studies with different m
ethodologies from
 1979-
1999. Range of sero
-positivity (12.5-68% in 1 1 studies)
All m
odern studies (1999 o
n
w
ards) using co
m
m
ercial ELISA o
nly, with
one ex
ception using Im
m
unoblot (M
uller et al, 2006)
All studies on anti-p53 in CRC (1979-2009)
Studies prior to 1999 u
sed individual different m
ethodology and n
ot included (see below). Enzym
e-linked im
m
unosorbency assay (ELISA); W
estern Blot 
(W
B); Im
m
unoprecipitation (IP)
a healthy, b benign disease,
c adenom
a. The study by M
uller et al (2006) w
as included despite suing im
m
unoblot technique as 
it w
as a recent study w
ith relatively large sam
ple size, and also reported the highest sero
-co
n
v
ersion rates (Section 3.5.4).
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3.5.1 Anti-p53 Auto-antibody in Diagnosis and Screening
Cancer screening tools are used where early detection and intervention leads to 
improved outcome, such as CRC where Dukes' A CRC has 95-100% 5-year cancer 
specific survival compared with 5% in Dukes' D. The ideal screening tool is 100% 
sensitive and specific, cost-effective, safe and acceptable but no such test exists. 
Colonoscopy is the current gold-standard diagnostic tool but is unsuitable for general 
population screening as it is painful, expensive and is associated with life-threatening 
complications such as colonic perforation (0.03 - 0.3%) and haemorrhage (0.6%) 
(Nelson et al., 2002, Lieberman et al., 2000). The potential benefits on serum anti-p53 
auto-antibody testing are that it serum assays are not subject to tumour sampling 
errors and are quicker, cheaper, easier and far less traumatic, thus making it more 
acceptable to the general population and hence more repeatable. The auto-antibody 
itself is remarkably stable, showing no significant changes in litres when stored at 
room temperature for up to 7 days, or at stored at -80°C for 3 years (Angelopoulou et 
al., 1997). Furthermore, repeated freeze-thaw cycles (up to 10 cycles) have minimal 
or no effect on serum levels as the immunoglobulins are generally very robust 
(Shimada et al., 2003). Results are reproducible using commercially available EL1SA 
with reported intra- and inter-assay coefficient of variation of 1.85-2.37% and 0.3- 
3.32% respectively (MESACUP anti-p53 Test; Medical and Biological Laboratories, 
MBL, Nagoya, Japan) (Shimada et al., 2003). Finally, anti-p53 auto-antibody appears 
to be independent of other conventional CRC tumour markers such as CEA which 
means it could detect CRC in CEA negative patients (Section 3.5.3). Despite these 
apparent benefits of serum testing and the auto-antibody properties, the low sensitivity
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and lack of specificity for CRC makes it unsuitable for diagnosis in general 
population. Selective screening in high-risk groups (e.g. IBD) instead may increase 
utility of anti-53 auto-antibody, which is discussed next.
p53 mutation has been reported to occur earlier, and APC/kRAS mutations are not as 
consistent as in sporadic CRC suggesting different mechanism carcinogenesis in UC- 
CRC. (Rosman-Urbach et al., 2004, Brentnall et al., 1994). As p53 mutations occur 
earlier and are partly induce anti-p53 production, 2 studies have investigated anti-p53 
auto-antibody in UC-CRC. The first study reported anti-p53 in sporadic CRC (52%, 
43/82), UC (15%, 43/286) (Yoshizawa et al., 2007). The 52% anti-p53 positivity in 
sporadic CRC is higher than other reported studies and already suggests an over- 
estimation or a lower cut-off point used in the method. Thus, the 15% anti-p53 in UC 
would also likely be an over-estimation (as the same ELISA was used) suggesting 
even lower true sensitivity in all UC, regardless of presence of dysplasia or CRC. 
Next, only 13 patients with UC had CRC / dysplasia. Only 5 of the 13 were anti-p53 
positive giving a false negative rate of 62% (8/13) for dysplasia/CRC. The positive 
predictive value was 14% as only 6 of the 43 anti-p53 positive-UC patients had 
dysplasia/CRC. None of the remaining anti-p53 positive UC patients (n=37) went on 
to develop CRC detected by colonoscopy or barium enema at the time of publication - 
minimum 2 year follow-up, with the patient cohort ranging from 2002-2005 and 
report published in 2007). The second study by Cioffi et al emphasised the benefits of 
serum testing but the results similarly showed only 9.3% (9/97) anti-p53 positivity in 
UC (Cioffi et al., 2004) again demonstrating a sensitivity which is far too low for 
clinical use.
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The anti-p53 auto-antibody has not been investigated in other high-risk groups such as 
inherited familial syndromes but can be expected to have even less sensitivity as 
majority of the familial syndromes are thought via MMR defects, rather than the CIN 
mechanisms of the adenoma-carcinoma sequence in sporadic CRC, and hence less 
likely to possess p53 mutation and mount an auto-antibody response.
In conclusion, whilst serum testing using an appropriate antibody marker is appealing, 
the anti-p53 auto-antibody has too low sensitivity, specificity, positive and negative 
predictive, and hence is of no value in screening for CRC in general or high-risk 
populations.
3.5.2 Anti-p53 Auto-Antibody and Clinico-pathological Parameters of CRC
p53 mutation occurs in the final stages of the adenoma-carcinoma sequence. Hence, 
anti-p53 auto-antibody production is unlikely to occur in early pre-invasive lesions 
where p53 mutations have not yet manifested (Fearon and Vogelstein, 1990). This is 
supported by the largest study which reports only 1% (2/211) sero-positivity in 
adenomas. Furthermore, micro foci of invasive cancer within these adenomas cannot 
be excluded, and could account for this sero-positivity (Tang et al., 2001). Sero- 
positivity rates increased modestly to 6% in carcinoma-in-situ, which would be 
expected of tumours at the end of the adenoma-carcinoma sequence and hence, 
greater proportion of p53 mutation. This is consistent with postulation that frequency 
of anti-p53 auto-antibody is partly related to that of p53 mutation.
Correspondingly, sero-positivity rates should then increase further with greater 
tumour progression (e.g. Dukes A to Dukes' D) but only two studies reported 0%
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(0 / 28) sero-positivity in Dukes A which increased to 9.6% (21 / 87) in Dukes' B, 
which was similar to Dukes' C sero-positivity of 8.6% (19/105) (Lechpammer et al., 
2004) and Bielicki et al reported 0% sero-positivity in Dukes' A which increased to 
28% Dukes' Bl and 22% Dukes' B2, which was again similar to sero-positivity in 
Dukes C (19%) (Bielicki et al., 1999). Both studies are based on absence of anti-p53 
auto-antibody in a small group of early CRC patients. A much larger study using 998 
patients reported no difference in progression from Dukes' A to B or with any stage 
progression, which was also confirmed by the majority of publications. This suggests 
that anti-p53 auto-antibody production is stimulated early in post-dysplasia 
(progression from carcinoma-in-situ > Dukes' A) which is consistent with p53 
mutation as a late event in malignant transformation. The humoral response is not 
induced by T-stage invasion beyond this (e.g. T2 >T4).
3.5.2.1 N-stage
The majority of studies report no difference in sero-positivity rates between Dukes' B 
and C suggesting nodal involvement does not affect anti-p53 auto-antibody presence. 
However, the largest study reported increased anti-p53 auto-antibody frequency in 
NO-N2 vs. N3 disease (Nl: 1 - 3 pericolic nodes; N2: 4 or more regional nodes; N3: 
10 or more regional nodes or systemic nodal metastases) (Tang et al., 2001). No 
significant differences in sero-positivity were observed between node negative NO 
(11.7%), early Nl (12.3%) or N2 (10.6%) disease (Tang et al., 2001).The difference 
in sero-positivity between NO-2 and N3 could be due to the dilution effect of the large 
number of sero-negative patients with NO disease (n = 407 / 506; 88%) in the 
combined NO-2 group. Secondly, the increased auto-antibody frequency was
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observed only in the "high" antibody titre group which was defined as patients with 
serum titres above that of the highest titre in the 611 controls subjects, which was 
76U. However, up to 2% control subjects will possess the anti-p53 auto-antibody as 
calculated in this thesis using data from historical studies (Table 3.1). As a result, this 
"high" antibody group is a biased selected patient population who possess the highest 
anti-p53 auto-antibody titres - but does not include all sero-positive patients. In fact, 
the majority of sero-positive patients were excluded in this analysis (Table 3.3). The 
"low" group which constitutes the majority of anti-p53 positive patients in this study 
actually demonstrate no significant increase in anti-p53 auto-antibody with nodal 
involvement.
Table 3.3: Anti-p53 auto-antibody sero-positive rates (%) in each N-stage
N stage (n)
N 0 (506)
N 1 (252)
N2(132)
N 3 (70)
Negative (<10 U)
88%
88%
89%
77%
Low(10-76U)
9%
8%
7%
High (> 76U)
2%
5%
4%
7 % t 1 6 °/0
Data from (Tang et al., 2001). Red box indicates highly select group used for analysis 
of N-stage. Yellow column indicates patients selectively excluded from analysis
The data from Tang et al was re-examined to obtain a more valid conclusion. Firstly 
the "low" and "high" groups were combined into a "positive" group. This avoided 
exclusion of the large number of sero-positive patients (yellow column in Table 3.3). 
Secondly, the nodal involvement was collapsed into node "negative" and node 
"positive" group which is more clinically relevant than individual N1/2/3 stages. The
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resulting comparison showed no difference between anti-p53 auto-antibody and N- 
stage (Table 3.4). Statistical significance could not be calculated as the sample 
numbers were calculated from % sero-positivity reported in the original publication.
Table 3.4: Reclassification of nodal stage and anti-p53 auto-antibody status
Node negative (506)
Node positive (454)
Anti-p53 Negative % ( n)
88 % (447)
87 % (393)
Anti-p53 Positive % (n)
12% (59)
14% (61)
(Tang et al., 2001). Exact patient numbers calculated from % reported
In summary, despite the reported increase in anti-p53 auto-antibody frequency 
observed with N3 disease in this study, there is no correlation between overall N - 
stage and anti-p53 auto-antibody status.
3.5.2.2 M-stage
The concept that early invasion may stimulate anti-p53 auto-antibody production by 
increasing likelihood of antigen presentation would suggest that haematogenous 
metastatic spread (Ml) should also trigger anti-p53 auto-antibody production. 
However, almost all studies report no increase in sero-positivity rates with Ml disease 
(Suppiah et al., 2008, Muller et al., 2006, Lechpammer et al., 2004, Bielicki et al., 
1999, Chang et al., 2005). Only one study reported increased anti-p53 auto-antibody 
with Ml CRC but there were substantial discrepancies within this study with low 
sero-positivity in small Stage I-III (9%, 4/45) group and high sero-positivity rates in 
Stage IV CRC (56%, 14/25) which is inconsistent with other studies (Shiota et al., 
2001). This association with Ml also led this to be the only study to report anti-p53 to
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correlate with CEA levels (section 3.5.3) and display independent prognostic 
significance (Section 3.5.5)
The most probable explanation for the absence of an increased anti-p53 auto-antibody 
response with distant metastases is that there have already been sufficient 
opportunities for antigen-presentation, either via local tumour invasion, microscopic 
haematogenous tumour cell dissemination, and/or lymph node invasion. The absence 
of a humoral response may no longer be dependant on antigen-presentation, but rather 
on patient specific biological factors which include (a) tumour factors e.g. p53 
mutation type and presence of co-factors required for antigen presentation; and (b) 
patient immunity-specific factors such as MHC expression required to mount a 
response. This may also explain why patients with same cancer type and same p53 
mutation type do not mount the same anti-p53 response, and also absence of positive 
sero-conversion despite disease progression in anti-p53 negative patients.
In conclusion, anti-p53 auto-antibody production may be induced in the final stages of 
malignant transformation where p53 mutation rate increases, in keeping with p53 
mutation being one of the final stages of the adenoma-carcinoma sequence. The 
minority of studies reporting increased anti-p53 auto-antibody production with local 
or nodal invasion are poor quality with conclusions drawn from selective group 
analysis. Anti-p53 auto-antibody is not associated with CRC stage.
3.5.3 Anti-p53 auto-antibody and Carcino-Embryonic Antigen (CEA)
Carcino-Embryonic Antigen (CEA) is the most common serum tumour marker used 
in CRC. It is a ISOkDa serum glycoprotein which is present at low levels in
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normal cells but over-expressed in adenocarcinoma, especially of the colon, rectum, 
breast and lung (Thomas et al., 1990). Pre-operative CEA presence has been 
associated with aggressive CRC and poor prognosis (Park et al., 2009, Goldstein and 
Mitchell, 2005). CEA has also been used as an adjunct in CRC screening, monitoring 
for disease recurrence following resection, or as part of tumour marker panel for 
metastases of unknown primary origin. CEA has high specificity which is reduced due 
to false elevations in smokers, inflammatory diseases, cirrhoses, obstructive jaundice, 
gastric ulcers, emphysema, diabetes and collagen vascular diseases (Wilson et al., 
1999, Begent, 1984).
CEA use is not recommended in screening, or use in isolation in detection of 
recurrence following surgery, due to its poor sensitivity (Tan et al., 2009, Hara et al., 
2008). The most recent large study reported mean pre-operative CEA sensitivity of 
20.6% (261 / 1263), which decreased further with early stage CRC - Stage I (6.6%, 
14 / 212), Stage II (21.4%, 110 / 514) and Stage III (25.5%, 137 / 537) (Park et al., 
2009). Although CEA sensitivity can be modulated by changing the cut-off values for 
"positivity" , a utility study showed this sensitivity remained low despite variations in 
the cut-off value used (Park et al., 2005) (Tan et al., 2009). Despite this, CEA remains 
the most reliable serum tumour marker in CRC. The American Society of Surgical 
Oncology (ASCO) guidelines suggest serial CEA measurements every 3 months in 
Stage II / III CRC for at least 3 years following diagnosis, and during treatment of 
metastatic disease surgery (ASCO, 2006). Sceptics remain unconvinced of the cost- 
effectiveness of this approach in screening or post-operative surveillance; or its ability 
to alter CRC outcomes significantly.
118
Tumour markers used in conjunction with CEA could increase the efficacy of serum 
testing in selected populations. Most studies report no correlation between CEA and 
anti-p53 auto-antibodies (Tang et al., 2001, Hammel et al., 1997, Bielicki et al., 1999) 
(Table 3.5). Only two studies reported a correlation between the two markers, the first 
study which used a small and poorly distributed sample size of 18 anti-p53 auto- 
antibody positive patients - 14 of whom were Stage IV and only 4 were Stage I-IIIb 
(Shiota et al., 2000). The second study reported 78% anti-p53 auto-antibody positivity 
in CEA-positive patients which was significantly higher than 56% sero-positivity in 
patients with normal CEA. However, the 56% sero-positivity is exceptionally high 
and probably attributable to methodological error which relied on WB, not ELISA 
(Shibata et al., 1996). Hence the discrepant results caused by the different 
methodology in one study, and atypical sample distribution in both studies lead to 
association between the 2 markers. It is generally accepted that anti-p53 auto-antibody 
is independent of CEA. Its potential role is discussed.
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Table 3.5: (a) Prevalence of anti-p53 auto-antibody and CEA in studies reporting the 
presence of both tumour markers in CRC; (b) Combined CEA and anti-p53 auto- 
antibody rates from all studies reporting the presence of both markers
(a)
(Tang etal., 2001)
(Shibata et al., 1996)
(Bielicki et al., 1999)
(Hammel et al., 1997)
Overall
CEA (%)
408/943(43.3)
23/47(48.9)
46/148(31.1)
20 / 54 (37.0)
497/1192(41.7)
Anti-p53 (%)
130/998(13.0)
32/47(68.0)
29 / 148(19.6)
14/54(25.9)
204 / 1247 (16.4)
(b) Total, n= 1192
Anti-p53 ab present
Anti- p53 ab absent
CEA normal
112(9.4%)
584 (48.9 %)
CEA elevated
90 (7.6 %)
406(34.1 %)
Table 3.5 (b) suggests that anti-p53 is present in 9.4% of CRC patients with normal 
CEA i.e. "information gain". The combined sensitivity of anti-p53 and CEA (51%, as 
CEA and anti-p53 are absent in 48.9%) exceeds that of CEA alone (42%) and anti- 
p53 alone (17%). This suggests an information gain of 9% and 34%. Muller et al was 
the only study to report information gain rates and similarly confirmed increased 
sensitivity when anti-p53 auto-antibody was combined with CEA. Sensitivity 
increased from 55% to 71% in colon cancer and 78% to 83% in 46 rectal cancers 
(Muller et al., 2006). The estimated "information gain" was 16% which is consistent 
with that calculated in this thesis using data from all published studies.
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This could be perceived as substantial "information gain" but must display 
appreciable clinical benefit if it is to be used. CRC has an overall low prevalence in 
the general population and hence screening detection rates will remain low despite the 
use of both markers, especially with poor sensitivity in a low prevalence disease. 
Also, both tumour markers have preponderance towards Stage II & III CRC and are 
most likely detect these CRC stages but are unable to detect early (stage I) CRC 
which would increase long-term survival. As such, although anti-p53 auto-antibody 
presence is independent of CEA with some "information gain", both markers used 
either in isolation, or in combination, are unlikely to alter clinical outcomes.
3.5.4 Anti-p53 Auto-antibody and Monitoring for Recurrence or Metastases
Serum anti-p53 auto-antibody titres are reported to be dependant on tumour load, with 
elevations in serum titres corresponding with disease recurrence / progression and 
decreased titres observed following surgery and / or chemotherapy. This trend has 
also been observed in lung, ovarian and breast cancer (Zalcman et al., 1998, 
Angelopoulou et al., 1994). However, all reports of variation in anti-p53 auto- 
antibodies titre with tumour load are highly selected case observations within larger 
studies. This is because no study aimed to investigate the temporal relationship 
between anti-p53 auto-antibodies and tumour load, the retrospective nature which 
limits serum samples available and significant selection bias. Patients examined 
sequentially for anti-p53 auto-antibody were those with ongoing treatment or disease 
progression and hence bias towards advanced CRC which were kept under intense 
surveillance. Almost all patients still demonstrate decrease in serum titres post-
121
surgery and during chemotherapy. Increases in auto-antibody during chemotherapy 
were associated with metastases (Angelopoulou et al., 1997, Polge et al., 1998). The 
results of these reports are summarised in Table 3.6.
Anti-p53 auto-antibody is an IgG class antibody. IgG antibody production occurs via 
an early primary response associated with MHC II - T-cell helper response (after the 
initial antigen presentation leads to IgM antibody production) and a later secondary 
response where matured plasma cells are able to produce the specific anti-p53 IgG 
without the need for direct antigen presentation. Takeda et al reported the highest 
negative sero-conversion rate (94%, 16 / 17) in a group of patients with superficial 
(mucosal and submucosal) CRC treated with endoscopic resection. This sero- 
conversion rate is higher than those reported by other studies which report a 
significant decrease in anti-p53 auto-antibody titres but not complete sero-conversion 
to anti-p53 auto-antibody negative status (Lechpammer et al., 2004, Hammel et al., 
1997, Angelopoulou et al., 1997). The observation by Takeda et al. is likely 
attributable to the early stage CRC population where the smaller mutant p53 load may 
not have adequately stimulated the humoral system sufficiently to produce a 
prolonged sustained immune response following removal, as opposed to other studies 
using advanced CRC and reporting decreased but persistent anti-p53 auto-antibody 
response (Takeda et al., 200Ib, Lechpammer et al., 2004, Polge et al., 1998, 
Angelopoulou et al., 1997). Decreasing titres are observed following treatment, 
possibly secondary to decreased tumour load but can also be caused by concurrent 
immuno-suppressive chemotherapy, which can continue to suppress IgG response 
after treatment cessation. Finally, the IgG response can persist for >20 years and has
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not considered a suitable marker for disease diagnosis or eradication in certain 
infective conditions e.g. Lyme disease (Kalish et al., 2001). The clinical relevance of 
this is that the anti-p53 IgG antibody response may in itself be unreliable, in addition 
to poor sensitivity and specificity for CRC.
The cost-efficacy is considered next. Assuming 20% sero-positivity at diagnosis, 3 
monthly titres over 3 years (as per CEA recommendation), and a very optimistic 3.6% 
positive sero-conversion (only 1 study reports positive sero-conversion) would yield 
2.8 positives out of 1200 samples (100 patients x 4 samples per year x 3 years) at a 
cost of £11,200 (approx £373 per ELISA, 30 ELISA kits required). Next, anti-p53 is 
not specific to CRC (Section 3.5.1). Thirdly, anti-p53 is itself an IgG which could be 
suppressed even long after chemotherapy, resulting in further decrease in sensitivity 
with increased false negatives. Hence, anti-p53 auto-antibody use is not justifiable in 
screening all CRC patients.
An alternative strategy would be to screen all CRC patients for anti-p53 auto-antibody 
at diagnosis and perform serial measurements only in those positive at diagnosis. 
Patients with rising titres may benefit from more intensive surveillance or expedited 
tests for potential disease recurrence. However, this would still involve testing all 
patients at diagnosis and also the confounding effect of chemotherapy which is 
increasingly used. A cost efficacy study on 50 post-resection CRC patients not 
requiring chemotherapy, would require a conservative estimate of 500 new CRC 
patients at initial screening (£4,660), to obtain 100 CRC anti-p53 positive patients. 
Quarterly titres in a 5-year surveillance program would cost approximately a further 
£18,600 (2000 samples). Again, the isolated increase of anti-p53 auto-antibody
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without corroborating clinical or radiological evidence will not alter clinical 
management. Finally, even if this cost was sustainable, anti-p53 would still be 
insufficiently specific, even in this highly selected population. It becomes obvious that 
none of the strategies are likely to be cost-effective or clinically justifiable.
In summary, based on the information available on small number of patients, anti-p53 
auto-antibody is a poor marker of CRC recurrence. Various strategies in utilising anti- 
p53 auto-antibody in CRC surveillance have been discussed in this chapter, alongside 
corresponding cost-efficacy approximates, but none of these approaches are justifiable 
at present due to the poor sensitivity and specificity and variability of the IgG 
response of the anti-p53 auto-antibody itself
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Table 3.6: Follow
-up anti-p53 autoantibody (anti-p53) m
easu
rem
ents in patients with colorectal can
cer (CRC) and sero
-co
n
v
ersion rates.
Study (Year)
Patients, M
ethod
Follow
-up
Findings
(M
uller et al., 
2006)
303 patients,
197 colon, 46 rectal
Im
m
unoblot
M
edian 6 m
o
nths
All cancers: 3.6%
 (11/303) sero(-)-> (+); 3.6%
 (11/303) sero(+)-» (-); Total 7.2%
(22/303) sero
-co
n
v
ersion.
Colon cancer: 3%
 (4/137) sero(-)-> (+); 3.6%
 (5/137) sero(+)-> (-); Total 6.6%
(9/137) sero
-co
n
v
ersion.
Rectal cancer: 6.5%
 (2/31) sero(-)-> (+); 3.2%
 (2/31) se
ro(+)^ (-); Total 12.9%
(4/31) sero
-co
n
v
ersion
(Lechpammer et 
al., 2004)
32 
, ELISA 
(Oncogene, Research 
Products, Cam
bridge, USA)
Up to 20 w
eeks; 
8 patients 
-
 48 
w
eeks
N
on-significant decrease at 4 w
eeks (pre-first cycle chem
o) and significant decrease
at 12 w
eeks post-surgery.
Significant decreases during chem
otherapy and 2 patients with anti-p53 increase at
12 w
eeks (during chem
otherapy) developed recu
rren
ce.
8 patients with extended follow-up: 7/8 had decreased anti-p53 with no recu
rren
ce.
1/8 anti-p53 decrease post-surgery/ chem
otherapy but increased at 12 w
eeks
co
rresponding with liver m
etastases. A
nti-p53 fluctuates in response to tum
our load
but does not disappear. A
nti-p53 levels reflects tum
our load even during
chem
otherapy
(Takeda et al., 
2001a)
30 CUR A,
5 CU
R B,
5 CU
R C),
(Anti-p53 EIA, Pharm
acell)
M
edian 26 m
o
nths 
(13-144)
CUR A (n=30): 28/30 sero(+) >(-) in 6 m
o
nths; 2 no sero
-co
n
v
ersion: 1 recu
rren
ce. 
CUR B (n=5): 2 sero(+) >(-) no recu
rren
ce. 3 no sero
-co
n
v
ersion, 2 had m
etastases. 
CUR C: N
o sero
-co
n
v
ersion. 
Correlation between post-operative n
egative co
n
v
ersion and operative cu
rability.
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(Takeda et al., 
2001b)
17 m
ucosal / subm
ucosal, 
EL1SA (Anti-p53 EIA, 
Pharm
acell, France)
Up to 2 years
94%
, 16/17 sero(+) >(-) within 3 w
eeks post-surgery.
No recu
rren
ces as early stage tum
ours and hence not able to co
m
m
ent on anti-p53
and recu
rren
ce rates
(Polge et al., 
1998)
10,
ELISA (Dianova, H
am
burg,
G
erm
any)
Up to 6 m
onths
8 followed-up: 5/8 rem
ained sero(+) post-operatively. All developed m
etastases. 
3/8 decreased anti-p53 litres. N
o m
etastases or recu
rren
ce. 
A
nti-p53 litres decreased within 1 
m
onth of su
rgery/chem
otherapy but no sero- 
co
n
v
ersion to anti-p53(-).
(Angelopoulou 
et al., 1997)
6. 
"In house" 
im
m
unofluorom
etric assay
Up to 17 m
onths
Anti p53 decreases with su
rgery/ chem
otherapy but persists at low levels. 
A
nti-p53 increases with recu
rren
ce.
A
nti-p53 reflects tum
our load m
o
re sen
sitively than CEA (n=5) and in n
o
n
-CEA 
producing tum
our (n= 1).
A
nti-p53 in 5/8 patients decrease by >25%
 within 1 m
onth. 
At 1 year, 3 with norm
al anti-p53 levels and 3 with substantial decrease in anti-p53 
rem
ain disease-free.
2 patients with post-operative increased anti-p53: 1 developed recu
rren
ce and 1 
developed m
etastases.
Anti-p53 decreased again following surgery in both patients. CEA and CA19-9 
w
ere norm
al in both cases, 
m
acroscopically; CUR B: No residual tum
our but not as evaluable as CUR A;
(Hammel et al., 
1997)
12, 
"In house" ELISA
Up to 20 m
onths
Sero(-), Sero-negative; Sero(+), Sero-positive; CU
R A: N
o residual tum
our 
CUR C: definite residual tum
our
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Section 3.5.5: Anti-p53 auto-antibody and prognosis in CRC
p53 mutations have been associated with poor prognosis, possibly due to chemo- 
resistance against p53-dependant chemotherapy (e.g. 5 - fluorouracil) although this is 
not consistently reported (IARC, 2008, Soussi, 2008, Soussi, 2000b). As anti-p53 
auto-antibody presence is partly associated with p53 mutations and serum testing is 
easier than DNA sequencing, attempts were made to assess the prognostic 
significance of anti-p53 auto-antibody. The majority of studies of anti-p53 auto- 
antibody in CRC report no independent prognostic value (Table 3.7). The minority of 
studies which report adverse prognostic significance of anti-p53 in CRC should be 
interpreted with caution (Shiota et al., 2000, Kressner et al., 1998, Houbiers et al., 
1995).
The first of these studies associated anti-p53 auto-antibody with decreased overall and 
disease-free survival, but only in selective analysis of Duke's A and Bl CRC 
(Houbiers et al., 1995). This prognostic significance was not maintained in 
multivariate analysis of all Dukes stages. Similarly, adverse prognostic significance 
was seen in univariate but again lost in multivariate analysis in the second study 
(Kressner et al., 1998). The third study by Tang et al associated the auto-antibody 
sero-positivity with N3 CRC (Tang et al., 2001). However, the N3 stage (regional and 
central lymph node involvement) in this study should be classified Ml as discussed 
previously (Section 1.1.7.1.2), in which case, anti-p53 auto-antibody was in fact 
associated with metastatic disease. Even so, univariate prognostic significance was 
lost in multivariate analysis. Only one study reports an independent anti-p53 auto- 
antibody prognostic significance and is discussed next.
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Table 3.7: Prognostic effect of anti p53 auto-antibody (anti-p53) in CRC. H
epatocellular carcinom
a (HCC)
Study (Year)
(Suppiah et al., 
2008)
(M
uller et al., 
2006)
(Tang et al., 
2001)
(Cbang et al., 
2005)
(Shiota et al., 
2000)
(Kressner et al., 
1998)
(Hou biers et al., 
1995)
%
 (n)
21.7(20/92)
28.8 (70 / 243)
13(130/998)
28.(147 / 167)
25(18/71)
32.1 (59/184)
25.5(65/255)
Follow-up
M
edian 97m
5 
-year trial 
protocol
Recruitm
ent 
1995-2000
M
edian 36.3 
m
onths (22 
-
 85)
Not stated
M
edian 6 years
36 m
onths
Findings
No difference in overall survival (62 vs. 60 m
onths) or disease-free survival (73 vs. 82 m
onths)
No survival difference with anti-p53 in CRC and other cancers. Trend tow
ards decreased survival 
in anti-p53 positive patients with HCC and breast carcinom
a
Anti-p53 associated with decreased survival in univariate analysis but not m
ultivariate analysis. 
Anti-p53 associated with advanced nodal disease (Stage N
2  >N3) and m
etastases (M
l)
P53 m
utation associated with poor differentiation and advanced stage. M
ultivariate analysis 
shows p53 m
utation m
ost significant survival predictor, followed by CRC stage. No prognostic 
significance of p53 protein expression or anti-p53
Anti-p53 associated with shorter overall survival (20 vs. 56 m
onths) but highly significant 
association with m
etastases (M
l). Cox regression showed prognostic significance with liver 
m
etastases, TNM
 stage. Dukes stage, Cal9-9 and anti-p53.(in that order).
Anti-p53 associated with decreased survival in univariate, but not m
ultivariate analysis. Anti-p53 
is independent prognostic indicator in D
ukes' A 
-
 C with curative surgery (i.e. when m
etastases 
excluded)
Anti-p53 associated with reduced overall (75% vs. 88%) and disease-free survival (56% vs. 64%) 
at 3 years in subgroup analysis of D
ukes' A and Bl. No difference in overall survival (61 vs. 
68%) or disease-free survival (51% vs. 58%) when all stages included
The final study reported significantly shorted median OS in anti-p53 auto-antibody 
positive patients (20 vs. 56 months). Stage IV CRC had uncharacteristically high sero- 
positivity rates thus strongly associating anti-p53 auto-antibody with metastatic disease. 
This was confirmed by the poor median survival of 20 months in the anti-p53 sero- 
positive group which contrasts with other studies reporting median 5-year survival rates 
of > 50% in anti-p53 auto-antibody positive patients (Muller et al., 2006, Suppiah et al., 
2008, Tang et al., 2001). The anti-p53 auto-antibody bias towards Stage IV disease led to 
the auto-antibody maintaining prognostic significance in the Cox regression model. 
However, its significance was still secondary to a multitude of other well established 
prognostic factors such as Duke's stage, liver metastases, rumour stage; and even lesser 
established factors such as CEA (Shiota et al., 2000). Incredibly, the anti-p53 auto- 
antibody in this study had lesser prognostic significance than CA19-9, a pancreatic 
tumour marker which is not even recommended for screening or surveillance purposes in 
pancreatic cancer. Hence this study should be disregarded (ASCO, 2006).
In summary, anti-p53 auto-antibody does not display independent prognostic value. 
Three studies report significance but only in univariate analysis due to association with 
stronger prognostic indicators, which was always lost in multivariate analysis. The only 
study to report independent significance should be disregarded. The auto-antibody on its 
own is most likely a para-neoplastic phenomenon which may accompany advanced 
tumours, but does not add any independent prognostic value.
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3.6 Conclusion
The anti-p53 auto-antibody represents the end-point of a complex multi-factorial 
humoral response to the accumulation of p53 protein, which is usually a result of 
mutation, but can also occur through a variety of other pathways. It has low (13 - 
32%) sensitivity, near 100% specificity for all cancer, but does not predict for CRC 
alone. Sero-positivity rates may increase in early post-dysplasia but does not correlate 
with local, nodal involvement of distal spread. It is not sufficiently consistent to form 
a separate stage classification. Similarly, low sensitivity, poor CRC-specificity and 
the variability of an IgG response makes it unsuitable for diagnosis, screening 
(general of high-risk populations) and post-resection surveillance. The sporadic 
association with advanced disease in flawed minor studies suggest adverse prognostic 
significance, which is always lost in multivariate analysis. Anti-p53 auto-antibody 
does not display independent prognostic significance.
4 Chapter 4: Anti-p53 Auto-antibody Results and 
Discussion
4.1 Introduction
The aim of this thesis was to investigate the long-term prognostic significance of anti- 
p53 auto-antibody. This was ensured by setting rigid inclusion criteria of samples 
with minimum 5-year follow-up which significantly limited the number of serum 
samples available for analysis. Measurement of anti-p53 auto-antibody in plasma 
samples could increase sample size but the accuracy of plasma titres has never been 
reported. Hence, a study of comparability between anti-p53 auto-antibodies in serum 
and plasma was firstly undertaken (Section 4.2), followed by results of the long-term 
prognostic significance of anti-p53 auto-antibody (Section 4.3).
4.2 Anti-p53 auto-antibody in serum and plasma
Serum is a processed liquid component of blood which retains the soluble components 
of blood (e.g. electrolytes, immunoglobulins) but without cells or clotting factors. 
Plasma is another liquid component of blood, which similarly contains electrolytes 
and hormones but in addition, also contains clotting and tissue factors. Anti-p53 auto- 
antibody has always been measured in serum. Eighteen "paired" plasma-serum 
samples were available. As plasma anti-p53 auto-antibody titres had not been reported 
before, and the ELISA manufacturer recommended serum for anti-p53 auto-antibody 
measurement, plasma anti-p53 auto-antibody titres required validation first.
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4.2.1 Validation ELISA Technique
The ELISA methodology for plasma validation was demonstrated by
  High R2 (0.9978) indicating near perfect reliability (Figure 4.1).
  CoV OD45onm < 20% in 41 out of 48 (>85%) duplicate assays indicating good 
technique.
Figure 4.1: Calibration Curve for ELISA comparing serum and plasma titres of anti- 
p53 auto-antibody; Optical density (jc-axis) = OD45onm
u,
1.2 
1
° 8
i- 0.6
Q 
OCD 04
0.2
0
-02
Plate: Comparison of Serum & Plasma
y = -0.1628X2 + 0.9021X - 0.0673 
R2 = 0.9978
, 0.67
0.4995, 0.33 
13635, 0.25___ 
£2425, 0.16
ro 089, 0
OPTICAL DENSITY
1.7155,1-
0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
4.2.2 Comparison of serum and plasma anti-p53 auto-antibody
The mean OD45onm of the negative control standard = 0.0895. Samples with OD450nm 
>0.0895 were labelled positive, and those below this were labelled negative. Anti-p53 
auto-antibody was present in 5 patients. There was perfect agreement in anti-p53 
auto-antibody presence between plasma and serum samples in qualitative assessment.
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The CoV comparing the mean plasma and serum titres in each patient was < 20% in 
85% (177 20) which suggested good agreement between serum and plasma titres in 
qualitative analysis. Quantitative analysis by linear regression (R2 = 0.9321) also 
concluded good correlation between serum and plasma titres. However, when 
graphically displayed, sero-positive samples (top right quadrant) were quite 
disparately away from the "line-of-best-fit" (Figure 4.2) which suggested the high R2 
value may be biased by the large cluster of negative samples (bottom left quadrant). 
The positive samples were then analysed separately.
Figure 4.2: Liner regression of serum and plasma antibody titres
Comparison of serum and plasma titres
Serum titres
4.2.3 Analysis of Sero-positive samples only
The mean CoV was poor (20%) between plasma and serum antibody titres and caused 
by a single outlier (Patient 164) and to a lesser extent, Patient 145 (Table 4.1). CoV 
decreased to 7% and R2 increased from 0.624 to 0.872 when Patient 164 was excluded 
(Figure 4.3). This discrepancy and the exclusion of plasma samples are discussed.
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Table 4.1: CoV between serum and plasma auto-antibody titre in positive patients
Patient
143
164
145
141
169
Mean Serum
22.053
6.307
24.755
7.074
27.364
Mean Plasma
23.125
19.911
31.764
7.329
CoV
0.033557
0.733807
0.175379
0.025038
25.585 jH 0.047515
.-.-.   '"
Figure 4.3: Linear regression with and without outlier (Patient 164)
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4.2.4 Discussion
The R2 comparing plasma and serum anti-p53 auto-antibody titres were the weakest in 
this thesis and may be attributed to small number (5) of patients. However, similar 
sample sizes of 7 calibrators were used to plot other ELISA calibration curves in this 
thesis, all of which R2 > 0.98 (Section 1.1) thus proving good R2 is obtainable despite 
small samples.
The discrepancy between serum and plasma titres may be a true result or 
methodological error. Methodological error would be shown by high CoV in duplicate 
assays. The CoV of duplicate serum (0%) and duplicate plasma (0.3%) shows nearly 
identical antibody titres making this highly unlikely attributable to methodological 
error. Similarly, the majority of the duplicate samples assayed in this ELISA also had 
CoV < 10%, again supporting good methodological technique. Finally, other studies 
report CoV < 3% in ELISA, albeit in serum samples only, suggesting reliable 
measurements with ELISA (Shimada et al., 2003). Hence, the discrepancy between 
plasma and serum auto-antibody titres most probably represents a true result. The 
most likely cause of the higher anti-p53 auto-antibody readings in plasma would be 
non-specific binding by plasma components which are not present in serum.
The inclusion of plasma samples could increase the cohort size but with potential 
introduction of substantial error (CoV 17 - 73% in 40% patients). As the sample size 
was already relatively large (92) with only modest benefit from plasma inclusion, 
plasma anti-p53 auto-antibody measurements were excluded from prognostic studies 
of anti-p53 auto-antibody in CRC.
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4.3 Results: Prognostic Significance of anti-p53 auto-antibody
Anti-p53 auto-antibody was measured (Section 2.2), the ELISA technique assessed 
(Section 4.3.1) and the association between anti-p53 auto-antibody and clinical 
parameters (Section 4.3) and prognosis (Section 4.4) was evaluated.
4 J.I ELISA Validation
Serum samples were labelled "positive" or "negative" (Table 4.2). "Critical" samples 
were re-assayed. Sera were not available for repeat assay in 3 "critical" patients and 
these were labelled negative. The R2 demonstrates good technique. Plate 1 & Plate 3 
display R2 ~ 1.0 suggesting near perfect correlation (Figure 4.4).
Table 4.2: OD45onm criteria used for labelling serum samples
Plate 1
Plate 2
Plate 3
"Positive"
> 0.253
> 0.073
>0.215
"Negative"
<0.212
< 0.06 1
<0.179
"Critical"
0.212-0.253
0.060 - 0.073
0.179-0.215
Figure 4.4: Calibration curve and R in all ELISA plates
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1 15 2 
OPTICAL DENSITY
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4.3.2 Anti-p53 auto-antibody in patients vs. controls
The control group comprised 8 healthy subjects (6 male, 2 female) and 20 patients (11 
male, 9 female) with benign neurological disease (Appendix 7.9 ). There were 17 
males and 11 females (1.6:1 ratio) with a mean age of 67.5 (63.5 -72.8) years. The 
patient group consisted of 58 male and 34 female patients (1.7:1) with mean age of 70 
years (32 - 91). There was no significant difference in age or gender between the two 
groups. Anti-p53 auto-antibody was significantly higher in the patient group, 21.7% 
(20 / 92), compared to 0% (0/20) in the control group (p = 0.008).
43.3 Anti-p53 auto-antibody and Clinico-pathological Features of CRC
Anti-p53 auto-antibody was present in 22% (20/92). The overall mean patient age was 
70 years (32 - 91) and hence age-specific analysis was divided to patients < 70 years 
and > 70 years of age. Anti-p53 auto-antibody was not associated with individual 
Dukes' stage or TNM stages, T - stage, N - stage, M - stage, differentiation or 
mucinous morphology (Table 4.3). Individual groups within a variable were then 
combined to form larger groups, for example, Dukes' A combined with Dukes' B, and 
Dukes C combined with Dukes' D (Dukes A/B vs. C/D) to obtain larger groups and 
more robust analysis. These groups could be statistically rationally combined as there 
were no significant differences (^) in anti-p53 auto-antibody frequency between each 
groups, for example Dukes' A and B could be combined as sero-positivity rates were 
similar (20% and 27% respectively). Again, there was no association between anti- 
p53 auto-antibody and these new combined groups (Table 4.3b)
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Serum anti-p53 auto-antibody titres were calculated but preliminary analysis showed 
substantial titre variation within a small sample (Range: 5.2 - 134.2 lU/lOOul in 20 
patients, Table 4.3a). There was no association with stage but the numbers were too 
small (e.g. 1 patient in Dukes D) for further analysis. Mean titres in each group were 
Dukes' A (15.9 lU/lOOul), Dukes' B (43.4 IU/100nl), Dukes' Cl (32.4 lU/lOOul), 
Dukes' C2 (19.2 lU/lOOul), overall Dukes' C (29.5 IU/100nl, 265.1/9) and 1 patient 
in Dukes' D (7.9 IU/100nl). Hence, further analysis was performed using categorical 
"positive/negative" rather than numerical values.
Anti-p53 titre (lU/lOOuJ)
5.2
7
7.9
8.6
9.2
10.2
10.5
14
14.4
18.6
19.2
19.8
25
28.9
35.2
38.1
43.5
50.8
123.9
134.2
Dukes' Stage
Cl
Cl
D
A
Cl
B
B
A
Cl
C2
B
C2
A
Cl
B
Cl
B
B
Cl
B
Table 4.3a: Increasing serum titres with corresponding coloured Dukes' stage
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Table 4.3b: Anti-p53 antibody (-) negative and (+) positive; and clinical parameters
Parameter
Age < 70
>70
Sex Male
Female
Dukes' A
B
Cl
C2
Cl/2
D
A/B
C/D
Stage Stage 1
Stage 11
Stage III
Stage IV
Stage I / II
Stage III / IV
T-stage Tl
T2
T3
T4
Tl/2
T3/4
N-stage NO
Nl
N2
NO
Nl/2
M-stage MO
Ml
Site Proximal
Distal
Rectum
Diff Well
Moderate
Poor
Well/Mod
Poor
Mucinous
Non-mucinous
n
44
48
58
34
11
35
35
7
42
4
46
46
5
41
41
4
46
46
6
7
67
12
13
79
47
33
12
47
45
88
4
24
28
40
11
44
37
55
37
11
81
Anti-p53 (-); n (%)
33 (75)
39(18.8)
46 (79.3)
26 (76.5)
8(72.3)
28 (80)
28 (80)
5(71.4)
33 (78.6)
3(75)
36(78.3)
36(78.3)
4(80)
32 (78)
33 (78.6)
3 (75)
36(78.3)
36(78.3)
5(83.3)
5(71.4)
50 (75.8)
II (91.7)
10(76.9)
62(78.5)
37(78.7)
26 (78.8)
9(75)
37(78.7)
35 (77.8)
69 (78.4)
3(75)
22(91.7)
21 (75)
29 (72.5)
8 (72.7)
32 (72.7)
32(86.5)
40 (72.7)
32 (86.5)
8(72.7)
64 (79)
- ——————————————————— ~T ——————————— T"
Anti-p53(+); n (%)
11 (25)
9(18.8)
12(20.7)
8(23.5)
3 (27.3)
7(20)
7(20)
2(28.6)
9(21.4)
1 (25)
10(21.7)
10(21.7)
1(20)
9(22)
9(22)
1 (25)
10(21.7)
10(21.7)
1 (14.3)
2 (28.6)
16(23.9)
1 (8.3)
3(23.1)
17(21.5)
10(21.3)
7(21.2)
3(25)
10(21.3)
10(22.2)
19(21.6)
1 (25)
2(8.3)
7(25)
1 1 (27.5)
3 (27.3)
12(27.3)
5(13.5)
15(27.3)
5(13.5)
3 (27.3)
17(21)
P
0.750
0.468
-
-
-
-
-
-
1.0
-
-
-
-
1.0
-
-
-
-
0.900
-
-
-
0.912
0.632 f
0.175
-
-
-
0.117
0.699 '
Diff. Differentiation; Mod. Moderate; p-value •£ test or Fisher's Exact (n<5)
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4.4 Anti-p53 auto-antibody and Survival
Survival analysis was performed by examining the follow-up period distribution 
(Section 4.4.1), patients' final status (Section 4.4.2) and overall and disease-free 
survival (Section 4.4.3)
4.4.1 Kolmogrov-Smirnov analysis of follow-up duration
The mean length of follow up was 45.3 months in the anti-p53 auto-antibody positive 
group and 50.8 months in the negative group (p = 0.411). The statistical tests to be 
used are determined by normality of follow-up distribution. The follow-up duration 
demonstrated significant (p=0.015) skew (Figure 4.5 & Figure 4.6). Therefore the 
choice of statistical tests for survival analysis was limited to non-parametric tests.
4.4.2 Final Disease Status
The median time from date of diagnosis to end of study period (1 October 2006) was 
97 months (IQR: 91-102). The patients' status at end of study period is shown in 
Table 4.4.
Table 4.4: Patient status by anti-53 auto-antibody presence. (%) are expressed as 
proportion within each column.
Status
Not known/moved
Alive, Disease free
Alive, with Disease
Died of Disease
Died, other cause
Total
Anti-p53 Negative 
n = 72 (%)
2 (2.8)
26(36.1)
0
24(33.3)
20 (27.8)
72(100)
Anti-p53 Positive
n = 20 (%)
1 (5.0)
6 (30.0)
0
9 (45.0)
4 (20.0)
20(100)
All patients 
n (%)
3(3.3)
32 (34.8)
0
33 (35.9)
24(26.1)
92(100)
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Figure 4.5: Overall Length of Follow-up Distribution
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Figure 4.6: Follow-up distribution by anti-p53 auto-antibody status
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4.4.3 Overall Survival and Disease Free Analysis
Median overall survival (OS) in all patients was 62 months (95% CI: 57.6 - 66.4). 
Thirty two patients were alive at the end of the study. Three patients who had moved 
away were excluded. Of the 57 patients who died, 33 died of the disease and 24 died 
of other causes. Dukes' / TNM stage, T-stage, N-Stage, M-stage and differentiation 
were selected for survival analysis to confirm consistency with current literature and 
hence increase validity of this cohort. The survival curve for each variable in OS is 
shown in Appendix 7.13. OS uni- and multi-variate analysis is summarised in Table 
4.5. Dukes' stage (C/D), T-stage (T3/4), Node positive disease, metastases at 
presentation and tumour location were associated with decreased OS in univariate 
analysis. Dukes' / TNM stage was significant in multi-variate model. Anti-p53 auto- 
antibody was not associated with OS in uni- or multi-variate analysis.
The median disease-free survival (DPS) of 73 months (95% CI: 60.0 - 86.0) was 
greater than the median OS of 62 months. At the end of follow-up, 24 patients had 
died of non-cancer related death leaving 68 patients for disease-specific survival 
analysis. The DPS survival curves are shown in Appendix 7.14. DPS in univariate 
and multi-variate analysis is summarised in Table 4.6. Dukes' stage (C/D), T-stage 
(T3/4), Node positive disease, metastases at presentation was highly associated with 
decreased DPS, even more so than in OS analysis. Dukes' / TNM stage was the only 
independent prognostic factor in DPS. Poor differentiation displayed a non-significant 
toward decreased DPS which is discussed later (Section 4.4.5). Anti-p53 auto- 
antibody was not associated with DPS in uni- or multi-variate analysis.
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Table 4.5: Median overall survival (in months) and prognostic significance of clinico- 
pathological parameters
Parameter
Anti-p53 Antibody
Dukes' Stage
TNM Stage
T stage
N stage
M stage
Site
Differentiation
Variable
Positive
Negative
A/B
C/D
1/11
III/ IV
Tl 12
T3/4
Node negative
Node positive
MO
Ml
Rectum
Left
Right
Well/Moderate
Poor
Median (95% CI)
62(43.8-80.3)
60(52.9-67.1)
73(58-88)
48(30.9-65.1)
73 (58 - 88)
48(30.9-65.1)
60(51.1 -68.9)
62(57.2-66.8)
73(58.0-88.0)
51 (34.5-67.5)
62(53.9-70.1)
7(0.0-34.4)
60(50.2-69.8)
72(54.9-89.1)
48.0(21.2-74.2)
62(50.4-73.6)
60(35.2-84.8)
*P
0.980
0.005
0,005
0.994
0.009
(Mill
0.036
0.191
*P
0.296
Nl
0.00 1
0.278
NI
NI
NI
0.258
f Univariate analysis using log-rank test. * Cox-regression using 4 covariates (anti- 
p53 autoantibody, T stage, TNM stage and poor differentiation); Nl - not included in 
Cox regression model
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Table 4.6: Median disease-free survival (in months) and prognostic significance of 
clinico-pathological parameters.
Parameter
Anti-p53 Antibody
Dukes 1 Stage
TNM Stage
T stage
N stage
M stage
Site
Differentiation
Variable
Positive
Negative
A/B
C/D
I/ II
III/ IV
Tl 11
T3/4
Node negative
Node positive
MO
Ml
Rectum
Left
Right
Well/Moderate
Poor
Median (95% CI)
73 (49-97)
82(52-112)
see below
54 (36-60)
see below
54(36-72)
(NA)
73 (62-84)
see below
54(36-72)
74 (56-92)
7 (0-34)
73(54-92)
74(69-79)
82 (NA)
74 (56-92)
62(49-75)
fp
0.874
0.000
0.005
0.475
0.000
0.001
0.419
0.376
*P
0.112
NI
0.001
0.856
NI
NI
NI
0.208
Median disease-free survival in Dukes" A/B and NO cannot be calculated due to
insufficient events (disease recurrence/cancer death) as reflected in highly significant 
p-value. ^ Univariate analysis using log-rank test. * Cox-regression using 4 covariates 
(anti-p53 autoantibody, T stage, Dukes' stage, poor differentiation); NI - not included
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4.4.4 Anti-p53 auto-antibody and disease progression
Anti-p53 auto-antibody was tested for ability to predict disease progression, defined 
as local recurrence or post-operative metastases. Adjuvant chemotherapy may 
influence local recurrence and systemic metastases. Hence chemotherapy provision in 
each anti-p53 auto-antibody group was compared first. Forty six patients with Stage 
III / IV were offered chemotherapy. Twenty seven received chemotherapy and 19 
patients not receive chemotherapy due to refusal or significant co-morbidity. There as 
no difference in chemotherapy use between the anti anti-p53 auto-antibody positive 
(25%, 5/20) and auto-antibody negative group (30.5%, 22/72).
4.4.4.1 Local recurrence
Anti-p53 auto-antibody positive patients had lower local recurrence rate (5% vs. 10%) 
which was not statistically significant (p = 0.479) (Table 4.7). The proportion of 
patients with the anti-p53 auto-antibody who developed local recurrence (13%; 1 / 8) 
was also similar to those without the auto-antibody who developed local recurrence 
(23%, 19/81). Hence, anti-p53 auto-antibody was not associated with local recurrence.
Table 4.7: Anti-p53 auto-antibody status and subsequent local recurrence.
NoLR
LR
Total
%
Anti-p53 Negative
62
7
69
10% (7/69)
Anti-p53 Positive
19
1
20
5% (1/20)
LR, local recurrence, (x~ test, p=NS)
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4.4.4.2 Post-operative distant metastases
Anti-p53 auto-antibody presence was tested for ability to predict post-operative 
metastases. Firstly, anti-p53 auto-antibody frequency was similar in patients with 
metastases and those without metastases at diagnosis (M-stage, Section 4.3.3). 
Secondly, anti-p53 auto-antibody was not associated with post-operative metastases 
which occurred in 15.8% (3/19) anti-p53 auto-antibody positive patients compared 
to 19.7% (13 / 66) anti-p53 auto-antibody negative patients (Table 4.8). Finally, the 
overall incidence of metastases (pre- and post-operative metastases) was similar in the 
anti-p53 auto-antibody positive group (20%, 4 / 20) and the anti-p53 auto-antibody 
negative group (23%, 16/69) (Table 4.8). Anti-p53 auto-antibody was not associated 
with metastases at diagnosis or long-term incidence of metastases. Anti-p53 auto- 
antibody was also not able to predict subsequent development of metastases.
Table 4.8: Anti-p53 auto-antibody association and metastases
Pre met
Post met
Total
Anti-p53 Negative
3
13
23% (16/69)
Anti-p53 Positive
1
3
20% (4 / 20)
Total
4
16
23% (20 / 89)
Total patients
92
89*
Pre met, pre-operative metastases; Post met, Post-operative metastases; Total, total 
number of patients with metastases. * indicates 3 patients who were lost from final 
analysis (x2 test, p=NS).
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4.4.5 Poor Differentiation and Metastases
Poor differentiation has been associated with more aggressive CRC (Section 1.1.7.2). 
Poor differentiation had no prognostic significance in multivariate analysis in this 
thesis. However, poor differentiation was associated with higher rates of post­ 
operative metastases which was not statistically significant (p = 0.212) (Table 4.9).
Table 4.9: Differentiation (Diff.) and post-operative metastases (pM) (x2 test, p=NS)
pMO
pM 1
Total % with pM
Well / Mod
41
11
21% (11 753)
Poor
22
11
31% (11 736)
Total
63
22
% with Poor Diff.
35% (22 7 63)
50% (11 722)
Poor differentiation was then compared with overall incidence of metastases (pre- and 
post-operative metastases). Poor differentiation was again associated with higher 
overall rate of metastases (39% vs. 23%) (Table 4.10). This did not achieve statistical 
significance at 95% confidence interval (p=0.098) but was significant at the 90% 
confidence interval.
Table 4.10: CRC differentiation (Diff) and overall metastases (M), (-£ test, p=NS)
MO
Ml
Total % with M
Well / Mod
41
12
23% (12 7 53)
Poor
22
14
39% (14 7 36)
Total
63
26
% with Poor Diff.
35% (22 7 63)
46% (12 7 26)
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4.5 Discussion : Confirming validity of thesis cohort and results
Table 4.11 schematically compares this thesis results with all ELISA reports of anti- 
p53 auto-antibody in CRC. The study by Muller et al used immunoblot but was 
included as this was a recent, large study. A summary comparison with % agreement 
with other studies is performed below to confirm validity of the thesis cohort,
Age and gender: Anti-p53 auto-antibody was not associated with age or gender in 
this thesis, which is consistent with all (100%) other published reports.
Dukes' stage: Anti-p53 was not associated with Dukes' stage in this thesis, which is 
similar to 4 out of 7 (57%) studies (Section 4.5.1)
TNM stage: Anti-p53 was not associated with TNM stage in this thesis, which is 
similar to 4 out of 6 (66%) studies (Section 4.5.1)
T stage: Anti-p53 was not associated with T-stage in this thesis, which is consistent 
with all 3 (100%) of the other studies reporting this (Section 4.5.1)
N-stage: Anti-p53 was not associated with nodal involvement in this thesis, which is 
consistent with 5 out of 8 (63%) studies (Section 4.5.1)
M-stage: Anti-p53 auto-antibody was not associated with metastases in this thesis, 
which is consistent with 5 out of 7 (71%) studies. (Section 4.5.1)
Differentiation: Anti-p53 auto-antibody was not associated with poor differentiation 
which is consistent with 6 out of 7 (86%) studies (Section 4.5.1)
Location: Anti-p53 auto-antibody was not associated with location, which is 
consistent with 6 out of 7 (86%) studies (Section 4.5.1)
Hence, this patient cohort and anti-p53 association with clinico-pathological factors is 
consistent with current evidence. This strengthens the data validity of this thesis 
cohort in long-term survival analysis of anti-p53 auto-antibody in CRC (Chapter 4).
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Table 4.11: A
ssociation betw
een anti-p53 auto-antibody and clinico-pathological param
eters of CRC in all published ELISA
 studies, 
except M
uller et al (im
m
unoblot).
A
uthor
(Y
ear)
C
urrent
(2010)
Nozoe
(2007)
M
uller 
(2006)
C
hang
(2005)
Lechpam
m
er
(2004)
Age
XXXNRX
G
ender
XXXXX
D
ukes'
X
A/B vs.
C/DV
A=0/3
XA=0
N
RV
A =0/28
A vs. B
A vs. C
TN
MX
I 
II vs.
tll/IVV
Tl/2
vs.
T3/4
XXNR
TXTl/2
vs.
T3/4
XNR
NR
N
B
NX
NO vs. N 1
V
NO vs. N 1
X
N
2/N
3(N
S)
NR
V A vs. C
X B vs. C
MX
M
O vs.
M
!
N
RX
M
l(N
S)
NRX
Location
X
Colon v.v.
Rectum
XNRX
N
R
Diff.
X
W
ell/M
od vs.
Poor,
X
W
ell vs. M
od
vs. Poor
X
W
ell vs. M
od.
I's. Poor (NS)
V
W
ell vs. M
od
vs. Poor
X
W
ell vs. M
od
vs. Poor
O
thers
X
m
ucin
V
lym
phatic
invasion
X
M
ucin
(M
S)
Prognosis
XNR
N
RXNR
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Broil
(2001)
Tang
(2001)
Shiota
(2000)
Bielicki
(1999)
H
oubiers
(1995)
A
uthor
(Y
ear)
NRXXXX
Age
NRXXXX
G
ender
XNRV
A
-C vs. D
X
A vs.
B/C/D
A
/B
vs.C
/D
X
D
ukes'
XX
I&
I1 V.V.
HI
vs. IVV
I-III vs.
IVNR
N
R
TN
M
N
RX
N
R
N
R
N
RT
N
R
V> 10 nodes
X
<10 nodes
X
A/B vs. C/D
XXN
NRVMO
vs. M
l
V
I-III vs.
IVXXM
XVLeft,
rectum
 vs.
right
XXNH
Location
XXX
*
N
RV
W
ell vs. M
od
vs. Poor
Diff.
> lOcrrr
(N
S)
X
m
ucin
>50cm
\
CEA.
Cal9-9
NS
>50m
m
diam
eter
NSV
shape.
vascular
invasion
O
thers
XV
U
nivariate
onlyV
M
ultivariate
N
RV
A & B 1 only
U
nivariate
Prognosis
The yellow cells indicate significant association between anti-p53 auto-antibody and a clinico-pathological param
eter in that study. 
The sm
aller font indicates the groups com
pared in the study. (X) No association; (V) Significant association. (NS) Increased trend but 
not Significant; (NR) Not reported; (Diff) differentiation; (M
od) m
oderate; (m
ucin) m
ucinous CRC
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4.5.1 Anti-p53 auto-antibody and Clinico-pathological features of CRC
The anti-p53 auto-antibody frequency in this thesis (21.7%) is consistent with the 
mean 22% frequency from all studies over the last 30 years (Table 3.1) and 19% in 
ELISA only studies (Table 3.2). Two ELISA studies reported an unusually high 
frequency of 63% and 47% but the discrepant results in these studies have been 
discussed (Nozoe et al., 2007, Takeda et al., 200Ib) (Section 3.5.2). The age and 
gender distribution was similar to other studies (and that expected of a CRC 
population) with no differences in anti-p53 auto-antibody frequency which is also 
consistent with other reports. The stage distribution was consistent with other studies 
which similarly demonstrate smaller proportion of Dukes' A & D stages with majority 
of patients in Dukes' B & C. This contrasts with CRC population trends of up to 30% 
Dukes' D at diagnosis (Andreoni et al., 2007). The discrepancy between study 
population and general CRC population is due to a significant proportions of Dukes' 
D patients presenting with gastrointestinal obstruction / perforation which requires 
emergency surgery, and hence are not included in trials. Another substantial 
proportion of Dukes' D patients are diagnosed electively and receive palliation only 
including chemotherapy and palliative surgery, but not curative surgery. In this study, 
only Dukes' D CRC, operated on electively and with curative intent were included 
resulting in a small proportion of highly selected Dukes' D patients (4%), compared 
to the CRC population trends of 30%.
There was no association between anti-p53 auto-antibody and CRC stage which is 
consistent with most reports. The four studies reporting a correlation between anti-p53 
auto-antibody and advanced stage is due to low numbers of Dukes A CRC (0/3) 
(Nozoe et al., 2007), or unusually low sero-positivity in early CRC (0/28)
(Lechpammer et al., 2004) or biased classification (Dukes A-C vs. D) (Shiota et al.,
2000). The fourth, and the largest anti-p53 auto-antibody in CRC study by Tang et al, 
reported increased anti-p53 auto-antibody with NO-N2 vs. N3 disease progression, a 
conclusion again based on biased selective group analysis, which when corrected for, 
showed no association between anti-p53 auto-antibody and TNM Stage (Tang et al.,
2001) (Section 3.5.2.1). Hence, anti-p53 is not associated with overall Dukes' or 
UICC TNM CRC stage.
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4.5.2 Anti-p53 auto-antibody and prognosis
The reported prognostic significance of anti-p53 auto-antibody in CRC was discussed 
(Section 4.4.5) and results of this thesis were compared to other studies (Table 4.11). 
This table shows that anti-p53 auto-antibody only displays prognostic value when 
anti-p53 is associated with other poor prognostic indicators within the study.
4.5.2.1 Overall and Disease-Free Survival
The median 97 month follow-up for survival analysis is the longest published follow- 
up period to date and reflects the primary objective of this thesis and the pre-set 
inclusion criteria of minimum 5 year follow-up. The closest published follow-up 
period to this was median 36 months (Chang et ah, 2005, Houbiers et al., 1995). 
Univariate analysis showed advanced Dukes' C&D, or Stage III & IV, nodal 
involvement (Nl / 2), metastasis at diagnosis (Ml) to be poor prognostic indicators in 
overall survival (OS) (Table 4.5). This is consistent with published evidence and 
strengthens the data validity of this cohort. Anti-p53 auto-antibody did not predict OS.
There smaller sample size (68) for DPS analysis is expected in a population with 
median age 70 years, co-morbidity, cancer diagnosis, major surgery and median 
follow-up of 97 months. No patients "with disease" were alive at the end of this study 
due to the natural history of CRC. Patients with metastases at presentation, or those 
with recurrence are unlikely to survive this follow-up period. The rate of attrition in 
this and many other survival graphs beyond 50 months follow- up increases 
(Appendix 7.13), most likely due to co-morbidity in this already elderly population.
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The overall median DPS was 73 months. Univariate analysis showed advanced 
Dukes' stage and TNM stage, nodal involvement and metastases to be poor 
prognostic indicators (Table 4.6) which is consistent with other studies. Only four 
factors were selected for inclusion into the Cox-regression model to reduce over- 
analysis - anti-p53 auto-antibody (the study objective), and Dukes' stage, T - stage 
and CRC differentiation. TNM stage is equivalent to Dukes' stage and its inclusion 
would dilute any prognostic significance of anti-p53 auto-antibody. Similarly, N- and 
M- stage were already categorised within Dukes' stage and would also have diluted 
any subtle prognostic significance. Of the remaining factors (differentiation and CRC 
site), poor differentiation was selected as it had stronger adverse prognostic 
significance than location. Multivariate DPS analysis showed only Dukes' stage to be 
an independent prognostic indicator which is consistent with all reports.
A few studies report anti-p53 auto-antibody prognostic significance in univariate 
analysis which is always lost in multivariate analysis supporting the observation that 
this is due to anti-p53 auto-antibody association with adverse clinico-pathological 
parameters (Shiota et al., 2000, Kressner et al., 1998, Houbiers et al., 1995). The only 
study to report independent anti-p53 auto-antibody prognostic significance in multi­ 
variate analysis linked anti-p53 auto-antibody extremely strongly with metastatic 
disease and should be disregarded. Anti-p53 auto-antibody significance was 
secondary to a vast array of traditional prognostic factors (e.g. stage). Incredibly, anti- 
p53 auto-antibody even had less prognostic value than CA 19-9, a pancreatic tumour 
marker which is not recommended for used in CRC or American and European 
pancreatic cancer guidelines (Locker et al., 2006, Duffy et al., 2009).
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4.5.2.2 Local Recurrence and Metastases
Subtle prognostic indicators (e.g. differentiation) can be over-shadowed by the 
influence of stronger factors in multi-variate analysis. Poor differentiation did not 
display prognostic significance in this thesis. Interestingly, when stage was excluded, 
poor differentiation was able to predicted post-operative metastases at the 90% CI, but 
not 95% CI (Section 4.4.5). This may explain the divergence in the DPS curves for 
differentiation (Appendix 7.14). Poor differentiation had significantly lower DPS in 
up to years following diagnosis which is the period when metastases most likely 
occurs. However, the DPS curves converge beyond 5 years when metastases are rare. 
Poor differentiation may not display prognostic significance as it was a weak 
prognostic indicator and its effect was masked by incorporation of Dukes' D or Ml 
status into survival analysis. As this supported the notion than subtle prognostic 
effects can be masked by strong prognostic indicators, anti-p53 auto-antibody was 
examined independently for ability to predict local recurrence or metastases. Anti-p53 
auto-antibody again did not predict disease progression (Section 4.4.4)
4.6 Summary
Table 4.11 compares reported associations between clinico-pathological parameters, 
prognosis and anti-p53 auto-antibody in individual studies. It is clear that anti-p53 
auto-antibody only displays prognostic significance if there is a correlation between 
the auto-antibody and other adverse prognostic indicators within the study. No study 
to date reports an independent adverse prognostic significance without the auto- 
antibody being associated with other prognostic indicators.
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The true prognostic significance of a survival variable can only be established in an 
adequately powered trial. Assuming 50% survival at 5 years for all Dukes' stages, an 
average of 1500 patients per group would be required (assuming no drop-out) to 
detect a 5% difference, i.e. 3000 anti-p53 auto-antibody positive patients (two-tailed 
analysis, a 0.05; P 0.2). The sero-positivity is approximately 20% in CRC patients, 
thus requiring 15,000 patients, with 0% drop-out for 5 years, to produce the 3,000 
patients for analysis. Based on conclusions of previous studies and the findings of this 
thesis, a trial of this magnitude is clinically and logistically unfeasible.
The majority of prognostic studies report short to medium term follow-up. This is the 
first study to confirm anti-p53 auto-antibody has no prognostic significance with 
extended follow-up into the long-term. Anti-p53 auto-antibody is a para-neoplastic 
phenomenon which occasionally accompanies advanced tumours but does not 
independently possess short or long-term prognostic value.
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5 Chapter 5: Optimisation of a Method to Detect Anti- 
hTERT auto-antibody
5.1 Introduction
The importance of p53 inactivation and hTERT up-regulation in the "2-hit" 
hypothesis in overcoming M1 (p53) and M2 (hTERT) mortality barriers for cancer 
cells to attain immortality has been discussed (Section 1.3.4). The humoral response 
to p53 inactivation, commonly regarded the "first hit", was demonstrated earlier in 
this thesis. The humoral response to hTERT re-activation, the "second-hit", has only 
been detected in one study which used recombinant hTERT as the target antigen in a 
cohort of patients with hepatocellular carcinoma (Masutomi et al., 2002). There have 
been no further publications since on the isolation of hTERT or the detection of anti- 
hTERT auto-antibody.
The aim of the thesis was to develop an alternative method to detect the anti-hTERT 
auto-antibody response. The anti-hTERT auto-antibody could be correlated with the 
anti-p53 auto-antibody to investigate the significance of the combined presence of 
both humoral responses to these two key events in CRC carcinogenesis. The initial 
objective was to develop a method of isolating hTERT which was more accessible 
than molecular recombinant technology. The isolated hTERT would be used to detect 
anti-hTERT antibody in Western Blot (WB), and later developed into a screening tool 
using ELISA. The processes of optimisation along with suggestions for improvements 
are discussed in this chapter.
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5.2 Selection of Cancer Cells based on Telomerase Activity
Telomerase activity (TA) is reactivated in cancer by hTERT re-expression. 
Telomerase activity is required for cancer cell immortality (Shay and Wright, 2000, 
Hahn et al., 1999, Kim et al., 1994). Several cancer cell lines were examined for 
telomerase activity using Telomerase Repeat Amplification Protocol (TRAP) in 
spectro-photometric ELISA. (TeloTAGGG Telomerase PCR-ELISAPLUS, Roche 
Diagnostics Ltd., West Sussex, UK) (Figure 5.1) (Amarnath, 2004). Detailed 
information of individual cancer cell lines is shown in Appendix 7.3.
Cancer cell lines were initially selected based on telomerase activity rather than cell 
of origin (breast or colon) for two reasons. Firstly, cells with the highest telomerase 
activity are likely to contain the largest amount of hTERT which maximizes the 
chance of hTERT detection. Secondly, several cell lines with different levels of TA 
could be included to determine if anti-hTERT levels corresponded with levels of 
telomerase activity. These selected cancer cell lines were subdivided to high 
(Colo205, T47D), moderate (LoVo, MCF7) and low TA cells (Colo320, Caco). 
However, early experiments were unable to detect any hTERT, possibly due to 
insufficient hTERT quantities. Hence subsequent experiments used only Colo205 cell 
lysates which had the highest TA and theoretically, the highest hTERT load. Colo205 
was also an adenocarcinoma of colorectal origin.
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5.3 Western Blot of Streptavidin Immuno-affinity Column Elute
The cancer cell lysates (5 x 106 -1 x 108 cell equivalents / 40 uj) were passed down 
the Streptavidin immuno-affmity column (Section 2.4.3). The elute was used in WB 
with 5% PAGE, native and reducing conditions and rabbit anti-telomerase (ab32020, 
Abeam, Appendix 7.7) based on preliminary data detecting hTERT in circulating 
tumour cells in the laboratory (Foster, 2005). hTERT was not detected and WB 
conditions were varied substantially by changing the acrylamide content, native vs. 
non-native and reducing vs. non- reducing conditions (Table 5.1). All WB and ECL 
were also repeated twice to minimise non-detection caused by methodological error.
Table 5.1: WB conditions. Each WB was repeated twice with multiple ECL exposure
Acrylamide %
5%
10%
15%
Native
Native
Non-native
Native
Non-native
Native
Non-native
Reducing
Reducing
Non reducing
Reducing
Non reducing
Reducing
Non reducing
Reducing
Non reducing
Reducing
Non reducing
Reducing
Non reducing
ECL
If no detection after 5 minutes, ECL 
repeated with 20 minute exposure, 
40 minute exposure and 60 minute 
exposure
hTERT was not detected despite the all the conditions above, performed in duplicate. 
It was possible the elute did not contain hTERT due to the harsh (pH 2.2) elution 
conditions used in the column which could also have denatured hTERT.
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5.4 Western Blot on Cancer Ceil Lysate
The next WB were performed directly on cell lysates using conditions in Table 5.1. 
This avoided column-related factors and elution conditions. TERT was not detected. 
The WB methodology was then examined in a step-wise manner which were 
performed entirely on Colo205 cell lysate to increase hTERT concentrations. hTERT 
was not detected. The various cell lysate concentrations were increased to maximise 
the amount of hTERT. hTERT was still not detected despite maximum possible lysate 
concentrations evidenced by lysate immobility in the wells (Figure 5.2).
Figure 5.2: Protein migration with maximal cell lysate concentrations
181.8 kDa
Lane 1&10: Benchmark™ Protein Ladder (labels and molecular weights shown on 
either side of figure); Lane 2&3: Colo205 (Ixl08 ceq); Lane 4&5: Colo205 (Ix 107 
ceq); Lane 6&7: MCF7 (Ixl08 ceq); Lane 8&9: Colo320 (IxlO8 ceq)
HeLa nuclear extract was used to increase hTERT in further WB (Table 5.1). hTERT 
was not identified. The reasons were narrowed down to the primary antibody (Section 
5.7) or the WB, which was examined (Section 5.5)
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5.5 Precast Gels and Protein Separation Process
The Pierce Precast Gels were available after the initial WB. The 4% - 20% precast gel 
were used as hTERT (Mw: 120 - 127) should be adequately separated based on 
manufacturers' information. Coomassie stain on "in-house" and precast gels showed 
similar resolution in both gels. The precast gels demonstrated significant advantages 
over "in-house" preparation gels. These were:
1. avoidance of technical problems e.g. gel not setting/ gel distortion or spillage 
during polymerisation/ setting apparatus problems
2. decreased electrophoresis time of 45 minutes compared with 60-90 minutes 
for in-house gels
3. reliability and robustness - precast gel cassettes were less likely to 
split/separate during PAGE and gel recovery
4. availability - precast gels can be stored at 4°C with 18-month shelf life, and is 
ready to use immediately
5. no time required for gel preparation or waiting for polymerisation, thus 
allowing more experiments to be conducted in a day
The precast gels were used in all remaining WB and after the protein separation had 
been validated by Coomassie staining.
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5.5.1.1 Coomassie stain validation of Precast Gels
The Coomassie stain (Figure 5.3) demonstrated the adequacy of the PAGE 
separation. Colo205 cell lysate was separated on the precast gel, and then incubated 
with Coomassie stain, the washed in distilled H20.
Figure 5.3: Coomassie stain of cell lysates in precast gel
- 2 - 3 - 4 H 5h (> - H Sh 9 - 10
Lane [1&10]: Benchmark Prestained Protein Ladder.
Lane [2 - 9]: Duplicate Cok>205 lanes of 5 x 10 ceq.
Lane [2 & 3] 1 :200dilution;
Lane [4 & 5] 1:500 dilution, 
Lane [6 &7] 1:50 dilution
Lane [8 & 9] Neat cell lysate
•18 1.8 kDa
. 115.5 kDa
82.2 kDa
64.2 kDa*
48.8 kDa 
37.1 kDa 
25>' kDa
14.8 kDa 
h.O kDa
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5.6 Validity of the WB method
The WB process was tested to confirm a working WB methodology. Several 
conditions were stipulated to ensure a WB as close as possible to those used in 
attempts to isolate hTERT.
Firstly, an intra -nuclear protein was required as hTERT is intranuclear and hTERT 
absence may be caused by harsh cell lysis conditions required to break the nucleus 
which may also denature the protein. Alternatively, insufficient lysis of the nucleus 
could have resulted in the nucleus and its associated proteins being discarded in the 
supernatant.
Secondly, the secondary antibody used required to be the same as that used in WB for 
hTERT. The two primary anti-hTERT antibodies used at this stage were goat anti- 
hTERT (Santa cruz, sc-7212) and rabbit anti-hTERT (Abeam, ab32020) and hence a 
secondary anti-goat or an anti-rabbit would be required.
A WB using the Gemini intra-nuclear protein was tested in WB as this fulfilled both 
the above conditions. The WB showed a clear band at 33kDa, with potential break­ 
down products or non-specific binding occurring at 45kDa in glioblastoma samples 
Figure 5.4 (Yousaf, 2010). The secondary antibody used in this WB (STAR54, 
Serotec, Sheep Anti-rabbit IgG: HRP, Appendix 7.8) was also the same secondary 
antibody used in WB for anti-hTERT.
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Figure 5.4: WB for Gemini proteins in glioblastoma (Yousaf, 2010)
6.0 kDa
R1-R4: Glioblastoma samples; N1-N4, normal cell samples (Ixl07 ceq.)
This WB not only confirmed the validity of the WB method and ECL detection, but 
more importantly, also confirmed intra-nuclear proteins are detectable using this WB 
technique. Furthermore, it confirms that the secondary anti-rabbit antibody binds to 
the primary rabbit antibody. Additional experiments by Mr. Yousaf, a laboratory 
colleague, also showed that no reactivity was obtained with the secondary antibody 
alone (figure not shown) (Yousaf, 2010). This suggested that the most likely reason 
for negative WB was a defective primary anti-hTERT antibody.
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5.7 Examination of the anti-hTERT antibodies
Preliminary work identified hTERT in circulating tumour cells using rabbit anti- 
hTERT (Ab32020, Appendix 7.8) which did not provide definite bands with all 
samples. The same antibody was used initially with varying cell lysate concentrations. 
No hTERT was detected. The company was contacted regarding the non-performance 
of this reagent but it had been withdrawn. No reason for the withdrawal was available. 
The WB (Figure 5.4) had already confirmed that intranuclear proteins extracted using 
the same lysis buffer could be detected. Three new primary anti-hTERT antibodies 
were tested (sc-7214, USBiotechnologies, ab5181) (Figure 5.5). HeLa extract was 
used as this was the manufacturer's control reagent for primary antibody.
Figure 5.5: Santa Cruz and US Biotechnologies with HeLa nuclear extract— ——————————————————————_
181.8 kDa 
H55kDa 
82.2 kDa 
64.2 kDa* 
48.8 kDa 
V.l kDa 
25.1 KDa 
R4 kDa 
14.8 kDa 
0.0 kDa
Primary antibodies: Santa Cruz, sc-7214 at 1:200 dilution; USBiotechnologies 1:100
dilution (initially 1:500);
Secondary antibodies at 1:5,000 (STAR54, Serotec) and 1:20,000 dilution (STAR88P,
Serotec)
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The Santa cruz (sc-7214) anti-hTERT showed large amounts of non-specific binding 
to the HeLa extract. In contrast, the USBiotechnologies (Figure 5.5) and Abeam 
(figure not shown) showed no binding to the HeLa nuclear extract. As previous WB 
with the other intranuclear proteins had already showed that the secondary antibodies 
bind specifically with minimal background staining (Figure 5.4), the problem was not 
with the WB technique or secondary antibodies, but with the primary anti-hTERT 
antibodies. The manufacturers were contacted again. The Santa Cruz and 
USBiotechnologies antibodies had again been withdrawn and replaced with the next 
generation of anti-hTERT antibodies. As the previous anti-hTERT antibodies from 
these companies had already been tested without success, a final attempt was made 
with Abeam anti-hTERT (ab 5181). Again, no hTERT was detected using this 
antibody with Colo205 cell lysate (5xl06 ceq) or HeLa nuclear extract.
5.8 Human Sera in WB
Five different anti-hTERT antibodies (Appendix 7.7) had been tested, none of which 
displayed any specific protein-binding of the eluate from immuno-affinity column or 
the various cancer cell lysates or the HeLa nuclear extract. In a final attempt to obtain 
a positive control and demonstrate specific protein binding, patient and control sera 
were used (Figure 5.6). The postulation was that CRC patient sera may contain 
antibodies against a variety of TAA including hTERT; and WB bands detected in 
patients' but not control subjects' sera, suggests an antibody unique to CRC. This was 
a validation method used by Masutomi et al to demonstrate anti-hTERT. The 
recombinant hTERT on membrane showed a distinct band only with patient sera.
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Figure 5.6: WB with serum and negative controls.
181.8 kDa
[1] Secondary-HRP only;
[2] Lysate, control sera, secondary HRP;
[3] Lysate, secondary-anti-human HRP;
[4-6] Lysate, patients sera (Patient 1, 2 & 3), secondary-HRP
The patients' sera contained a vast array of antibodies which bound non-specifically 
to Colo205 lysate. Despite modifying the blocking, washing and ECL conditions 
vastly, the results ranged from over-developed membranes which obscured the 
potential regions where hTERT would be expected to be present (figure not shown), 
to a gray non-specific background.
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The next observation of interest was in the 2 negative controls [Membrane 1 & 3]. 
The first membrane [1] contained no cell lysate, primary antibody or serum and was 
incubated only with the secondary anti-human HRP. This displayed non-specific 
binding suggesting the secondary antibody could bind non-specifically, even to an 
empty membrane.
The second observation was in negative control [3] which consisted membrane with 
Colo205 lysate with the secondary anti-human antibody, but not primary anti-hTERT 
antibody or sera. This also showed general protein binding. This suggested the 
secondary anti-human would again bind directly to the Colo205 cell lysate without the 
requirement of primary antibody or patient sera. This may be expected as Colo205 is 
of human origin.
The conclusion from the early optimisation process was that the primary anti-hTERT 
antibodies were not sufficiently specific. This final experiment concludes that normal 
subject sera cannot be used to identify hTERT due to non-specificity; and a secondary 
species specific antibody (in this case, anti-human) also cannot be used to identify 
hTERT in cancer cell lysates using sera as there are far too many human-specific 
proteins in cancer cell lysate. A purified hTERT is required.
In summary, after 18 months and despite (a) all the varied WB conditions used, (b) 
performed in duplicate resulting in an excess of 100 membranes, (c) each with further 
multiple ECL exposures; and (d) having proven that the WB technique itself was 
viable for intranuclear protein detection and secondary antibody specificity, the 
optimisation process was stopped.
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5.9 Discussion
The authors of the only other study on anti-hTERT auto-antibody produced hTERT 
using insect-expressed recombinant, initially in 2000, and only later detected serum 
anti-hTERT auto-antibody in 2002 (Masutomi et al., 2000, Masutomi et al., 2002). 
The time lag between the two studies and the authors' description of the difficulty in 
expressing and isolating hTERT with standard bacterial expression systems and 
eventual resort to baculovirus system demonstrates the complexity in obtaining pure 
hTERT even with advanced molecular and recombinant techniques. Furthermore, 
there have been no further reports of anti-hTERT since 2002 which again suggests 
hTERT production or detection was not viable at that stage. Hence one of the aims of 
this study was to isolate hTERT directly without the need for extensive molecular 
biology techniques, and establish an ELISA for anti-hTERT detection using hTERT 
isolated by standard laboratory techniques.
The optimisation was severely hampered by the inability to confirm hTERT presence 
by WB. This meant that it was not possible to confirm or refute if hTERT was 
isolated from the lysates. Although all the primary anti-hTERT antibodies tested were 
sold as suitable for WB, none worked in this current study and several had been 
withdrawn during this thesis period.
The immune-affinity column and WB is a standard method of protein isolation and 
detection (Springer, 1996, Harlow and Lane, 1988). This was unsuccessful as either 
the hTERT was not present, or if present, it was not captured by the anti-hTERT. 
Assuming the primary antibodies were functional, then hTERT must indeed be
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absent in the column eluate. The possible reasons for this are that hTERT was not 
bound when passed down the column, hTERT was denatured during the elution (pH 
2.2) process, or hTERT levels were too low for detection, or a combination of 2 or 
more of these possibilities. These potential issues were addressed first, prior to 
addressing the potential issues with the primary antibody
In order to address this, firstly, the column was discarded and WB performed directly 
on the cell lysate to avoid potential column related factors such as non-capture of 
hTERT and the elution conditions. hTERT was not detected in WB of cell lysates. 
Secondly, the cell lysate concentrations were increased to the maximum possible, and 
then switched to HeLa nuclear extract to address the issue of potentially insufficient 
hTERT for detection. Again, hTERT was not detected.
As none of these solutions provided identifiable hTERT, the WB process itself 
required re-examination. A comparative WB was designed to test this WB ability to 
detect intranuclear proteins. This WB showed Gemini intranculear protein could be 
detected using this method. Furthermore, the secondary antibody was sufficiently 
specific. The results of these examinations led to the possibility of non-functioning 
anti-hTERT antibodies. This would also explain the lack of binding within the 
immune-affinity column, a usually reliable method of protein isolation. This was a 
major negative result and setback in the early work, but did help direct subsequent 
experiments and targeting cell lysates only with different primary and secondary 
antibodies. However at the end of the optimisation development, this could not be 
tested directly as there was no means of proving or disproving the presence of hTERT 
in any of the samples as all the primary antibodies were not sufficiently specific.
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Other hTERT isolation methods were considered. Magnetic beads have been used to 
isolate antigens and had previously been used in this laboratory to isolate circulating 
tumour cells from blood of CRC patients (Thornton, 2003, Horgan and Shaw, 1995) 
(Khair, 2010). The magnetic beads required streptavidin coating, incubation with 
biotinylated anti-hTERT antibody and then incubation with cancer cell lysate. A 
magnetic field could isolate the microbead-streptavidin <->anti-hTERT <->• hTERT 
complex. However, the harsh elution conditions in the immuno-affinity column could 
also cause hTERT denaturation here. Alternative methods of enzymatic rather than 
chemical cleavage to break the biotinylated hTERT <-» hTERT bond were explored 
but were not attempted as there was increasing evidence that the anti-hTERT primary 
antibodies were non-functioning. The development of alternative methods would be 
futile without a functioning anti-HTERT to capture or detect hTERT.
The authors (Masutomi et al., 2002) were contacted but the recombinant hTERT was 
not available. As large amounts would be required for WB optimisation and 
subsequent development of ELISA screening method, commercial laboratories had 
been contacted but were unable to help as this product is not available and custom 
production was prohibitively expensive. The idea of producing recombinant hTERT 
in this laboratory had also been explored. This was unfeasible due to time constraints 
and potential problems with Genetic Manipulation approval as recombinant hTERT 
could be considered a potential biohazard due to its key role in tumorigenesis. It 
became increasingly apparent in the final stages of this study that the recombinant 
hTERT was required in order to develop any further methodology as the anti-hTERT 
antibodies could not be relied upon.
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5.10 Summary
In order to undertake the analysis proposed, it was essential that a proven source of 
hTERT is obtained, and recombinant technology seems the only realistic technology. 
However, the authors of the only study to isolate hTERT also describe difficulty in 
expressing and purifying hTERT even with this technology. Future studies should 
focus on development of technologies to obtain hTERT, and the raising of an 
antibody specific to hTERT. Only then can attempts at detecting hTERT be 
realistically attempted.
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6 Chapter 6: Final Discussion
CRC is a common malignancy and a major contributor to cancer related death. It has 
multifactorial aetiology and multiple biomarkers are implicated in its carcinogenesis. 
The potential importance of the humoral response to tumour associated antigens, 
mainly p53 mutation and telomerase (hTERT) re-activation is discussed.
6.1 Limits of current therapy
Surgery is the traditional mainstay in CRC treatment. Advances in neo-adjuvant 
therapy and modern surgical techniques enable complete tumour resection with clear 
excision margins. Surgery has potentially reached the limit of its curative role in 
resection of the primary tumour. The main cause of cancer related-death is local 
recurrence (despite clear surgical margins) and distant metastases. These issues are 
addressed primarily by chemo- and chemo-radiotherapy treatments. Significant 
advancements have been made in these fields. Traditional 5-FU / Leucovorin (LV) 
treatments have improved disease-free and overall survival substantially by 35% and 
22% respectively (O'Connell et ah, 2005, Sargent et al., 2001, de Gramont et al., 
2000). Additional therapy with oxaliplatin and irinotecan have led to further success 
in controlling disease (Goldberg et al., 2004, Hurwitz et al., 2004, Andre et al., 2004). 
The expanding knowledge of tumour molecular biology has led to the addition of 
immunotherapeutic agents such as EGFR, VEGF and COX-2 inhibitors which all aim 
to reduce disease recurrence and systemic metastases (Van Cutsem et al., 2008, 
Cassidy, 2007, Cunningham et al., 2004). However, this remains a blanket treatment
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approach, and these treatments are associated with significant morbidity. Furthermore, 
recent advances now show non-efficacy of these treatments in certain CRC groups 
due to individual tumour biology (e.g. kRAS and PTEN mutations in EGFR and 
VEGF inhibition) and highlights the need for continuous research into identification 
of accurate biomarkers to guide new treatments and reduce disease progression. The 
humoral antibody response is specific to individual TAA in CRC and may provide 
benefit in this respect.
6.2 CRC stem cell theory
CRC stem cells are defined as the distinct subpopulation within a heterogeneous 
tumour that is able to self-renew and differentiate (Yeung et al., 2010, Clarke et al., 
2006, Radtke and Clevers, 2005). The traditional cancer model suggests every cancer 
cell has the ability to progress indefinitely (Stochastic model). The stem cell model 
suggests that only a few cancer cells are the source of indefinite CRC replication (the 
"stem cell"). The vast majority of CRC cells arise from these stem cells and do not 
possess indefinite replicative capacity. Only a few select cells inherit the ability to 
become future cancer stem cells ("daughter cells") (Bonnet and Dick, 1997). It is 
though that this subpopulation, and not the rest of the non-stem cancer cells that 
drives tumour progression in CRC.
The implication of the cancer stem cell model on CRC treatment is that the excision 
of these cells cannot be assessed despite complete surgical excision as assessed by 
histopathological examination, thus leaving the possibility of residual cancer stem 
cells. These residual stem cells may be the driving force for local recurrence despite
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complete tumour excision. Certain biomolecular markers have been identified to aid 
recognition of CRC stem cells but with limited success. The most recent systematic 
review on colorectal cancer stem cells reported CD-133 as a promising marker but 
whilst able to identify cells which initiate carcinogenesis was unable to identify CRC 
cells driving further progression (Yeung et al., 2010). Other markers under 
investigation include CD44, CD24, EPCAM groups, Wnt and FAP mutation 
(Haraguchi et al., 2008, Lang et al., 2004, Winter et al., 2003).
Telomerase activity is present at low levels in normal proliferating gastrointestinal 
crypt cells (Forsyth et al., 2002). It is likely that CRC stem cells arise from these 
normal self-renewing stem cells as part of the mortality barrier has already been 
overcome. Thus less mutation are required for carcinogenesis, compared to the 
normal non-proliferative cells which require more alterations to overcome the 
mortality barriers (Barker et al., 2009, Boman et al., 2008, Johnston et al., 2007). This 
increase in telomerase activity (by upregulation of hTERT) in progression from 
normal to CRC stem cell may be valuable tool in diagnosing CRC. The only study on 
anti-hTERT auto-antibody reported significant increase serum titres in progression 
from normal to pre-malignant (cirrhosis) and pre-malignant (chronic active hepatitis) 
to malignant (HCC). The anti-hTERT response is most likely in response to hTERT 
upregulation of hTERT suggesting that this response is sensitive to TAA which occur 
in the pre-malignant stage. This feature could be utilised in various roles in CRC such 
as screening, or serum testing for potential residual tumour despite histologically 
completely excised margins, or guiding local excision.
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6.3 Screening
Serum anti-hTERT auto-antibodies could be used as an early screening tool to guide 
endoscopic surveillance. Substantial stage shift was observed in the initial CRC 
screening program with up to 40% Stage I / II CRC but yet survival benefit is not 
observed. This may be because of the lag-time required to observe survival 
differences (5-10 years). Anti-hTERT or anti-p53 auto-antibody can be tested more 
frequently and in the pre-malignant stage which may increase detection of early 
tumours. Patients positive for the auto-antibody but with no clinical evidence of CRC 
may benefit from regular screening endoscopy or tests for other occult malignancies.
6.4 Post-operative CRC
Monitoring of serum anti-hTERT titres following surgical resection may aid disease 
monitoring. Despite complete excision of low risk tumours, the cancer stem cell 
hypothesis suggests that stem cells may drive tumour progression and remain 
untreated. No biomolecular markers are able to accurately predict this. Persistently 
elevated anti-hTERT levels may suggest residual stem cells even if the cells are 
macro- or microscopically undetectable. The anti-hTERT response could be used to 
stratify risk of disease recurrence or metastases, and requirement for adjuvant chemo- 
immunotherapy in the immediate post-operative period. The sensitivity of anti- 
hTERT to tumour load requires further assessment as elevations in anti-hTERT auto- 
antibodies may also suggest the re-activation of TAA in preparation for disease 
recurrence or progression.
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6.5 Local excision
There is paradigm shift in the definition of cancer treatment "success". The optimal 
aim of surgery is no longer lowest recurrence rates, but to balance surgical morbidity 
with post-operative quality of life (QOL). This is demonstrated by the mandatory 
inclusion of multiple QOL-related outcomes in all new CRC trials. Local excision has 
less morbidity but is hampered by high recurrence rates caused by lack of accurate 
radiological imaging and pathological staging despite addition of features such as 
mucinous production, signet cell, Kikuchi grade and tumour budding. The auto- 
antibody response may aid in predicting tumour aggression, or residual CRC, which 
would then be an indication for extensive radical surgery or adjuvant chemotherapy.
6.6 Final Conclusion
The humoral response is aimed at identifying the tumour-associated antigens and its 
presence as an early marker in carcinogenesis or disease recurrence. The anti-p53 
auto-antibody in CRC is not associated with clinico-pathological or prognostic factors 
in CRC. Although limited subgroup analysis suggest anti-p53 is a marker of early 
disease recurrence and may guide screening strategies in high-risk groups, its 
sensitivity and specificity for CRC is low but may be used in conjunction with other 
markers as part of a tumour panel. Anti-hTERT may have similar uses. However, the 
main obstacle in assessing the anti-hTERT response is isolation of hTERT molecule 
itself and the development of a sufficiently specific antibody. The association between 
telomerase activity, hTERT expression and anti-hTERT in conjunction with CRC 
stem cells is an exciting future possibility.
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7 Appendix
7.1 Commonly Used Reagents
Ammonium Persulphate (APS); Melford Lab Ltd, Ipswich, Suffolk
Bicine; Melford Lab Ltd, Ipswich, Suffolk
Glycine; Fisher Scientific, Loughborough, Leicestershire
HEPES; Melford Lab Ltd, Ipswich, Suffolk
Sodium dodecyl sulphate (SDS); Melford Lab Ltd, Ipswich, Suffolk
Tris Base; Melford Lab Ltd, Ipswich, Suffolk
Phospate Buffered Saline (PBS); Sigma-Aldrich, St. Louis, MO, USA
Methanol; Department of Chemistry, University of Hull
TEMED; Sigma-Aldrich, St. Louis, MO, USA
2(3 Mercaptoethanol; Sigma-Aldrich, St. Louis, MO, USA
Butanol; BDH Ltd., Poole, UK
Amersham ECL Plus™ Western Blotting Detection Reagents; GE Healthcare, 
Buckinghamshire, UK
7.2 Cell Lysate Preparation: Lysis Buffer
Lysis Buffer
lOmMTrisHcl, pH 7.4
1% (w/v) NP-40 Iqepal A - 630 (Sigma-Aldritch, Poole, UK)
150mMNaCI
1 mM EDTA
1:200 Protease Inhibitor 
Darmstadt, Germany)
Cocktail Set III (Calbiochem, Merck4Biosciences,
7.3 Cell Lysate Preparation: Cancer Cell Lines
Cell Line
MCF7
T47D
Caco-2
LoVo
Ht29
COLO320
Colo205
Line
Breast
Breast
Colon
Colon
Colon
Colon
Colon
ATCC No.
HTB - 22
HTB- 133
HTB - 37
CCL-229
HTB -38
CCL- 220.1
CCL-222
Origin and Description
69 year female Caucasian, adenocarcinoma, pleural 
effusion, ER+,
54 year female, adenoarcinoma, pleural effusion ER, 
PG, AR, calcitonin, GC, Prolactin +
Monolayer heterogeneous adenocarcinoma, EGF+
56 year male. Dukes' C, Grade 4, homogenous 
adenocarcinoma, left supraclavicular nodule, myc, 
myb, ras, fos, p53 +
44 year female Caucasian adenocarcinoma, mucinous, 
CEA+; myc, ras, myb, fos, p53 +
55 year female Caucasian, Dukes' C, 
adenocarcinoma, CEA
70 year male Caucasian, Dukes' D, adenocarcinoma, 
ascitic fluid, CEA+, IL-10+
ATCC, American Type Culture Collection (Manassas, VA, USA)
7.4 Western Blot: PAGE Gel Recipes
4% Stacking Gel
Acrylamide
1 M Tris Base; pH 6.8
SDS(w/v) 10%
dH2O
TEMED
APS(w/v) 10%
10% Separating Gel
Acrylamide
TrisHCl, l.5M;pH8.8
SDS(w/v) 10%
dH20
TEMED
APS(w/v) 10%
Reducing
1.3ml
1 .25 ml
•.U.I ml
7.4 ml
20 ul
50 ul
2.5ml
2.5ml
0.1 ml
4ml
10 til
50 ul
Native
1.3ml
1 .25 ml
X
7.4ml
20 ul
50 ul
3.33 ml
2.5 ml
X ^
4 ml
10 ^1
50 ul
7.5 Western Blot: "In-house" Buffer Recipes
Sample Buffer
TrisHCl, !M;pH6.8
SDS (w/v) 20%
Glycerol
Bromophenol blue (w/v) 0.5%
Running Buffer
Tris Base (Dry)
Glycine (Dry)
SDS (w/v) 10%
dH2O
Transfer Buffer
Tris Base (Dry)
Glycine (Dry)
Methanol
dH2O
Reducing
13ml
6.5ml
5.2ml
0.26 ml
3g
14.4 g
10ml
Make up to 1L
3g
I4.4g
200ml
Make up to 1 L
Native
13ml
X
5.2ml
0.26 ml
3g
14.4g
X
Make up to 1 L
3g
14.4g
200ml
Make up to 1 L
7.6 Western Blot: PreciseTM Precast Gel Buffers Recipes
Sample Buffer
Tris HC1, 0.5M
SDS(w/v) 10%
Glycerol
Bromophenol blue, 0.1% (w/v)
2-p Mercaptoethanol, 2-5% (w/v)
dH2O
TRIS-HEPES-SDS Running Buffer
Tris Base
HEPES
SDS
ddH2O
Transfer Buffer
Tris Base
Bicine
Methanol
ddH2O
2.5ml
4ml
2ml
1 ml
10ml
12.1 g
23.8 g
lg
Make up to 1 L
3g
4.08g
100ml
Make up to 1 L
7.7 Primary Antibody List
Antibody
Biotinylated anti-hTERT 
(H-231):sc-7212
(Santa Cruz, Biotechnology,
Autogen Bioclear UK Ltd., 
Wiltshire, UK)
Rabbit Anti-hTERT (H- 
231): sc-7212
(Santa Cruz, Biotechnology,
Autogen Bioclear UK Ltd., 
Wiltshire, UK)
Goat Anti-hTERT (L-20):
sc-7214
(Santa Cruz, Biotechnology.
Autogen Bioclear UK Ltd.,
Wiltshire, UK)
Rabbit Telomerase
antibody [Y1821
(ab32020; Abeam pic.
Cambridge, UK)
Mouse Telomerase
antibody [2C4]
(ab5181; Abeam pic, Cambridge.
UK)
Rabbit Anti- Telomerase,
CT,T2399-15B
(USBiological, Massachusetts,
USA)
Reactivity
Mouse,
Rat,
Human
Mouse,
Rat,
Human
Human
Human
Human
Human
Dilutions
1:100- 1:5,000
1:100- 1:5,000
1:100-1:5,000
1:100-1:1000
1:200 -IrfOOO
1:200-1:1000
Control
A B 
201K
122 K - —— (-TERT 
102 K
A B 
201 K
122 K --.<- TERT 
102 K
204 K - - -
123 1C - —— <— TEHT
BO K -
«*
J8K -
250-
150-
vg-
50-
37-
i;-kD «»I,TKRT
——
No image provided
7.8 Secondary Antibody List
Antibody
Mouse Anti-Human 
(MCA5I5G; Serotec Ltd, Oxford, UK)
Mouse Anti-Human IgG (Fc):HRP 
(MCA647P, Serotec Ltd, Oxford, UK)
Rabbit Anti-Mouse IgGrHRP. 
(STAR13B; Serotec Ltd, Oxford, UK)
Sheep Anti-Rabbit IgG:HRP 
(STAR54; Serotec Ltd, Oxford, UK)
Donkey Anti-Sheep IgG:HRP 
(STAR88P, Serotec Ltd, Oxford, UK)
Reactivity
Human IgG2
Human IgG Fc
Mouse and rat IgG
Rabbit IgG
Sheep IgG
Dilutions Used
1 :5,000 - 1 :20,000
1:1,000- 1:15,000
1:2,000- 1:15,000
1:5,000-1:20,000
1:5,000- 1:20,000
7.9 Control Sample Characteristics
No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
Label
Conl
Con2
Con3
Con4
Con5
Con6
VIA
V2A
rll
r!2
r!3
rl6
r18
r!9
r21
r22
r23a
r24
r27
r28
r29
r31
r32
r33
r35
r37
r40
r44
Sex
M
M
M
F
M
F
M
M
M
F
M
M
M
M
F
M
M
F
M
F
F
F
F
M
M
F
M
F
Age
62
67
75
65
65
72
71
67
73
56
63
67
73
70
59
77
67
65
61
72
61
69
73
85
69
68
76
53
Status
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
Benign Disease
7.10 Plate 1: OD450am and CoV
A
Mean
SD
CoV
B
Mean
SD
CoV
C
Mean
SD
CoV
D
Mean
SD
CoV
E
Mean
SD
CoV
F
Mean
SD
CoV
G
Mean
SD
CoV
H
Mean
SD
CoV
1 2
2.688 2.663 
2.6755 
0.0177
II. (M 1?
1.995 2.061
2.028 
0.0467
D.H23
1 .508 1 .698
1.603 
0.1344
0.11X4
1.09 1.172
1.131 
0.0580
D us !
0.914 0.893
0.9035 
0.0148 
0.01ft
0.602 0.623
0.6125 
0.0148
( i 1 12-[
0.229 0.223
0.226 
0.0042
!i.()l'»
0.019 0.011
0.015 
0.0057 
0.377
3 4
0.721 0.748 
0.7345 
0.0191
ii.I)2ii
0.091 0.027
0.0590 
0.0453
0.767
0.094 0.091
0.0925 
0.0021
(1.1123
0.106 0.073
0.0X95 
0.0233 
0.261
0.373 0.4
0.3865 
0.0191
(Hi4'i
0.174 0.164
0.169 
0.0071 
• <>42
0.072 0.075
0.0735 
0.0021
(1.1129
0.35 0.318
0.334 
0.0226
O.fJtiX
5 6
0.112 0.151
0.1315 
0.0276
(1.210
0.054 0.056
0.055(1 
0.0014
01 2'.
0.95 0.399
0.6745 
0.3896 
tl.578
0.138 0.164
0.151 
0.0184
ii | •>•>
0.129 0.165
0.147 
0.0255 
0.173
0.11 0.167
0.1385 
0.0403 
0.291
0.107 0.106
0.1065 
0.0007
(1.0(17
0.101 0.232
0.1665 
0.0926 
0.556
7 8
0.069 0.082
0.0755 
0.0092
ii 122
0.059 0.062
0.0605 
0.002 1
n (135
1.187 1.241
1.214 
0.0382
(i in I
0.038 0.038
0.038 
0.0000
M nnr i
0.492 0.556
0.524 
0.0453
(I.(IX6
0.076 0.076
0.076 
0.0000
11. Ill 10
0.137 0.117
0. 27 
0.0141
o. 1 i
0.051 0.082
0.0665 
0.0219 
0.330
9 10
0.064 0.09
0.077 
0.01X4
0.214 0.226
0.2200 
0.0085
IHJlV
0.109 0.069
0.089 
0.0283 
0.318
0.058 0.061
0.0595 
0.0021
(i i|} (.
0.073 0.092
0.0825 
0.0134 
0.163
0.089 0.075
0.082 
0.0099
1.313 1.276
1.2945 
0.0262
iui2'i
0.293 0.268
0.2805 
0.0177
11 12
0.245 0.238
0.2415 
0.0049
0.038 0.038
0.0380 
0.0000
0.073 0.077
0.075 
0.0028
I ! 1 1 ~i X
0.147 0.142
0.1445 
0.0035
n tPJ
0.113 0.077
0.095 
0.0255 
0.268
0.134 0.152
0.143 
0.0127 
0.089
0.093 0.069
0.081 
0.0170 
0.210
0.165 0.1
0.1325 
0.0460 
0.347
The rows below each reading indicate the mean, standard deviation (SD) and the Co­ 
efficient of Variation (CoV), defined as the ratio of the SD to the Mean (SD / M). The 
red shaded cells indicate CoV > 20% in OD450 of duplicate samples. Samples were 
unable to be re-assayed due to limited availability.
7.11 Plate 2: OD450nm and CoV
A
Mean
SD
CoV
B
Mean
SD
CoV
C
Mean
SD
CoV
D
Mean
SD
CoV
E
Mean
SD
CoV
F
Mean
SD
CoV
G
Mean
SD
CoV
H
Mean
SD
CoV
1 2
1.409 1.717 
1 .563 
0.2178 
ii. 39
1.016 1.052 
1 .0340 
0.0255 
0.025
0.858 1.028 
0.943
0.1202
0.662 0.776 
0.719 
0.0806
(i.i i:
0.581 0.588 
0.5845 
0.0049
O.tlHS
0.401 0.462 
0.43 1 5 
0.0431
ii. HIM
0.111 0.099 
0.105 
0.0085
o." IN 1
0.043 0.046 
0.0445 
0.0021
I|.(UK
3 4
0.114 0.127 
0.1205 
0.0092
0.076
0.091 0.118 
0.1045 
0.0191 
II.IX3
0.082 0.077 
0.0795 
0.0035
(1.044
0.103 0.097 
0.1 
0.0042
0.113 0.101 
0.107 
0.0085
f!.ll7<»
0.086 0.062 
0.074 
0.0170 
0.22')
0.091 0.078 
0.0845 
0.0092
n. |iii»
0.082 0.086 
0.084 
0.0028
0 D'4
5 6
0.106 0.135 
0.1205 
0.0205
n ! ~< .
0.106 0.143 
0. 1 245 
0.0262 
0.2 10
0.798 1.017 
0.9075 
0.1549
ii.|7|
0.304 0.254 
0.279 
0.0354
n 127
0.0085 0.129 
0.06875 
0.0852 
!.:jn
0.067 0.073 
0.07 
0.0042
i] 'i(i 1
0.092 0.107 
0.0995 
0.0106
1) )(I7
0.096 0.105 
0.1005 
0.0064
(I.Mfi3
7 8
0.211 0.166 
0.1885 
0.0318 
1).I6'J
0.549 0.6 
0.5745 
0.0361
1 1 . ( n i ';
0.104 0.094 
0.099 
0.0071
n (171
0.506 0.492 
0.499 
0.0099
i) inn
0.1 0.096 
0.098 
0.0028
n n2'»
0.111 0.074 
0.0925 
0.0262 
(1.283
0.126 0.109 
0.1175 
0.0120
o. HO
0.106 0.107 
0.1065 
0.0007 
(1.007
9 10
0.157 0.132 
0.1445 
0.0177 
(1. 22
0.116 0.1
0.1080 
0.0113 
11.1115
0.107 0.08 
0.0935 
0.0191 
11.21(4
0.07 1 0.072 
0.0715 
0.0007
(I'll!)
0.057 0.057 
0.057 
0.0000
n iirio
0.076 0.069 
0.0725 
0.0049
ll (ihX
0.084 0.091 
0.0875 
0.0049
0.057
0.066 0.063 
0.0645 
0.0021
(MlV,
11 12
0.112 0.099 
0.1055 
0.0092 
0.0X7
0.009 0.145 
0.0770 
0.0962 
1,241
0.109 0.103 
0.106 
0.0042
i,.i .ji.
0.082 0.097 
0.0895 
0.0106
".1 1')
0.099 0.079 
0.089
0.0141
' I ^'•J
0.084 0.114 
0.099 
0.0212 
0.214
0.072 0.083 
0.0775 
0.0078
n |nii
0.091 0.079 
0.085 
0.0085
The rows below each reading indicate the mean, standard deviation (SD) and the Co­ 
efficient of Variation (CoV), defined as the ratio of the SD to the Mean (SD / M). The 
red shaded cells indicate CoV > 20% in OD45o of duplicate samples. Samples were 
unable to be re-assayed due to limited availability.
7.12 Plate 3: OD4SODm and CoV
A
M ean
SD
CoV
B
Mean
SD
CoV
C
Mean
SD
CoV
D
Mean
SD
CoV
E
Mean
SD
CoV
F
Mean
SD
CoV
G
Mean
SD
CoV
H
Mean
SD
CoV
1 2
1.966 2.016 
1.991 
0.0354
n ins
1.343 1.404 
1.3735 
0.043 1
ii.<>.; i
1.038 1.15 
1 .094 
0.0792
0.1)72
0.671 0.692 
0.6815 
0.0148
on::
0.534 0.617 
0.5755 
0.0587 
0.102
0.396 0.403 
0.3995 
0.0049
.nl2
0.201 0.22 
0.2105 
0.0134
n. DM
0.037 0.026 
0.0315 
0.0078
0.74'
3 4
0.081 0.062 
0.0715 
0.0134 
II.IKM
0.069 0.077 
0.0730 
0.0057
0.1)77
0.112 0.095 
0.1035 
0.0120
" l!>
0.674 0.6 1 8 
0.646 
0.0396
II.Ddl
0.076 0.084 
0.08 
0.0057
0.082 0.074 
0.078 
0.0057
o.d?;
2.389 2.439 
2.414 
0.0354
0.094 0.087 
0.0905 
0.0049
n.ov
5 6
0.087 0.102
0.0945 
0.0106
n. 12
0.064 0.066 
0.0650 
0.0014
" '.02
0.124 0.094 
0.109 
0.0212
1 1 . '•> '-•
2.684 2.501 
2.5925 
0.1294
0.1)50
0.061 0.063 
0.062 
0.0014 
0.023
0.066 0.074 
0.07 
0.0057 
0.081
0.046 0.09 
0.068 
0.03 1 1 
0.458
0.098 0.102 
0.1 
0.0028
ii i OH
7 8
0.145 0.139
0.142 
0.0042 
0.030
0.086 0.064 
0.0750 
0.0156 
0.207
0.062 0.059 
0.0605 
0.0021
<MH?
0.068 0.061 
0.0645 
0.0049 
0.077
0.154 0.145 
0.1495 
0.0064 
0.043
0.074 0.081 
0.0775 
0.0049
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0.222 0.166 
0.194 
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0,204
0.048 0.06 
0.054 
0.0085
J i 4 ";
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0.116 0.186 
0.151 
0.0495 
0.328
0.076 0.149 
0.1125 
0.0516 
0.459
0.043 0.054 
0.0485 
0.0078
(1. |hfl
0.086 0.056 
0.07 1 
0.0212 
0.299
0.951 0.915 
0.933 
0.0255 
0.027
0.052 0.057 
0.0545 
0.0035 
o.nto
0.107 0.122 
0.1145 
0.0106
0.047 0.05 
0.0485 
0.0021
1 1 . ; i i
11 12
0.142 0.134 
0.138 
0.0057 
0.041
0.074 0.06 
0.0670 
0.0099
,1 1 IV
0.079 0.068 
0.0735 
0.0078
(i 1 1 ifi
0.115 0.11 
0.1125 
0.0035 
0.0? |
0.076 0.057 
0.0665 
0.0134 
(1.2U2
0.095 0.114 
0.1045 
0.0134
(I. 2 l
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0.0071
I 1 ' 'u L
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0.12 
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The rows below each reading indicate the mean, standard deviation (SD) and the Co­ 
efficient of Variation (CoV), defined as the ratio of the SD to the Mean (SD / M). The 
red shaded cells indicate CoV > 20% in 00450 of duplicate samples. Samples were 
unable to be re-assayed due to limited availability.
7.13 Kaplan Meier Survival Curve : Overall Survival
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